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ABSTRACT 
Background: Patients’ beliefs and perceptions play an important role in adherence to 
medicines. Several studies have documented differences between individuals from different 
ethnic groups in terms of the way in which medications are viewed. These views can 
potentially impact on medication adherence. However, comparisons of adherence between 
rheumatoid arthritis (RA) patients from other minority ethnic groups and South Asians have 
not been reported. The aims of the present thesis were twofold. Firstly, it set out to synthesise 
data on adherence in diabetes and cardiovascular disease in South Asian patients and to 
identify factors that influence differences in adherence. The understanding gained was then 
applied to identify influences on adherence to medication in RA in South Asian patients 
compared with White British patients.  
Method: A systematic qualitative meta-synthesis of adherence in diabetes and cardiovascular 
diseases was conducted to gain an understanding of South Asian patients’ health beliefs and 
the consequent influence of these beliefs on medication adherence. Following this, two 
studies were undertaken in patients with RA: a quantitative survey (180 patients) to 
investigate the relation between demographic, diseases related and psychological variables 
and a qualitative study (20 patients: 10 high and 10 low adherers) explored the reasons for 
poor adherence to medications used in RA.  
Results: The results of the systematic review highlighted that beliefs about medicines play an 
important role in medication adherence in South Asian patients. The quantitative survey 
undertaken for this thesis demonstrated that South Asian RA patients exhibited more negative 
beliefs about medicines and lower levels of adherence to RA medicines than did their White 
British counterparts and were more dissatisfied with the information they received about their 
medicines. Results from the interviews showed that four interlinking themes influenced 
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adherence in both South Asian and White British ethnic groups; [i] symptom severity; [ii] 
illness perception; [iii] perceived benefits and risk of medicines; [iv] quality and quantity of 
information.  
Conclusion: This thesis has demonstrated that some beliefs about medicines and illness 
perceptions differ between the South Asian and White British ethnic groups; these beliefs and 
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LIST OF TERMS AND ABBREVIATIONS  
Terms and abbreviations Explanation 
 
ADHERENCE The extent to which a patient’s behaviour matches agreed 
recommendations by the health professional.  
ANTI- TNF Anti-tumour necrosis factor, TNF. Drugs used to suppress 
rheumatic diseases. 
BMQ Beliefs about Medicines Questionnaire. A tool that assesses 
beliefs about medicines.   
CVD  Cardiovascular disease. A condition that causes disorders 
of the heart and circulatory system. 
CRP C-reactive protein. A test that measures the level of 
inflammation during active disease.   
CROSS-SECTIONAL DESIGN A research method in which groups of patients are 
observed and compared at a given time. 
DMARD Disease modifying anti-rheumatic drug. These medicines 
are used to minimise and/or control inflammation, swelling 
and destruction to the joint (s).  
ETHNICITY A group of individuals who share origins or social 
background, culture, traditions, language and religious 
traditions. 
ESR Erythrocyte sedimentation rate. A test that measures the 
level of inflammation during active disease. 
GENERAL HARM SCALE  An assessment of beliefs about the intrinsic properties of 
medicines and the degree to which the individual perceives 
them as harmful. 
GENERAL OVERUSE SCALE  An assessment of individuals’ views about medicines being 
overused by doctors.   
HAQ 
 
Health Assessment Questionnaire. A tool that measures 
disability in rheumatoid arthritis. 
IPQ Illness Perception Questionnaire. A tool that measures 
illness perceptions. 




Medication Adherence Report Scale. A tool that measures 
the level of adherence to medicines.   
NCD Necessity Concern Differential. When individuals weigh 
the benefit of treatment against concern. 
QUALITATIVE Where individuals’ experiences, beliefs and attitudes  
towards health, illnesses and treatments can be measured 
through in-depth interviews. 
QUANTITATIVE  A method whereby numerical data are collected and 
analysed mathematically to support prove or refute a 
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hypothesis.    
RA Rheumatoid arthritis. A chronic inflammatory disease that 
causes damage and deformity to joints. 
SATURATION A process in collecting qualitative data when no new 
themes are generated, and data collection is stopped. 
SIMS  Satisfaction with Information on Medication Scale. A tool 
that measures satisfaction with information given about 
medicines.   
SRM-CSM Self-Regulation Model. A framework that captures 
individuals’ common sense about symptom appraisal. 
SPECIFIC NECCESSITY SCALE  An assessment of an individual’s beliefs about personal 
need for medicines. 
 
SPECIFIC CONCERN SCALE An assessment of an individual’s beliefs about potential 






CHAPTER 1: BACKGROUND 
1.0 Overview 
Rheumatoid arthritis (RA) is a common chronic condition that impacts on patients’ health 
related quality of life.1 Furthermore, RA has been associated with reduced life expectancy  as 
it increases the risk of death from various causes including cardiovascular disease,2 and 
infections. Effective medications exist to control RA but these have side effects and patients 
do not always adhere to them.3 It has been shown that culturally related health beliefs can 
influence medication adherence in chronic disease and this may affect long term outcomes.4-7 
This may be the case for RA patients of South Asian origin. For example, in the UK, South 
Asian patients with RA have been shown to have different beliefs about medicines from 
White patients.8 However, it is not known to what extent these beliefs impact on medication 
adherence in RA. The South Asian population represents one of the largest minority ethnic 
groups in the UK, comprising over 4% of the UK population.9 To fully engage patients from 
this minority ethnic backgrounds in RA management, it is important to know how health 
beliefs interact with perceptions about the disease and medicines used to treat it. This 
research was therefore designed to look at the factors and behaviours affecting medication 
adherence amongst South Asian compared with White British RA patients.  
This chapter provides a definition of RA and its epidemiology, the clinical features of RA, 
management of RA, the team approach to the patient’s journey in the clinic and the sociology 
of health and illness in the context of RA. It also defines adherence, examines adherence 
measures and provides a literature review on the benefits of adherence. Views about 
medicines through theoretical models are explored and the relationship between ethnicity and 
RA is discussed. The chapter concludes by setting out the aims and objectives of this thesis.   
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1.1 Definition of rheumatoid arthritis  
RA is a chronic inflammatory disease of whose aetiology, is incompletely understood. It is 
characterised by a symmetrical, peripheral, erosive polyarthritis, with multi-system 
involvement.10  
1.1.1 Epidemiology of rheumatoid arthritis 
In the UK, RA affects approximately 400,000 people and is more common amongst 
women.11 RA has an estimated prevalence of 0.5-1%, with a geographical variation around 
the world.12 Although the causes of RA have yet to be fully determined, mechanisms that 
contribute to the persistence of inflammation and to joint destruction have been relatively 
well characterised.13 The chronically inflamed joint is a complex environment in which T 
cells, B cells, macrophages and fibroblasts interact through direct cell contact and through 
secreted cytokines to drive persistent inflammation and bone and cartilage destruction 




Diagram 1: Illustrating normal and damaged joint  
 
1.1.2 Clinical features of rheumatoid arthritis  
The start of the disease is usually insidious but can be acute.10 RA usually presents as a 
symmetrical polyarthritis affecting particularly the small joints, such as the 
metacarpophalangeal and proximal interphalangeal joints. Early disease is characterised by 
pain and other features of inflammation, such as heat, swelling, and loss of function.14 If the 
disease remains active and uncontrolled, the inflammation (synovitis) will usually spread to 
additional joints and gradual irreversible tissue damage will occur, causing deformity and 
instability of joints.15 There are a number of laboratory tests that can assist in diagnosing RA 
(Table 1). In addition, plain radiographs and other imaging modalities are also used to help 
detect or exclude synovial inflammation and joint damage.    
16 
 
Table 1. List of blood tests used in the diagnosis of RA 
 Rheumatoid Factor   
Anti-cyclic citrullinated protein antibody  
Erythrocyte sedimentation rate (ESR) 
C-reactive protein (CRP)  
 
1.1.3 Imaging 
Plain radiographs of hands may show swelling of soft tissue, loss of joint space, erosions or 
peri-articular osteoporosis. Erosions typical of RA can develop within the first year following 
the onset of the disease.16 More recently, there is evidence to suggest that the use of 
ultrasound in RA patients helps to detect more inflammation than is felt on examination and 
seen on radiographs.17 The synovial vascularity is measured by power Doppler. Ultrasound 
has been shown to be an objective measure that adds value to clinical examination both in 
improving the early diagnosis of RA and in establishing true RA remission.18 Many studies 
have led to the conclusion that outcomes are improved when clinical assessment is 
complemented by imaging assessment in guiding therapeutic decisions.17 Current evidence 
suggests that ultrasound may be better at detecting erosions than plain radiographs alone 
therefore, acting as a guide for treatment escalation.19 Furthermore, there is evidence to 
suggest that patients prefer ultrasound to Magnetic Resonance imaging (MRI).20 Patients 
have reported feeling claustrophobic during MRI examinations and were found to be 
dissatisfied with the procedure.    
1.1.4 Management of Rheumatoid arthritis  
Drugs that have the capacity to alter disease processes in RA and to moderate the natural 
history of the disease, for example slowing radiological disease progression, are known as 
17 
 
disease modifying anti-rheumatic drugs (DMARDs)21. Drugs in this class (Figure 1) include 
methotrexate and sulphasalazine. Furthermore, anti-tumour necrosis factor (anti-TNF) drugs 
(e.g. adalimumab, etanercept and infliximab), rituximab, tocilizumab and abatacept have also 
proved very effective in suppressing the disease process Methotrexate, given alone or with 
additional DMARDs, is recommended as optimal treatment for RA patients, assuming that 
there are no contraindications to this drug.22 The use of methotrexate plus anti-TNF is 
suggested in those patients who show insufficient response to methotrexate or other 
DMARDs.23;24 The combination of methotrexate together with anti-TNF has been shown to 
reduce disease activity, improve joint function and reduce the rate of radiographic 
progression.25;26 For example, patients treated with infliximab in combination with 
methotrexate were reported to have better response in terms of disease control compared with 
those who received infliximab alone: median 16.5 versus 2.6 weeks (p=0.006).27 In another 
study, adalimumab used with methotrexate was shown to be superior to adalimumab alone: 
62% of patients were reported to have achieved an American College of Rheumatology 50 
(ACR50) response on this combination compared with 41% on adalimumab alone; 
furthermore, fewer erosive changes were noted in the combination group (p=0.001).28 In a 
separate trial where etanercept and methotrexate were used, the study reported a higher 
response rate with the combination than when using etanercept alone: ACR50 86% versus 
75%.29 Whilst these studies demonstrate the beneficial effects of these treatments, these 
treatments are known to have high risk of side effects.30 Despite the efficacy and cost 
effectiveness31 of these treatments, evidence suggests that the reason for patients 
discontinuing methotrexate was mainly due to side effects: this was the case in 10-77% of 
patients after 3 to 12.7 years of use.25;28;29;32 This suggests that patients’ experiences of taking 




Figure 1: DMARDs and biologic drugs commonly used to treat RA.  
Name of DMARD Indication for use 
Methotrexate  Initial DMARD  
Hydroxychloroquine  Often used in combination with methotrexate 
or when methotrexate contraindicated  
Sulphasalazine Often used in combination with methotrexate 
or when methotrexate contraindicated 
Leflunomide  Alternative to methotrexate or combination with 
methotrexate 
Anti-tumour necrosis factor drugs  
Etanercept  Failed prior to DMARDs 
Adalimumab Failed prior to DMARDs 
Infliximab Failed prior to DMARDs 
Tocilizumab Failed prior to DMARDs 
Other agents   
Rituximab Failed prior to DMARDs and anti-TNF 
Abatacept Failed prior to DMARDs and anti-TNF 
 
1.2 The team approach to the patient’s journey in the clinic  
Most people with RA cope better if they understand their disease and the need for therapy.35 
The main objectives of clinical intervention are to reduce symptoms including pain, slow the 
rate of disease progression and enable the patients to maintain as near normal a life as 
possible. In general, a typical rheumatology team is multidisciplinary and includes a 
rheumatologist, nurse specialist, physiotherapist, occupational therapist, podiatrist, 
pharmacist, surgeon, general practitioner, psychologist and supporting organisations such as 
Arthritis Research UK and the National Rheumatoid Arthritis Society.11 The aim of the 
rheumatology team is to provide holistic care to patients.36 Studies in RA show that a 
multidisciplinary approach is associated with lower healthcare costs and better patient 
satisfaction.37;38   
Once the diagnosis is confirmed, it is imperative, to establish a treatment plan with patients. 
As well as understanding the disease process and associated symptoms, patients should be 
motivation to be actively involved in formal physiotherapy exercises and be ready to make 
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lifestyle changes.39 The rheumatology team members are described below to indicate their 
role in the management of RA.  
1.2.1 Rheumatologist  
The rheumatologist is trained to make diagnoses, estimate the prognosis, and then balance the 
possible hazards of treatment against their likely benefits. Amongst other things the role of 
the rheumatologist is to seek causal relationships of the disease and decide on treatment plans 
in collaboration with the patient11.  
1.2.2 Nurse Specialist  
There is growing interest in health promotion for RA patients1;11 and nurse specialists play a 
key role in this.11 A study demonstrated that nurse-led clinics had a better effect on disease 
control40 than did a rheumatologist clinic. In addition, the authors found nurse-led care had a 
better effect on health status and coping with RA compared to a rheumatologist clinic.40 
Another study reported economic benefits of nurse-led care.37 Nurse specialist clinics play a 
vital role by educating patients about their disease and drug therapy, monitoring drugs used in 
RA and acting on symptoms that require urgent attention.38 Even simple analgesics have side 
effects and non-steroids anti-inflammatory drugs and immunosuppressive drugs may lead to 
more severe side effects.41 The aim of monitoring patients on immunosuppressive drugs is 
firstly to measure clinical improvement and secondly to detect and reduce the risk of 
toxicity.42;43 To fully engage patients in disease management, the challenge remains to 
understand patients’ experiences and health beliefs.11 These concepts are thought to be rooted 
in patients’ social environments.44 Some authors have argued that nurses are unlikely to 
achieve good health outcomes unless they have an adequate understanding of the factors that 
hinder effective disease management.11 Thus, if good disease outcomes are to be achieved, 
nurses need to explore the barriers that patients may face in engaging in disease management 
and develop and align interventions to overcome these barriers. It has been argued that 
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patients’ psychosocial backgrounds needs to be explored in detail.3 Section 2.0 will discuss 
the social factors influencing patients’ disease management.  
1.2.3 Physiotherapy  
As well as medication, many patients with RA benefit from physiotherapy.45 Since the 
fluctuant disease can lead to restriction in joint movement, exercise has a number of benefits 
for patients such as strengthening muscles, maintaining  a full range of joint movements, and 
further combating RA-related fatigue.39 It is widely recognised that RA patients tend to be 
less active compared to the general population.46 De Jong et al47 demonstrated that an 
intensive exercise programme significantly improved functional ability in patients with RA. 
That study showed that RA patients who took part in either aerobic or muscle strengthening 
exercise had less pain compared to the control group and had better functional ability. 
However, patients’ behaviour towards exercise varies.48 Studies have documented that 
patients’ motivation, social support, stress levels and attitudes towards exercise influence 
exercise behaviour.49 Many patients have been found to think that exercising with a joint 
disease might damage their joints.50 Studies looking at the effect of exercising on joints offer 
promising conclusions.51 In a randomised control trial51, long term high intensity 
weightbearing exercise was shown to be effective in increasing physical capacity and 
improving the emotional state of RA patients. In addition, that study examined bone integrity; 
interestingly, no additional damage to large weighbearing joints was found. Views about 
exercise amongst South Asian patients with RA are yet to be explored.    
1.2.4 Occupational therapist 
There is an increasing awareness of disability and economic costs related to RA.11 The 
National Audit Office Report on services for people with RA11 encourages rehabilitation in 
RA patients, and importantly, encourages the development of strategies to allow patients to 
stay in employment. Patients, particularly those with severe arthritis, should be offered early 
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occupational therapy assessment and subsequent follow-up.45 A randomised controlled trial 
has shown that joint protection reduces pain and early morning stiffness and improves 
functional ability in RA patients.52 However, patients’ perceptions about wearing splints have 
been noted to act as a barrier.53 Studies further report low adherence to advice on wearing 
hand splints.54 Data on views about wearing wrist splints in South Asian RA patients are not 
available.   
1.2.5 Orthopaedic surgeons 
Orthopaedic interventions, including joint replacement surgery, are required for some patients 
with RA.1 The main benefits of surgical intervention include pain relief and improvement of 
joint function.11 Increased pain and immobility of joints are known to cause depression in 
patients and decrease their self-confidence.11 Although surgical intervention is one way to 
relieve pain for some patients, there is evidence that some patients use alternative options 
prior to considering surgery (such as glucosamine supplements or fish oils).55 There is  
extensive literature to suggest an improvement in quality of life after joint replacement.56 A 
study showed significant improvement in physical activity and social life and found better 
psychological and emotional well-being in patients following surgery.56 Another study 
showed that physical and mental health were linked to patient expectations of improved 
abilities in daily activities.57 Furthermore, patients were found to have higher expectations for 
recovery.57 Some studies56 suggest that the prospect of decreased pain, increased functional 
ability and improved quality of life are compelling reasons why patients choose surgical 
intervention.58 Mahomed et al58 concluded that health professionals need to be aware of the 
patients’ high expectations and explain both risks and potential benefits to them in order to 
avoid disappointment that might occur after surgery. Whilst surgery is highly beneficial in 
selected cases, it must be stressed that a central objective of the current approach to the 
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medical management of RA is to prevent joint destruction and therefore avoid the need for 
joint replacement surgery altogether.   
1.2.6 Supporting organisations 
Several organisations (e.g. the National Rheumatoid Arthritis Society and Arthritis Care) 
exist to support patients with arthritis59;60  Many patients find it helpful to meet people with 
similar problems. Rheumatology departments are equipped with information about support 
groups, diseases and their treatments.1 While there is a great deal of interest in engaging 
charitable organisations as part of patient care, they have yet to reach the heart of some ethnic 
communities. One local charity in Birmingham (Birmingham Arthritis Resource Centre-
BARC) is a unique educational and support resource to improve self-care and understanding 
of arthritis and musculoskeletal conditions. It was based on a formal needs assessment to 
serve Birmingham’s diverse community.61 The BARC service has been shown to benefit 
patients, including those attending rheumatology clinics.62 
1.2.7 General Practitioner  
General Practitioners (GPs) play a major role in referring patients with a new onset of RA 
symptoms to secondary care for prompt treatment initiation (section 1.1.4).63 However, 
evidence suggests that people with RA symptoms can be reluctant to seek help from their 
GPs.64 In a qualitative study looking at the reasons of delay amongst twenty-four patients64 it 
was revealed that patients attributed their delay in help seeking to their experience of 
symptoms, symptom evaluation, knowledge of RA, experience of and attitudes towards 
health care providers to seek medical care.64 In a separate qualitative study of ten South Asian 
RA patients65, the themes appeared similar to those found among White British patients with 
many highlighting that initially they had paid little attention to their symptoms hoping that 
they would go away. Most South Asian patients had specific beliefs as to the cause of their 
symptoms that were frequently related to physical or other environmental factors: the 
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identification of an often relatively harmless cause for their symptoms frequently led to delay 
in consultation. Further that study reported two cases where a family member had suggested 
that the disease represented a curse: this suggestion hindered rapid presentation. Therefore, 
general practices are an important source for raising awareness about RA related symptoms.  
The burden of rheumatological conditions is increasing and there is a drive towards an 
exploration of new models of care for patients with RA.66 The enhanced role of the GP in 
managing patients with RA is in line with the government’s desire to transfer aspects of 
chronic disease management from secondary care to the primary care setting.67 In the context 
of RA, Quality Outcomes Framework (QOF) indicators for GPs to monitor RA patients’ 
cardiovascular risk were included.68 However, recently revised QOF indicators for 2014-15 
do not include the management of cardiovascular risk in RA patients.69 The original aim of 
the QOF indicators was to manage the cardiovascular risk associated with RA. Tighter 
control of RA not only results in less joint damage but may also help to improve 
comorbidities such as cardiovascular disease (CVD).70;71 Studies reveal that patients suffering 
with RA will have added co-morbidities.72 Moreover, musculoskeletal conditions, such as 
back pain, lead to approximately 7 million GP consultations per year73 adding a huge 
pressure to GPs’ workload. One of the key reported comorbidities of RA is depression:74 the 
prevalence of depression observed in RA patients (13-42%) is higher than that observed in 
the general population and is similar to that seen in patients with diabetes.74 In RA, two 
possible mechanisms have been suggested to explain the development of depression. Firstly, 
disability resulting from RA prevents patients from functioning in the way they used to, 
therefore, generating feelings of loss and depression.75 Secondly, the disease’s acute flares 
may promote sickness behaviour.76 For GPs, the added challenges of looking after RA 
patients are further complicated by lower socioeconomic factors.77 Different studies have 
reported that RA patients of low socioeconomic status (education, occupation) had a worse 
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outcome in terms of disease activity, functional disability, pain, mental health and quality of 
life.78;79 GPs therefore, play a major role in balancing different aspects of patient care in RA.   
1.3 Sociology of health and illness in the context of rheumatoid arthritis  
An overview of how health and illness interact within a social context is presented in this 
section to illustrate how social interactions impact on patients with RA. 
A number of hypotheses have been proposed to explain the ways in which individuals 
attempt to make sense of the problems that arise following the onset of illness and or 
individuals’ responses to their symptoms. These hypotheses are based, predominantly, on 
studies focussed on social and psychological cognitive approaches and these will be 
discussed here.  
The term “disease” is defined as abnormalities in the structure and functioning of the organs  
notion that maps onto the biomedical model.80 However, sociologists favour the view that 
illness should be defined as the individual’s experience of disease,81 dependent on amongst 
other factors, their cultural background.82;83 Pioneering work by Bury82 highlighted that 
patient experiences are not only influenced by the social context in which individuals live but 
also by the nature of their symptoms. For example, stigma and discrimination about chronic 
illnesses such as diabetes and RA which can lead to disability, are noted to be more of an 
issue in certain cultures.84;85 In turn this stigma may influence experience of illness and 
coping strategies. This notion that there is a relationship between illness and how a culture 
perceives it is at the heart of the health belief model.86-88 Moreover, this model helps to 
identify the extent to which the individual is motivated to change their health behaviour by 
assessing their belief as to whether they have control over the management of their 
condition.89 A change in bodily function is portrayed differently within various cultural 
groups. For example, amongst South Asian populations, both in India and in the UK in the 
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1980s 89 and more recently90 certain diets and indeed particular medicines are seen to either 
promote “heat” or release “cold”, an imbalance between which is believed to harm the natural 
harmony of the body.89 It is believed that such imbalances within the body can be restored 
with traditional diets or by making use of complementary medicines.89 Previous work 
conducted in Birmingham, UK, has shown that patients of South Asian origin with RA view 
alternative medicines and traditional diets as having fewer side effects compared to western 
medicines.91 
Sociologists argue that most views about illnesses and their management are related to 
patients’ health beliefs.81 It is argued that health beliefs are rooted in wider socio-cultural 
contexts and understanding patients’ interpretations of the meaning of “health” and health 
beliefs is important so that these can be mapped onto disease management,92 in which the 
patient plays an important role.93 The understanding of lay health beliefs can be beneficial in 
many ways in chronic disease management.94-96 For example, it is thought that it can promote 
good professional-patient interaction.97;98 It can benefit the promotion of health and most 
importantly can help to counter some patients’ fatalistic views of disease causation and 
encourage positive interactions with the health care system.93 
It is well documented that the health care system is under-utilised amongst some ethnic 
groups.99 Studies have shown that patients may not recognise their disease related symptoms, 
and as a result, may delay seeking appropriate medical help, as reported for patients with 
RA.65;100 While some studies in rheumatology highlight the delay in help-seeking behaviour 
amongst South Asian patients,101 others have reported differences in lay beliefs about 
medicines between ethnic groups, which could potentially be detrimental to medication 
adherence in RA.102 
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Sociologists argue that better understanding of lay beliefs is vital in order to improve patient 
care, particularly in certain ethnic groups.93 For example, patients of South Asian origin are 
more likely to hold fatalistic views on illness causation.103 These concepts have been reported 
in South Asian patients with RA, many of whom believed that the occurrence of RA was due 
to an act of God.91 The data from a UK study suggests that South Asian RA patients who 
interpret the cause of the disease as a biological one, had different views about treatments to 
those who interpret their disease as being caused by fate, God or Karma.91 
In summary, the existing evidence suggests that patients’ views about illness and health 
beliefs in relation to disease causation are related to which treatment they use. Furthermore, 
these lay health beliefs vary among different ethnic groups. The existing data suggest that this 
variation is mainly accounted for by the social and cultural context to which each individual 
belongs. Since this thesis is structured around illness beliefs, these concepts will be discussed 
further in section 1.6.  
1.4 Adherence: definitions, measures, and literature review of benefits of adherence 
1.4.1 Defining adherence 
This section reviews definitions of medicine taking behaviour and describes different types of 
non-adherent behaviour. Methods of measuring adherence behaviour will be discussed. 
Finally, literature on the benefits of adherence and the consequences of non-adherence in RA 
and other chronic diseases will be presented.  
Patients’ medicine-taking behaviour has been referred to in a number of different ways in the 
literature. These include ‘adherence’, ‘compliance’ and ‘concordance’.104 These terms can be 
applied to patients’ actions towards, for example, not initiating treatment, not taking 
medicines as prescribed and terminating treatment prematurely.105 
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The World Health Organisation (WHO) has promoted the use of the term ‘adherence’ in 
chronic illness, as it denotes a willingness to take medicines.104;106 The term ‘adherence’ in 
this thesis is applied specifically to medicine-taking behaviour104. This term involves “the 
extent to which the patient’s behaviour matches agreed recommendations”98 (p 13). Here, 
adherence focuses on the agreement between the Health Care Professional (HCP) and the 
patient.107  
Before focusing on the term ‘adherence’, however, it is important to mention other 
overlapping terms. In the 1950s the term ‘compliance’ was widely used. This term was 
defined as “as the extent to which the patient’s behaviour coincided with the health 
professional’s advice” (p 13).98 This phrase has been criticised by authors such as Horne98 as 
it implied that the HCP held more control over medicine-taking than the patients. During the 
1990s, the concept of concordance was introduced.108 This concept drew attention to the 
relationship between the HCP and the patient in reaching clinical decisions. Here, it was 
suggested that the patient’s values and beliefs about medicine-taking were to be discussed 
and considered when prescribing medicines.109 Underlying the principles behind concordance, 
patients may expect that their views will be elicited before medication is prescribed and that 
they may contribute towards the development of a treatment plan, which they would then be 
expected to work towards achieving. Satisfaction with information about medicines110 and 
satisfaction with the HCP and patient relationship may be an outcome which distinguishes an 
adherence-based approach from a concordance approach.111 Part of the HCP’s role within an 
adherence-based approach is to provide information about treatment (which may enhance 




Philosophically, adherence and concordance are different ways of expressing autonomy and 
patient-HCP interactions.104;112 However, in reality the two terms are frequently used 
interchangeably, often because they can both be applied to the same behaviours113 and both  
measure the degree to which medicine-taking (or other health-related behaviour) diverges 
from the instructions of an HCP. The underlying assumption of many healthcare interactions 
is that deviations from HCPs’ recommendations (as long as the diagnosis and prescription are 
correct) will lead to an increased probability of adverse consequences.98 The term ‘adherence’ 
is used from here onwards to describe the degree to which a person takes medicines as 
prescribed by an HCP.  
1.4.2 Types of non-adherence 
Adherence, like many other health behaviours, is a dynamic and multi-faceted concept. 
Researchers have sought to categorise the range of behaviours that could be regarded as non-
adherent. Two categories of behaviour have been identified: intentional and unintentional 
non-adherence.114;115 Intentional non-adherence may be a behaviour driven by reasoned 
decisions about medicines. These decisions are based on beliefs, personal circumstances, 
interpretations of healthcare advice and a person’s motivation to take medicines. 
Unintentional non-adherence reflects a person’s ability at medication taking. The most 
commonly cited reasons behind unintentional non-adherence are forgetting, lack of manual 
dexterity, losing medications and not being able to afford medicines.116 Intentional non-
adherence is thought to be driven by beliefs and preferences, whereas unintentional non-
adherence may be more strongly associated with demographic (such as age) and clinical 
factors (such as time since diagnosis).117 
However, the picture is complex. Links between intentional and unintentional non-adherence 
behaviours are theoretically possible: for example, a person’s motivation to be adherent may 
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influence their ability to remember to take their medications.118 Also, Clifford et al114 
hypothesised that a person may report both intentional and unintentional non-adherence to the 
same medication at different times.114 Furthermore, intentional and unintentional non-
adherence may vary depending on the number of medications a person is prescribed.98   
1.4.3 Measurement of adherence  
Accurately measuring adherence is important for researchers; however, to date, there is no 
gold standard measure of adherence.119 Essentially, the tools that measure adherence can be 
categorised by [1] what they measure and [2] how they measured it. Literature reports that 
adherence tools seek to obtain different information on medication adherence;120 for example, 
barriers to medication adherence,121 beliefs associated with adherence122 and medication-
taking behaviour123. There are a range of measures described in the literature124 including 
self-report questionnaires, drug assays, physician estimates, prescription filling and electronic 
medication monitors. There are two broad categories of adherence measures:125 direct and 
indirect. Direct measures include drug assays and the use of drug biomarkers.126 Indirect 
measures include pill counts, use of electronic monitoring devices and review of prescription 
records and self-report. For example, within the UK, pharmacy/prescription refills may be 
classified as a indirect measure if informed consent is sought for a prospective study. 
However, pharmacy/prescription refills may also be direct where retrospective information is 
collected about previous pharmacy records and prescription use.126 The following are the 
methods of measuring medication adherence: 
Prescription-filling observations are an indication of adherence intentions at the time when 
the prescription is dispensed. However, a prescription filled is not a medicine taken: for this 
reason, prescription filling is not a direct adherence measure (although it provides an 
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indication of adherent behaviour).127 Furthermore, this method is unable to measure 
unintentional non-adherence.  
Electronic Medication Monitors (EMMs)128 record the date and time at which a medication 
container was opened, obtaining a chronological measurement of medication adherence. 
However, EMMs are expensive and time consuming to administer correctly; also, a review of 
EMM use found inconsistent reporting of data129. Average adherence, daily under-dosing, 
late dosing and premature timing were methods used to report non-adherence using EMMs. 
Also, EMMs cannot determine whether a medication has been ingested and a study found 
that 75% of people used EMM devices incorrectly and some people divulged that they 
removed more than one dose at a time.130 
Drug assays and biological medication markers measure the concentration of a drug within 
the blood, saliva or urine.127 A drawback to this measurement is that there are individual 
differences in metabolism and few drugs can be monitored in this way. There is also a 
suspicion that people may over-adhere in the days before the test (known as ‘white coat’ 
adherence).127 
A variety of self-report measures have been developed, mainly questionnaires, although 
interviews and diaries are also self-report formats.110;131 Garber and colleagues reviewed 
these measures across the adherence literature.132 Questionnaires and diaries had the best 
relationship with EMMs, while data obtained from interview methodologies showed the 
greatest amount of unexplained variance.133 The unexplained variance found in interviews 
may be due to increased social desirability bias brought about by face-to-face contact.119 
However, interviews produce rich accounts of data, and would naturally cover topics not 
identified by other methods. Furthermore, it is unreasonable to compare interview methods 
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with quantitative methods of adherence assessment, as they originate from a different 
research philosophy.110;131 
Questionnaire measures of adherence are quick to administer and are also relatively 
inexpensive, aspects that make them attractive for large surveys.132 Postal questionnaires can 
also be anonymised, allowing confidentiality to be assured this can help to reduce social 
desirability bias. A drawback to questionnaire measures is the problem of missing data, as 
patients may not complete the entire measure. Finally, the response rate for questionnaire 
measures can be problematic, especially for unsolicited postal surveys.134;135 
Self-report methods have been criticised for their lack of objectivity and the potential to be 
influenced by extraneous factors.136 For example, patients who are suffering from depression 
are less likely to self-report medication adherence and/or less likely to accurately remember 
their doses taken.133 Social desirability is a drawback to self-reported adherence measures.136 
People may be reluctant to disclose non-adherence and present themselves in an unfavourable 
way. Lie scales ask questions or statements which are framed in an extreme way, making a 
positive response unlikely (i.e. ‘I have never missed a dose of any of my medications 
ever’).137 A popular adherence questionnaire is the Medication Adherence Report Scale 
(MARS).138 The questionnaire has six items and uses a five-point Likert scale to assess the 
frequency of self-reported adherence for each item. The responses to the scores can be 







Table 2. The six-item Medication Adherence Report Scale  
 MARS questionnaire items  
Statement 1 I forget to take them 
Statement 2 I alter the dose 
Statement 3 I stop taking them for a while  
Statement 4 I decide to miss out a dose  
Statement 5 I take less than instructed  
Statement 6 I take more than instructed  
 
The MARS was originally validated in people diagnosed with asthma, chronic obstructive 
pulmonary disease, diabetes and renal failure.139  
1.4.4 Adherence and non-adherence in chronic diseases  
The fundamental premise of a treatment plan involves the recognition of two entirely 
different roles played by medication: [1] drugs which simply relieve symptoms and [2] 
disease modifying drugs which modify the disease process.15 In a patient’s view relieving 
symptoms may be the preferred choice but the alternative view of the HCP may be that the 
disease modifying drugs have a preventive role in modifying long term disease related risks. 
A number of studies have demonstrated clinical benefits of adherence in a range of chronic 
diseases.98  
This section discusses medication adherence in cardiovascular disease and diabetes and links 
to Chapter 2 which discusses issues related to South Asian patients; subsequently the clinical 
benefits of adherence and consequences of non-adherence in RA are discussed.  
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The WHO estimates that in patients with chronic disease, 50% of medicines are not taken as 
prescribed.104 One review reveals that adherence to medicines is greater for short-term 
regimens when acute conditions are being managed.124 Studies show that if patients’ 
frequency of treatment is lower, or it is of shorter duration, or it has lower levels of side 
effects, then the likelihood of patient adherence is high.140 The clinical benefits of adherence 
include improved treatment effectiveness, reduced morbidity, reduced hospital visits and 
reduced monetary costs to the healthcare system.105 In a study that examined the adverse 
consequence of non-adherence on hospitalisation and healthcare costs across four chronic 
illnesses (diabetes, hypertension, hyperlipidaemia and heart failure) in elderly patients141 it 
was found that higher levels of non-adherence were related to an increased risk of 
hospitalisation and a significant increase in medical and drug-related costs.  
In a cross-sectional survey of patients with type 2 diabetes, adherence to medicines was not 
correlated with quality of life.142 Greater knowledge about illness and medicines and a 
positive attitude (assessed through a semi-structured interview) on the other hand did 
correlate with quality of life.143 It is possible that non-adherence may represent a person’s 
attempt to achieve their goals and preserve their quality of life; therefore, no relationship 
between quality of life and adherence would not necessarily be expected.  
Patients who take fewer risks have been found to live longer,144 and adherence to medicines, 
as long as the prescription is correct and safe, is a low-risk behaviour.144 Adherence may, 
therefore, be a component of a healthy lifestyle.145 To examine this theory, Horwitz and 
colleagues146 measured adherence, disease severity, socio-demographic factors, smoking, 
psychological characteristics, stress and social isolation during a randomised controlled trial. 
However, the adherence effect was not accounted for by any of the socio-demographic 
variables measured. The adherence effect remains unexplained by lifestyle factors; however, 
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as in RA, the role of beliefs in explaining this effect has not extensively been explored. For 
example, authors have theorised that patients who adhere may anticipate beneficial health 
outcomes from their actions, and experience better health as a result of the self-fulfilling 
prophecy (a prediction that, in being made, actually causes itself to become true).147 
Therefore, adherence to medicines may give patients ‘hope’ that their condition will improve.  
The positive cognitions and effects associated with adherence may lead to the anticipated 
health benefits appearing. This may be reflected in a person’s adjustment to his or her illness 
and treatment. Those who are more accepting and adjusted to their condition and treatment 
may behave in a way that reflects their cognitions, potentially engaging with the self-
management ethos98 and allowing their treatment to have an optimal effect. The beliefs a 
person holds about his or her illness and treatment may have beneficial consequences for 




1.4.5 Adherence and non-adherence in rheumatoid arthritis  
As discussed in the previous section, medication adherence is central to good clinical 
outcomes. In RA, the first few weeks of treatment are occupied with the search for the ideal 
symptom relief while subsequent treatment proceeds with a view to long term prevention of 
joint damage.15 A more aggressive approach to the treatment of RA is more widely practised 
today than ten years ago:23 however as mentioned in section 1.1.4, DMARDs medications do 
have a significant potential for side effects.25;28;29;32 This section presents an overview of 
specific research which has found adherent behaviours to be of clinical benefit in RA. The 
benefits for people with RA taking medicines include reduced disease activity and 
radiological damage and improved long-term functional outcomes.3;149 
Non-adherence in patients with RA has been shown to be associated with disease flares and a 
significant level of disability.150;151 Remission of disease in RA can be measured using 
recommendations made by the European League Against Rheumatism (EULAR), in which 
patients’ disease activity (DAS28) is scored and if scores remain under 3.6, this is viewed as 
low disease activity with a score of 2.6 or below being viewed as disease remission.150 
Evidence from clinical trials of DMARDs, shows a reduction in disease activity thus resulting 
in clinical benefit.152-154 Like other chronic diseases, non-adherence is also documented to be 
an issue in rheumatology.3;155 Overall, the rate of adherence in chronic conditions is estimated 
to be lower (50%) than it is in acute conditions.156 This is compared to 20-40% of medicines 
for acute conditions not being taken as prescribed.3;149 Unlike drugs such as analgesics, 
DMARDs do not lead to rapid symptom relief. Since the benefits of DMARDs are not 
apparent for the first two to three months,15 a person may lose his or her motivation to keep 




Studies in RA show some links between non-adherence and sociodemographic factors for 
example, age, gender, education, social support, and marital status.3 Studies have found that 
older age is associated with better adherence however; others have reported younger patients 
to be better adherers. Furthermore, it is likely that within the study design a broad spectrum 
of ages may not have been collected.150;151;157 Better educated people have been shown to 
make more use of resources that help them to weigh up the risks and benefits of medication 
adherence158 Those with extensive social support have been suggested to have higher 
motivation to take medicines.157 Other studies report that gender, education and marital status 
do not influence adherence.155 A study conducted amongst the Dutch population.158 looking 
at “compliance” (the term used in the paper) with sulphasalazine in 65 RA patients revealed 
that there were no significant differences in patients’ adherence levels between the patients in 
the control group (who received a single brochure) and in the experimental group (who 
received a patient education pack). Moreover, they suggested that active RA disease might 
have motivated patients to take sulphasalazine. Similar results were shown in another study159 
conducted amongst 175 RA patients. That study reported that patients’ main incentives for 
taking their medication were based around their perception of disease severity for example, 
duration of early morning stiffness. Furthermore, patients who had little or no active 
inflammation as measured by Erythrocyte Sedimentation Rate were less compliant. 
Interestingly, social characteristics had no impact on medication adherence in that study. 
Receiving increased patient education has been shown to improve adherence levels in RA 
patients in a UK study.35 The authors found a drop in CRP and lower self-reported pain 
scores in patients who had received an education pack.  
A study conducted by de Klerk et al160 investigated medication “compliance” in patients with 
RA, polymyalgia rheumatica, and gout. The authors found that less frequent dosing was 
strongly related to better compliance. A study reported by Agrawal et al161 demonstrated that 
37 
 
patients in India had fewer side effects to methotrexate when prescribed alone better than 
when it was used in combination with other DMARDS. In that study patients who were more 
likely to discontinue their treatments were housewives, those who were worried about side 
effects and patients with lower levels of education. Studies of RA and Lupus patients of 
White, African American and Hispanic origin showed a statistically significant difference 
between the ethnic groups in skipping medications.162 The African American patients 
believed that the drugs were harmful and felt depressed. The results of that study also 
suggested that a higher level of education is associated with better medication adherence. In 
addition they revealed that patients who had reported more severe side effects showed lower 
adherence and had negative views about medicines; no difference was observed between RA 
and Lupus patients.  
Though the sociodemographic factors show interesting associations with non-adherence, in 
practice studies within a psychological framework appear to offer a better way of 
understanding adherence.3;155 This is because unintentional non-adherence (forgetfulness, 
complicated drug regimens) or intentional non-adherence (cost of prescription health, cultural 
beliefs) can be dependent on an individual’s circumstances.125 Therefore, careful examination 
of a patient’s intentions to take or not to take medications helps to tease out the issues related 




1.5 Summary of the section - adherence and non-adherence in chronic diseases and 
rheumatoid arthritis   
Patients’ medication adherence is affected by many factors in chronic diseases. Studies show 
that high medication adherence can lead to optimal clinical benefits. There seem to be some 
similarities between patients’ views about medicines in different chronic diseases. Non-
adherence, for example in RA patients has been shown to be related to demographic factors, 
level of education and therapy factors such as side effects of medications. However, the way 
in which patients perceive treatments and understand their condition has been highlighted as 




1.6 Understanding views about medicines through theoretical models  
A core element in understanding behaviour is being able to explain why and in what 
circumstances the behaviour occurs.163 Models enable the potential processes behind a 
behaviour to be structured and then empirically tested.164 Many studies have shown a weak 
(or in some cases absent) relationship between demographic variables and adherence.165  
Rather, it has been suggested that one of the most important factors affecting adherence is 
patients’ beliefs about treatment109;166 (section 1.4.5). These will be discussed next.  
A belief is the cognitive linking of an ‘object’ to an ‘attribute’, e.g. ‘inhaler’ to ‘toxic’, 
forming the belief that inhalers contain toxic substances.167 Attitudes include appraisal of 
symptoms and in this respect are similar to beliefs in that they include an evaluative 
component.164 Therefore, a person who believes that ‘inhalers contain toxic substances’ may 
have an attitude that ‘taking inhalers is bad for you’, leading to a behaviour of intentional 
non-adherence. However, before an attitude can be realised as behaviour, it first becomes an 
‘intention’.167 This is a plan to act, at a particular time, with a particular object and in a 
particular context. Psychologically based models such as the Common Sense Model 
(CSM)168 and the Necessity-Concerns Framework (NCF)119 have been applied to adherence 
behaviours169 to help provide an explanation of adherence behaviours. The next section will 
review key psychological models and theories that have helped to inform health professionals 




1.6.1 Self-Regulation Model  
Leventhal’s Self-Regulation Model164 (SRM) (also known as the Common Sense Model - 
CSM)170 proposes that personal models of illness help individuals to make sense of their 
condition-(s). This model provides a framework to define cognitions and emotional reactions 
that lead to illness-related behaviours such as adherence and general self-management.170 The 
model emphasizes five illness cognitions: illness identity, illness cause, illness timeline, 
illness consequences and illness controllability. These cognitions are processed in parallel 
with emotional reactions such as fear and worry about the illness.171 The model describes 
people as problem solvers who go through stages when faced with an illness.  
This involves the interpretation of an individual’s illness, and at this stage, information is 
sought (through symptoms or social messages) to develop a cognitive representation of the 
illness. Weinman and colleagues168 developed the Illness Perception Questionnaire (IPQ) to 
assess the cognitive components of the CSM. A revised Illness Perception Questionnaire 
(IPQ-R)163 was developed later to provide a better representation of the core components of 
the CSM and contained subscales on the coherence of illness beliefs, personal control, 
treatment control, illness timeline (acute vs. chronic), cyclical timeline (e.g. is the illness 
likely to recur and return) and an emotional functioning scale.  
For conditions such as hypertension, which is typically asymptomatic, the beliefs and coping 
strategy adopted can differ from those in more overtly symptomatic conditions.172 The  IPQ 
has been used in one study in RA and has been shown to predict medication adherence.173 
Hughes et al173 found that some of the domains of the IPQ were associated with low and high 
adherence. Since the domains of the IPQ inform the CSM and are more widely used in the 
field of cardiovascular disease research, these are considered next.  
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A study of myocardial infarction (MI)174 showed that MI patients who had more negative 
expectations about their illness and future work capacity were less likely to return to work. In 
another study of MI patients,175 the authors examined the illness perceptions of 143 MI 
patients and found that they were associated with their beliefs about recovering from MI. 
More specifically, patients who believed that their illness was curable or could be controlled 
were more likely to view rehabilitation more seriously. Further work by Copper et al176 also 
found that patients who had negative beliefs about being in control of their MI were less 
likely to attend cardiac rehabilitation. A further advantage of the CSM is that the 
psychological dimensions it describes are potentially modifiable as shown by Petrie et al.177 
For example, the study found that a brief psychological hospital-based intervention could 
change inaccurate and negative illness perceptions of MI leading to improved cardiac 
outcomes.  
Risk perceptions are an important part of the threat that people associate with their condition. 
Perceived threat has been shown to determine the level of engagement in self-management 
activities, including adherence. A questionnaire study of 96 people admitted to a Coronary 
Care Unit in New Zealand following an MI, identified relationships between illness 
perceptions and risk perceptions.178 The level of perceived risk of a future heart attack was 
assessed with three questions. The majority of illness perceptions were related to perceived 
risk of a future MI. Higher risk perceptions were significantly associated with longer 
perceptions of illness timeline, higher levels of emotional distress and higher perceived 
consequences. Higher MI risk perceptions were also related to lower perceptions of personal 
control, lower perceptions of treatment control and lower comprehensibility. Perceptions of 
concern and identity (symptoms) were not related to MI risk perceptions. This research 
highlights the important role that illness perceptions may play in self-management, especially 
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as the relationship between illness perceptions and risk perceptions has been shown to be 
significant for six out of eight types of illness perception.178 
1.6.2 Treatment Necessity-Concerns Framework 
Two categories of treatment perceptions have been identified: general beliefs about 
medications and beliefs about specific medications.125 General perceptions relate to beliefs 
about medicines as a category of treatment. General beliefs include perceptions about the 
‘General Harm’ that medicines cause and perceptions about ‘Overuse’.138 Specific beliefs 
about treatment cover both beliefs about the ‘Necessity’ of that particular treatment and 
‘Specific Concerns’ about it. Horne125 reviewed research on treatment beliefs and identified 
two core themes: perceptions of treatment Necessity (personal need for treatment) and 
concerns about treatment. Treatment necessity beliefs are perceptions about personal need for 
medication for both current and future health. Examples of treatment necessity beliefs include 
beliefs about the effectiveness of medicines or whether missing medications would have a 
negative impact on health. Concerns about medicines arise from beliefs about the potential 
negative effects of a medication. The Necessity-Concerns Framework125 suggests that 
treatment concerns do not influence perceptions of treatment necessity. Therefore, strong 
treatment necessity beliefs can often be accompanied by strong treatment concerns. 
Treatment beliefs are suggested to influence adherence alongside illness cognitions. 
It has been suggested that beliefs about treatment run in parallel to beliefs about illness. 
Similar to the SRM, the Necessity-Concerns Framework specifies that an emotional response 




The Beliefs about Medicines Questionnaire (BMQ) assesses perceptions of medication 
necessity and perceived concerns about medicines.139 The specific treatment necessity and 
treatment concern subscales measure personal evaluations of the benefits and costs of specific 
treatment these evaluations can be seen in other cognition models such as the Health Belief 
model or the Theory of Planned Behaviour.167 Research has shown that strong treatment 
concerns and low treatment necessity beliefs tend to predict low levels of adherence, while 
low concerns and high levels of treatment necessity beliefs predict high levels of 
adherence.179;180 Other research has shown that adherence to medicines can also be predicted 
by subtracting the score for treatment concerns from the score for treatment necessity 
beliefs.119  
Horne proposed that perceptions exist about medications as an overall class of treatment: 
these are called ‘general beliefs about medicines’.138 General beliefs include perceptions of 
“over-prescribing” and “harm from chemicals”. It has been suggested that these beliefs 
originate from concerns about chemicals in medicines, addiction, unethical prescribing and 
messages in the media.181 General beliefs have been suggested to indirectly influence 
adherence via specific treatment concerns.138 Also, as general beliefs refer to medicines as a 
classification of treatment, these beliefs may be related to other classes of treatment such as 
complementary medicines or lifestyle interventions.  
Horne suggested that treatment necessity beliefs for chronic illnesses would be high.109 
Furthermore, Horne suggested that the variance and strength of treatment necessity beliefs 
would differ between conditions that were symptomatic and those that were non-symptomatic. 
Therefore, one may anticipate that treatment necessity beliefs correlate with identity beliefs 
(as measured by the IPQ, as this subscale almost exclusively focuses upon 
symptoms).  However, a better understanding of the interplay between representations of 
illness and treatment is needed.  
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Treatment necessity beliefs have been suggested to be better predictors of adherence when 
the medication is for an acute condition, is prescribed in a preventative capacity or is for a 
condition where the symptomatic benefit of taking the medication is not apparent to the 
patients.125  Treatment concerns have been suggested to be the best predictors of adherence in 
chronic conditions. Neame and Hammond34 found that concerns about medicines were higher 
in non-adherent than in adherent RA patients and were associated with feelings of 
helplessness. Patients with higher levels of concern were those who worried about the long 
terms adverse effects from DMARDs. Also, disease severity plays a key role in patients’ 
decisions to either take or not take their treatments.182;183 
Three studies were found which used both the BMQ and the IPQ in Type 2 diabetes or in an 
aspect of CVD.174;184;185 The first was undertaken by Ross and colleagues184 with 514 people 
with hypertension. Alongside the IPQ and the BMQ, the Morisky scale was used to assess 
adherence in this cross-sectional study.184 Treatment necessity beliefs were positively 
correlated with adherence and treatment concerns were negatively correlated with adherence. 
This finding supports the predictions of the Necessity-Concerns Framework. Emotional 
consequences and personal control were negatively correlated with adherence. Therefore, 
higher levels of emotion, the perception of more consequences and greater perceived control 
were related to lower adherence. Treatment control and cure beliefs (when a distinction was 
made between cure and control beliefs) were positively correlated with adherence. Therefore, 
stronger beliefs in treatment efficacy and a belief in control were related to higher levels of 
adherence.  
Barnes and colleagues185 aimed to identify cultural differences in illness and treatment beliefs 
for Type 2 diabetes between patients of European and Tongan descent in New Zealand. A 
cross-sectional sample of eighty two adults completed the IPQ, the BMQ and the MARS. A 
significant positive correlation was found between treatment necessity beliefs and adherence 
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to medicine regimes. A significant negative correlation was found between adherence and 
timeline (cyclical), consequences and causal beliefs.185 
These findings indicate a similarity between Type 2 diabetes and hypertension consequences 
and treatment necessity beliefs. Higher levels of emotional distress, more cyclical beliefs 
about symptoms (frequency of symptoms) and greater external attributions were found 
amongst Tongan patients compared to their European counterparts with Type 2 diabetes. 
Also, the Tongan population sampled had less confidence in the medicines’ ability to control 
their illness. Low levels of adherence among Tongan patients with Type 2 diabetes were 
related to the perception that the medicine was unnecessary. 
Byrne and colleagues174 assessed the role of illness and treatment beliefs in predicting 
adherence to secondary preventative medicines in 1084 adults with coronary heart disease 
(CHD). Illness timeline was found to have a significant and positive relationship with 
adherence. Therefore, the belief that CHD would last a long time was related to higher levels 
of adherence. This is similar to the findings for hypertension reported by Ross and colleagues. 
Also, as found by Ross and colleagues,184 treatment necessity beliefs were significantly and 
positively related to adherence, while treatment concerns were negatively and significantly 
related to adherence.    
Despite the extension of the SRM to explore treatment perceptions, to date the BMQ only 
examines perceptions of medicines; non-pharmacological treatments (i.e. surgery, 




1.7 Summary  
The SRM-CSM and the Necessity-Concerns Framework offer different interpretations of the 
processes behind adherence behaviour. The CSM and the Necessity-Concerns Framework are 
psychological models that attempt to capture people’s experience during illness. Essentially, 
the CSM is an illness psychology model as opposed to a model of health psychology. The 
CSM is a process model, in that it explains the process from cognition to behaviour. The 
CSM goes further by detailing the types of cognitions and emotions involved in this process. 
Recent additions to the CSM’s cognitive content and processes have increased the specificity 
of this model to address adherence behaviours. Developments in health psychology research 
encourage the use of theoretical models such as the CSM. For example, the research 
presented within this section indicates that the context of illness and treatment are important, 
and may interact with perceptions to produce behaviour. It is important to note, however, that 
models such as the CSM and the BMQ have not been widely used in patients from different 
ethnic groups in the context of investigating medication adherence, particularly in South 





This section begins by providing a brief overview on ethnicity and its various definitions. It 
looks briefly at migration and then proceeds to discuss the issues related to RA and South 
Asian patients.  
The need to engage patients from differing minority ethnic backgrounds in the management 
of their RA has long been recognised by the UK rheumatology community.186 However, there 
have been limited studies of patient outcomes amongst South Asians; recent work in 
Birmingham has shown that patients from a South Asian background had more negative 
beliefs about medicines than did White British patients.8 Furthermore, it has been shown that  
South Asian patients delayed seeking medical help for their symptoms for longer than did 
non-South Asians.65 Since these perceptions could be detrimental to clinical outcomes it is 
important to establish patients’ beliefs about medicines and RA.  
The concepts of culture and ethnicity overlap. One of the most widely used definitions of 
ethnic group is “a group of people who identify themselves to an ancestral social heritage and 
a cultural group is “a group of people who share the same values, language, diet and 
religion”187 these definitions were adopted for this thesis.187 In contrast, epidemiological 
research pays greater attention to “biological” features such as race.188 It has been suggested 
that this approach ignores the wider societal context of ethnicity.189 The concept of “ethnicity” 
permits the incorporation of socio-environmental and behavioural factors that are linked with 
differing ethnic groups and may go beyond genetic and biological factors.190;191 The emerging 
view is that ethnicity is fundamentally a matter of self-perception, with boundaries often 
being fluid and imprecise.192 Individuals can be difficult to classify: for example, a migrant 
from the Indian subcontinent could be a member of a particular ethnic group, e.g. Sikh 
Punjabi. However, their children born in the UK may classify themselves differently,193 
perhaps as belonging to a wider group such as Indian, Asian or Black, or as having an 
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additional ethnic identity, such as British, English, Welsh or Scottish. Earlier studies argue 
that ethnic identity may be an aspect of acculturation whereby the focus is on how individuals 
relate to their ethnic group within a larger society194-197 whereas recent research highlights  
that it is how individuals accommodate the beliefs and values of the country they live in and 
their ethnic identity.198 Research including ethnic populations particularly of South Asian 
origin in the context of RA has mentioned the level of acculturation and its relationship to 
self-reported pain.199 It has been suggested that these concepts are important to document 
when conducting research with individuals from different ethnic groups as self-reported 
ethnicity does not necessarily mean that the individual is acculturated in the traditional 
customs of that particular ethnic group. Research into the nature of ethnic identity has been 
widely discussed and reviewed by Gill187 and Bhopal.200  
In the UK, the term ‘Asian’ often refers to an individual with origins in the Indian 
subcontinent.188 Therefore, to avoid confusion, Bhopal proposed that ‘Asian’ should only 
appear in the title of research if the work is generalizable to the whole Indian sub-
continent.188 
1.9 South Asian Migration 
In the contemporary world, there is a great deal of international movement.192 Many people 
have moved in search of better economic prospects and a higher standard of living.201 Among 
the consequences of this migration is the growing cultural and social diversity in the western 
world. An example of this diversity is found in Britain202 which is one of the most multi-
cultural nations, with a substantial and diverse ethnic population.203 There has been a large 
amount of migration into Britain  particularly from India and Pakistan.187 
The Birmingham conurbation had the most rapid growth of any urban area in Britain between 
1911 and 1951.9 High rates of economic growth continued until the early 1970s. This growth 
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was primarily driven by the expansion of the engineering and motor industries and coincided 
with a time of mass migration of ethnic minorities204. Many individuals were recruited 
specifically to work in the region’s industries. At the same time, the inner cities of the West 
Midlands conurbation were losing their indigenous population to the outer areas, so the ethnic 
minority population became the replacement population.204 
The minority ethnic groups therefore became concentrated, relative to the White population, 
in a few local authority wards and typically in certain streets in these areas.205 These 
coincided with areas of relative economic and housing deprivation. Households were living 
in high density (typically more than 1.5 persons per room), in shared dwellings (houses in 
multiple occupation) and there was a high prevalence of males employed in social class V 
(unskilled or labourers). South Asians were far more likely to be self-employed than were 
Whites, particularly people of Indian origin.205 Many South Asians have succeeded in 
establishing themselves in Britain and have achieved considerable upward mobility.187 
Working outside the home is generally frowned upon for many South Asian women, so the 
lower employment rates for women in this group can be partly explained by cultural 
factors.206 
One of the cities that became home for many migrants was Birmingham.205 Birmingham is 
the UK’s second largest city with a population of one million that is almost as great as that of 
Wales,9 containing large concentrations of people from minority ethnic groups. The 
population is made up of people with many different characteristics. These include 
differences in their social, cultural and linguistic features. Accessing health services and 
uptake of screening services has been also noted to be poor amongst South Asian patients.99  
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1.10 Rheumatoid arthritis in South Asians  
Although the prevalence of RA is reported to be the same however, a recent paper shows that 
the prevalence of RA in South Asia has been reported to be lower than in Western Europe 
(Western Europe 0.44% Asia 0.16%).12 There is evidence that the clinical manifestations of 
RA in South Asians may differ207;208 from those seen in European patients. Some studies in 
South Asian patients with RA such as the work of Chandrasekaren and Radhakrishna209 
conducted in the 1980s have suggested that the disease is less severe in Indian populations. In 
contrast, Hameed et al,210 compared clinical features between Pakistani and Caucasian 
patients with RA. The patients in their study were matched for age, sex, and disease duration, 
and it was found that Pakistani patients had higher disability scores. However, the Caucasian 
patients were noted to have more erosive disease. Similarly Griffiths et al208 found that White 
Caucasian patients of northern European origin experienced more severe RA compared with 
South Asian and Mediterranean populations with respect to erosive and extra-articular 
manifestations. That study further documented that South Asians had an equivalent amount 
of inflammation and swollen joints and a paradoxical increase in pain and tenderness, leading 
to a significantly increased level of disability. Other studies looking at inflammatory markers 
between ethnic groups found a difference in ESR.211-214 Barton et al211 looked at disease 
activity scores between ethnic groups and found DAS28 (ESR) scores to be higher amongst 
the Asian and Afro-Caribbean patients compared with those of White origin. In a separate 
study, Greenberg et al215 reviewed a cohort of patients with RA from different ethnic groups 
including, non-Hispanic White, Hispanic, African-American and Asian populations. Similar 
to Hispanic patients, Asian patients were noted to have higher disease activity levels than 
African-American and White patients. The authors drew the conclusion that patients’ health 
beliefs could contribute towards the differences in disease activity and the way they respond 
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to their symptoms. The authors further raised the issue of the limited representation of 
patients from minority ethnic backgrounds who had been studied.216  
There are several fundamental deficiencies in the literature with regard to South Asian 
patients. The first is in the reporting of lower prevalence of RA in the South Asian 
community This is questionable, as there are studies that still report long delays in patients 
seeking medical help216 indicating that there might be more patients who suffer from RA 
symptoms but are not reporting them to the family doctor.216 Furthermore, criteria used for 
reporting the prevalence of RA are still based on the 1987 classification criteria.217 The new 
American College of Rheumatology European League Against Rheumatism classification 
criteria intended to classify both early and established RA but these new criteria are yet to be 
applied in South Asian patients.218 Secondly, South Asian patients may view western 
medicines to be more harmful than traditional remedies and therefore, adherence levels need 
to be assessed. Thirdly, there is inadequate reporting of the health outcomes for South Asians 
with RA. There are few details about the health outcomes for patients who delay in 
presenting with their symptoms, although one recent study has reported high disease activity 
in patients who delay presentation (DAS 5.1>).216 Furthermore, this study found that 72% of 
patients had developed radiological damage by the time of initial presentation. Thus, the 
results of the very few earlier studies conducted where authors concluded the disease was 
mild in South Asians compared to European patients cannot be accepted with confidence.208 
Another  striking point is that there are limited data on South Asian patients to suggest 
whether those who delay have worse outcomes or might struggle to engage with treatments 
compared to those who present earlier: these issues were not documented by Chandrasekaren 
and Radhakrishna209 who reported that the average time from the onset of symptoms to the 
first visit for medical advice was ten months, missing the window of opportunity for initiating 
RA treatment. None of the Indian studies had investigated the reason for patients’ delay in 
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seeking medical help. However, data on delays in symptom presentation in the UK65 have 
made possible a more precise account of the reasons for patient delay and found some of 
them to be linked to cultural influences. In that study, some South Asian patients were found 
to make more use of traditional remedies than were non-South Asian patients prior to seeking 
medical help. A study conducted in India, found that 73% of RA patients had taken another 
form of alternative treatment even when a diagnosis of RA had been made.216  
To date, steady progress in the field of RA has been made and has led to a completely new 
paradigm of treatments, especially with the introduction of biologic therapies.15 But clearly 
the literature reporting South Asian patients’ delays in seeking medical help suggest that 
patients of South Asian origin may not be receiving the same benefits of RA management as 
their counterparts from other minority ethnic groups.  
There are a large number of patients of South Asian origin with RA attending rheumatology 
outpatient clinics in Birmingham.219 Although the researcher has recently explored patients’ 
views and beliefs about their disease and about medicines in Birmingham,8;91 the extent to 
which these impact on medication adherence in South Asian RA patients has not 
systematically been studied. The current thesis was designed to help build comprehensive, 
evidence-based findings of determinants of patients’ adherence.  
Compared with RA, there are more data on South Asian patients’ beliefs about medicines and 
their impact on medication adherence in diabetes and cardiovascular disease (CVD). The 
present thesis therefore synthesises the qualitative literature on adherence in diabetes and 
CVD in South Asians in order to help develop an understanding of the relationship between 
variables that influence medication adherence in patients with RA of South Asian compared 
with White British origin. The data on medication adherence in diabetes and CVD in South 
Asians will be discussed in Chapter 2.  
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1.11 Aims of the thesis  
The primary aim of the thesis is to understand the association between demographic (e.g. age, 
gender, level of education, socioeconomic status, occupation, employment status) disease 
related variables (such as disease duration, functional disability) and psychosocial variables 
(namely, beliefs about medicines, illness perceptions, and patient satisfaction with 
information about medicines), in relation to medication adherence in patients with RA of 
South Asian compared with White British origin.  
Therefore the objectives of the thesis are:  
1) To synthesise qualitative data on South Asian patients with cardiovascular disease 
and diabetes.  
2) To assess the relationship between adherence to medicines and a range of 
variables (e.g. age, gender, level of education, socioeconomic status, occupation, 
employment status and disease duration) in patients with RA of South Asian 
(defined as originating from India or Pakistan) and White British origin.  
3) To explore the reasons underlying high and low adherence amongst these two 
ethnic groups of patients. 
Objective (1) will be achieved by conducting a systematic qualitative meta-synthesis of 
adherence in diabetes and cardiovascular diseases to gain an understanding of South Asian 
patients’ health beliefs and the consequent influence of these beliefs on medication adherence. 
Objectives (2) and (3) will be achieved by undertaking: a quantitative survey (180 patients) 
and a qualitative study (20 patients: 10 high and 10 low adherers). 
The thesis is laid out in the following sequence: Chapter 2 will present the systematic 
qualitative meta-synthesis of adherence in diabetes and cardiovascular diseases. Chapter 3 
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highlights the methodological approach while Chapter 4 describes the methods and results of 
the quantitative survey. Similarly, Chapter 5 will describe the methods and results of the 
qualitative interviews. Chapter 6 links the findings of the systematic qualitative meta-
synthesis of adherence in diabetes and cardiovascular diseases and the discussions of this 
thesis are presented with implications for research, clinical practice, future recommendations 




CHAPTER 2: BELIEFS ABOUT MEDICINE FOR DIABETES AND 
CARDIOVASCULAR DISEASE AMONGST PEOPLE FROM A SOUTH 
ASIAN BACKGROUND: SYSTEMATIC META-SYNTHESIS 
2.1 Introduction to chapter  
Compared with White British patients, South Asian patients with RA have different beliefs 
about medicines.8 Given that diseases such as diabetes and CVD are more prevalent amongst 
South Asian patients and that more data on beliefs about medicines have been 
documented4;103;148;220 for these diseases, the aim of the review described in this chapter was 
to establish evidence that would help the researcher to understand beliefs about medicines. 
Furthermore, how these contributed towards medicine-taking in diabetes and CVD in order to 
inform her future work in the context of RA.  
2.2 Method 
Standard systematic review guidelines were used.221 Four databases (Medline, Embase, 
Science of Citation and CINAHL) were searched from January 1980 to January 2013 
(Diagram 2) using a combination of search terms (Figure 2). Since the mass migration did not 
occur until the 1970s (As per section 1.9) any research on this patient group would be 
unlikely to be published until the 1980s.  Google scholar and Index Medicus for the Southeast 
Asian Region database were searched to identify research conducted in South Asian countries. 
The systematic review search structure was verified by a senior librarian based at the 
Sandwell and West Birmingham Hospitals NHS Trust library (Figure 2).  
Inclusion and exclusion criteria were applied as follows; Inclusion criteria: papers were 
restricted to English language only as there was no funding to get non-English language 
papers transcribed into English. Qualitative studies using an interpretative method to analyse 
and report data on adherence to medicines in South Asian adults (>18 years), diagnosed with 
diabetes or CVD were included. Exclusion criteria: papers were excluded if they did not 
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specify which data were derived from people of South Asian origin. Editorials, conferences 
proceedings, letters, news articles, government reports and practice guidelines were reviewed 
and were excluded if they did not have primary data (e.g. patient quotes). 
Diagram 2: Flow of studies through review  
  
183 unique references identified 
from electronic search of four 
databases  
    
57 records were duplicates and were 
removed  
126 articles were screened for 
eligibility  
101 records were excluded: 
Not qualitative, qualitative but not 
in South Asians and insufficient 
sample in South Asians 
25 full-text articles were assessed 
for eligibility  
11 full-text articles were excluded: 
Studies were focused on adherence 
to cardiac rehabilitation, diet and 
lifestyle. 
  
14 articles were included in the 
search 
  
A further 7 studies were from Grey 
literature and were suitable 
  
A total of 21 articles were included 




Figure 2: Systematic-meta synthesis search terms 
Diabetes mellitus*OR gycaem* OR insulin 
OR oral hypoglycaem* OR blood glucose OR 
hypoglycaemic agents OR hyperglycaemia.  
 
Cardiovascular diseases* OR hypertension OR 
hyperlipidemia OR oral cholesterol OR blood 




India* South Asia* Pakistan* 
Bangladesh* Culture.  
 
Qualitative research  
 
Adherence OR adherent OR compliance 
OR concordance OR persistent OR 
retention OR drop out OR medication 
adherence OR attitude to health OR 
health beliefs.   
The search contained terms from each box in order to extract relevant papers.   
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2.3 Data Extraction  
The Critical Appraisal Skills (CASP) Programme quality criteria were used for data 
extraction.222 Two reviewers (researcher and RS) independently extracted data. A meta-
synthesis approach was used to synthesise data223 which involved the translation of findings 
into first, second and third order themes across the different studies. Table 3 below shows an 
example of first, second and third order synthesis. To identify first order themes quotations 
where interviewees expressed their views about adherence to medicines were extracted. To 
identify second order themes, sections of the results of the authors’ interpretation of findings 
were extracted. The third order of themes were developed through combining first and second 
order themes.223 Articles were analysed using an approach informed by a thematic and 
grounded theory framework224;225 to systematically identify shared concepts and themes.223 
The researcher and RS then conducted a second review of the papers and identified whether 
they contained text about barriers to medication adherence. At each stage of data abstraction, 
the reviewers discussed the studies to achieve consensus regarding the identification and 










Table 3: An example of the process of developing an order construct 
 
Study                   Theme/category              Data extract (first order construct)             Data extract (second order construct)            Conclusion (synthesis)   
  
 










“....And now in the morning I take three 
pills, sometimes two, meaning I check it 
(blood glucose) and according to that I 
do or don’t take all the pills”.   
 
Popular ideas about medicines, 
derived from the Indian subcontinent, 
may have informed the ways 
respondents perceive and take their 
oral hypoglycaemic agents (OHAs). 
On the Indian subcontinent, people 
commonly self-medicate, make 
selective use of prescribed drugs, and 
abandon drugs that do not provide 
prompt relief of symptoms.  This 
might explain why some respondents 
adjusted their OHAs without seeking 
medical approval and according to the 
presence or absence of symptoms. 
 
Symptom control significantly 
influenced adherence to treatment. 
Patients’ health beliefs and 
medication adherence may be 
affected by the severity of disease. 
Patients make critical decisions 
that affect the therapeutic 
outcome of their disease. Patients’ 
beliefs about disease and 
medications may be crucial to 
their intentional adherence 
behaviours and may be very 
different to those of the health 
professional. 
 





God / fatalistic 
view 
 
“....God has given me these diseases, 
and they will never go away, you just 
get more and you cannot do much about 
it”. 
 
Whilst fatalism has been attributed to 
belief in God’s will, which is a strong 
feature of the Muslim, Hindu and Sikh 
religions our findings suggest that 
call/recall systems may reinforce 
patients’ perceptions that they are not 
responsible for disease self-
management, when they have 
migrated from a country where they 
are expected to seek out medical care.     
 
Generally south Asian patients 
were more likely than their 
European counterparts to 
contextualise their diseases in 
relation to their religion beliefs. 
This often resulted in lack of 
motivation to improve their 




2.4 Results  
Twenty-one publications were included in the final analysis (Table 4). Sixteen studies were 
UK based,4;112;148;220;226-236 three from Canada,237-239 and one from Norway.240 Only one 
study241 was based in the South Asian region. Seventeen studies focused on diabetes and four 
on CVD. The majority of the patients included in the study were female. The following 
themes were identified: [1] Beliefs about the need for and efficacy of medicines; [2] Toxicity 
of medicines and polypharmacy; [3] The necessity of traditional remedies versus “western 
medicines”; [4] Stigma and social support; and [5] Communication. These themes are 
described in detail below (page 66 section 2.4.4.1) and are illustrated with quotations 




Table 4: Study Characteristics.  
For studies where patients from multiple ethnicities were included the sample characteristics column only includes data relevant to the South 
Asian patients studied. Where it was not possible to identify which patients were of South Asian origin such papers were excluded from the 













Quality method and 




Bissell et al, 
2004112 
 
To explore barriers to 
accomplish a re-
framed model of 
health care in English- 
speaking patients of 
Pakistani origin with 




[1] Twenty one patients 
[2] Patients diagnosed with 
diabetes 
[3] Gender not reported   
In-depth semi-structured 
interviews, analysis using 
grounded theory. 
Transcripts were 
independently reviewed by 
research team.    
Fagerli et al, 
2005240  
To explore how ethnic 
minority persons with 
diabetes experience 
dietary advice given 




[1] Fifteen patients 
[2] Patients diagnosed with 
diabetes 
[3] M = 4 / F= 11 
In-depth semi-structured 
interviews, analysis using 
grounded theory. 
Transcripts were 
independently verified by 
interpreters. 
Fleming et al, 
2008242             
 
To explore the 
influence of culture on 
type 2 diabetes self-
management in 
Gujarati Muslim men.  
 
Canada 
[1] Five patients 
[2] Patients diagnosed with 
diabetes 
[3] M = 5 
  
Case study approach. 
Analysis using theory 
building and fieldwork.   
None reported. 
Galdas et al, 
2010 237  
To explore the cardiac 
rehabilitation 
experiences of Punjabi 
Sikh patients post 
 
Canada  
[1] Fifteen patients 
[2] Patients diagnosed with CVD  
[3] M = 10 / F= 5 
In-depth semi-structured 
interviews, analysis using 
grounded theory. 
Transcripts were 
independently reviewed by 















Quality method and 




myocardial infarction.  
Keval et al, 
2009227 
To explore South 
Asian Hindu Guajarati 
speaking people’s 




[1] Eighteen patients  
[2] Patients diagnosed with 
diabetes 
[3] M = 10 / F= 8 
In-depth semi-structured 
interviews, analysis using 
grounded theory. 
Transcripts were 
independently reviewed by 
research team.    
King et al, 
2006238  
To explore the 
influence of gender on 
managing coronary 
artery disease.  
 
Canada  
[1] Eighteen patients 
[2] Patients diagnosed with CVD  
[3] M = 10 / F= 8 
In-depth semi-structured 
interviews, analysis using 
grounded theory. 
Transcripts were 
independently verified by 
interpreters.  




To explore British 
Pakistani and British 
Indian patients’ 
perceptions and 





[1] Thirty two patients (fifteen 
South Asian) 
[2] Patients diagnosed with 
diabetes 
[3] M = 4 / F= 11 
In-depth semi-structured 
interviews, analysis using 
grounded theory. 
Transcripts were 
independently reviewed by 
authors. 
Lawton et al, 
2005220 
 
To explore Pakistani 
and Indian patients’ 
experiences of, and 




[1] Thirty two patients 
[2] Patients diagnosed with 
diabetes 
[3] M = 15 / F= 17 
In-depth semi-structured 
interviews, analysis using 
grounded theory. 
Transcripts were 
independently verified by 
research team in addition 
software for qualitative data 
analysis was used.  
Lawton et al, 
2006226 







[1] Thirty two patients 
[2] Patients diagnosed with 
diabetes  
[3] M = 17 / F= 15 
In-depth semi-structured 
interviews, analysis using 
grounded theory. 
Transcripts were 
independently verified by 
















Quality method and 




people of Pakistani 
and Indian origin with 
type 2 diabetes.  




To explore patients’ 
perceptions and 
understanding of 
disease causation.  
 
UK 
[1] Thirty two patients (fifteen 
South Asian) 
[2] Patients diagnosed with 
diabetes 
[3] M = 4 / F= 11 
In-depth semi-structured 
interviews, analysis using 
grounded theory. 
Transcripts independently 
were verified by authors. 
Lewis 2007228 To examine the lived 
experience and 
cultural illness 
explanations of a 
sample of British 
Indian diabetic 
patients living with 
leg and foot ulcers.  
 
UK 
[1] Sixteen patients 
[2] Patients diagnosed with 
diabetes 
[3] Gender not reported  
In-depth semi-structured 
interviews, analysis using 
Greens’ Framework used to 
code data. (framework not 





To examine the 
dietary pattern of self-
care for a group of 
Asian and Caucasian 
diabetes patients.  
 
UK 
[1] Twenty five patients 
[2] Patients diagnosed with 
diabetes  
[3] M = 8 / F= 17 
In-depth semi-structured 
interviews, analysis using 
grounded theory.  
Transcripts were 
independently reviewed by 
research team.    
Meetoo 
2005230 
To explore the 
Explanatory models of 
diabetes by a group of 
Asian and Caucasian 
patients.   
UK [1] Twenty five patients  
[2] Patients diagnosed with 
diabetes 
[3] M = 8 / F= 17 
In-depth semi-structured 
interviews, analysis using 
grounded theory.  
Transcripts were 
independently reviewed by 
research team.    
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2010 239  connections between 
masculinities and diet 
among senior Punjabi 
Sikh Canadian 
immigrant men.  
Canada 
 
[2] Patients diagnosed with CVD  
[3] M = 18 
interviews, analysis using 
grounded theory. 
interpreters and NVivo 
software was used.  
Rafique et al, 
2006241  
To assess the needs, 
awareness and barriers 
to diabetes education 
for self-management 
in diabetic patients.   
 
Pakistan 
[1] Twenty seven patients 
[2] Patients diagnosed with 
diabetes 
[3] M = 11 / F= 16 
In-depth semi-structured 
interviews, analysis using 
grounded theory. 
None reported. 
Rhodes et al, 
2003231  
To examine the 
experience of diabetes 





[1] Eighteen patients 
[2] Patients diagnosed with 
diabetes  
[3] Gender not reported  
In-depth semi-structured 




between authors. Member 
checking was undertaken 
with authors checking 
codes.  
 
Rhodes et al, 
2003232  
To examine access 
from the point of view 
of Bangladeshi 
diabetic patients.  
 
UK 
[1] Twelve patients 
[2] Patients diagnosed with 
diabetes  
In-depth semi-structured 
interviews, analysis using text 
detective software package.   
None reported. 
Singh et al, 
2012 233  
To explore 
experiences of UK 
based South Asian and 




[1] Twelve patients 
[2] Patients diagnosed with 
diabetes 
[3] M = 6 / F= 6 
In-depth semi-structured 
interviews, analysis using 
phenomenology  
Transcripts were 
independently verified by 
authors.  
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2008234  perceptions towards 
multiple medicines 
expressed by people 
managing co-
morbidities.  
UK [2] Patients diagnosed with 
diabetes & CVD  
[3] Gender not reported 
interviews, analysis using 
grounded theory. 
independently verified by 
authors. 
Stone et al, 
2005235  
To explore the 
experience and 
attitudes of primary 
care patients with 
diabetes living in UK.  
UK [1] Fifteen patients 
[2] Patients diagnosed with 
diabetes 
[3] M = 6 / F = 9  
In depth semi-structured 
interviews, analysis using 
grounded theory.   
Transcripts were 
independently verified 
between two researchers.  
 
Wilkinson et 
al, 2012236  
 
To explore renal 
complications of 
diabetes from the 
patients’ perspective.  
 
UK 
[1] Twenty five patients 
[2] Patients diagnosed with 
diabetes  
[3] M = 16 / F= 9 
In-depth semi-structured 
interviews, analysis using 
grounded theory.  
Transcripts were 
independently verified 
between authors. NVivo 




2.4.4.1 Beliefs about the need for and efficacy of medicines  
Many patients of South Asian origin regarded medicines for the treatment of diabetes and 
CVD as necessary. The benefit of taking medicines was recognised and the role of medicines 
in reducing the risks associated with illness were described (Quotes 1 and 2). Patients also 
recognised that it was necessary to take these medicines on a long term basis (Quote 3).  
[Quote 1]“If I didn't take them then I would be in danger.” Male of Pakistani origin 
diagnosed with diabetes: UK study.4 
 
[Quote 2]“Once you start on these then you have to be on them for the rest of your life. So 
either you do that, or you risk dying. So you have no choice but to take the medicine.” 
Female of Pakistani origin diagnosed with diabetes: UK study.4 
 
[Quote 3]“My health depends on these and I continuing to take my medications now”. 
Female of Indian origin diagnosed with CVD: Canada Study.237 
 
Not only were medicines seen as necessary but they were also viewed as effective. However, 
the perceived effectiveness of medicines varied depending upon where they had been 
prescribed. Patients who had migrated to the UK described the medicines they received in the 
UK as being more effective than those they would have received in places like India and 
Pakistan (Quotes 4 and 5). These “pro-western medicine” thoughts were seen also in those 
who also tried alternative medicines. Patients appeared to place a high value on evidence 
based medicines prescribed in the west (Quote 5). However, traditional and alternative 
medicines that originated from the South Asian region were also valued, and held by some in 
the same regard as medicines prescribed in the west (Quote 6).   
[Quote 4]“I don't think you can get the same kinds of medicine that you can get here, you 
know, like metformin. This is one of the most important drugs to take for it.” Female of 
Indian origin diagnosed with diabetes: UK study.4 
 
[Quote 5]“See, in Pakistan, the medications are not right, they're just a waste of time, waste 
of money. I mean these [referring to hypoglycaemic agents] are the real stuff. These are what 




[Quote 6]“At the moment I’m eating ‘Methi’ [fenugreek] because I believe in Ayurvedic 
medicine. But I’m also very pro-western medicine as well – it’s a question of trial and error.” 
(gender not stated) South Asian of Indian origin diagnosed with diabetes: UK study.227   
 
However, while some spoke of the need for their medicines, many patients reported having 
missed doses of their medicines intentionally (Quotes 7 and 8). In some cases, somatic cues 
such as “feeling fine” were given as reasons for not taking medicines (Quotes 7 and 9). Some 
felt that there was less benefit in taking lipid-lowering medicines as they did not notice any 
symptomatic difference whether they took the medication or not (Quote 10).   
[Quote 7] “Sometimes you do say that to yourself, you know, you say to yourself, ‘Oh I feel 
fine and I'll take one today, I won't take two”. Female of Pakistani origin diagnosed with 
diabetes: UK study.4 
  
[Quote 8]“I don’t take my tablets on many times [laughs].” Male of Pakistani origin 
diagnosed with diabetes: UK Study.4 
[Quote 9]“They said that I need to take three, but for the last three months I'm just taking 
them twice a day. It's just when I feel I'm tired I take another one. If I'm fine then I won't. ” 
Male of Pakistani origin diagnosed with diabetes: UK study.4 
 
 
Another factor that influenced decisions not to take medicines was perceived symptom 
severity (Quote 10). Some adjusted their diabetic medicine, according to what they ate 
(Quote 11).  
[Quote 10] “I don’t find any difference but because they say that my cholesterol level is 
slightly higher that it should have been – I think if I don’t take I, I don’t find any difference”  
Male of South Asian origin diagnosed with CVD: UK Study.234 
 
[Quote 11]“Sometimes I will take two when I don't spread too much jam on my toast or even 
sometimes I don't even spread any. If I feel like a bit of a pleasure then I will put some on and 






Some patients made a conscious decision to stop their treatment during social gatherings 
(Quote 12). South Asian patients often stopped their medicines to fully partake in activities 
such as weddings (Quote13).  
[Quote 12]“I never comply with my treatments at weddings and parties...”. Female of Indian 
origin diagnosed with diabetes: UK study.229 
 
[Quote13]“I visit families and friends a lot of the time. I don’t comply especially when I go to 
weddings and when I visit friends and relatives. At other time I don’t always comply with 




In some cases, patients were influenced by other family members’ experiences of taking 
medicines. Some patients felt that the complications of their illness were unavoidable and 
inevitable even if medicines were taken (Quote 14). A few patients used self-management 
strategies and life style changes as a rationale for stopping their medicine (Quote 15).  
[Quote 14]“My father also had diabetes. He used to be very adherent [to diet and 
medication]. But despite this he died of a stroke. Since then, I have become non-adherent. I 
think, what is the point?" Male of Pakistani origin diagnosed with diabetes: UK study.241 
 
[Quote 15 ]“Last time I went to Pakistan, I went for ten months and I brought with me my 
blood-sugar monitor and two kinds of tablets. The first five months I used the medications, 
but not the last five. That’s because I went hunting every second day and walked for 15 to 20 
km. In the evenings when I checked, my blood sugar was ok, and I didn’t have to use the 




2.4.4.2 Toxicity of medicines and polypharmacy 
Concerns were expressed about potential side effects of medicines, and beliefs about toxicity 
(with medicines viewed as poison) (Quote 16). Some patients were also concerned about 
increasing numbers of prescribed medicines being added to their treatment regimes, adding to 




[Quote 16]“Initially it was just two metformins a day, and then it was increased to four by 
the doctor. And then there's blood pressure tablets to take and then aspirins and so on. So it 
all adds up and, you 'know, if you take seven, eight pills a day and you wonder [laugh] is it 
the right thing? This can't be good for me in the long run these can be poisons.” Male of 
Indian origin diagnosed with diabetes: UK study.4 
 
[Quote 17]“…. like the thought of something going wrong with my kidneys, like something 
going wrong with your lungs or your heart, it’s scary. So I think I would have - I probably 
wouldn’t even be on insulin now”. (Gender not stated) South Asian of Indian origin 
diagnosed with diabetes: UK Study.236 
 
 
A number of patients feared that taking too many medicines, would lead to death (Quote 18). 
South Asian patients suggested that taking too many medicines caused them to feel ‘dull’ and 
‘dry’ (Quotes 19 and 20). In instances where toxicity had been experienced, anger was 
expressed. Patients felt frustrated when one tablet resulted in a complication to control which 
they had to take an additional medicine (Quote 21). 
[Quote 18]“Yes, they told me to take it every day, but I said ‘do I want to die by taking it 
every day…I don't want to die by taking so many”. Female of Pakistani origin diagnosed with 
diabetes: UK study.4 
 
[Quote 19]“Already I am dull, my body is, by taking so many tablets.”  Female of Pakistani 
origin diagnosed with diabetes: UK study.4 
 
[Quote 20]“Sometimes I don't take them, you know, they make you dry if you take too many.” 
Female of Pakistani origin diagnosed with diabetes: UK Study.4  
 
[Quote 21]“For my asthma, they gave me tablets and they were sweet tablets [steroids], and 
I had to take eight tablets all at once . . . I stayed [in hospital] for a week and they gave me 
all those tablets, and because of that I got sugar . . . I was angry that I got sugar because of 
their medication”. Female of Indian origin diagnosed with diabetes: UK study.148 
 
 
2.4.4.3 Stigma and social support   
Stigma and social support had a major influence on medicine taking. Patients were reluctant 
to disclose their use of insulin to their families and community. Some patients were told by 
family members not to tell anyone that they were taking insulin, which meant that it could not 
be taken during social occasions. Coping strategies were developed to ensure that the insulin 
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was not used during social situations, including taking insulin before attending the social 
function (Quote 22). The social stigma attached to diabetes and insulin therapy was 
associated with embarrassment. This made some patients reluctant to initiate insulin therapy 
(Quote 23). Patients felt that illnesses such as diabetes were not socially acceptable within 
South Asian communities (Quote 24).  
[Quote 22]“When I am back in Pakistan they (family) don't let me tell anybody that I have it, 
which makes it very difficult for me when I go out. If I am going around somebody's house 
for a meal, they make me do the injection before I go. I can sit there and they won't have 
their meal ready till two hours later and I will just have to keep popping myself with coke…” 
(gender not stated) Patient of Pakistani origin diagnosed with diabetes: UK study.233 
 
[Quote 23]“I got a shock when they put me on insulin … I asked doctors to give me two 
weeks to decide whether I want to start taking insulin or not , it is not difficult in the 
personal sense … it is more because of our culture and community. People look at you and 
go, ‘Oh God! Is he taking insulin?’ … people feel that you have a very dangerous kind of 
disease …it is really embarrassing.” (gender not stated) South Asian of Indian origin 
diagnosed with diabetes: UK study.233 
[Quote 24]“In our culture you’re not wanting to know that you‘ve got any kind of disease 
like diabetes which is why we don’t want the injections”. Male of Pakistani origin diagnosed 
with diabetes: UK study.226 
 
 
For people from a South Asian background, diabetes and insulin were viewed in very 
negative terms, and it was expressed that they were culturally accepted. In contrast, close 
family were felt to be positive agents in supporting self-management and often helped to 
facilitate medicine taking (Quote 26). Some patients had a support mechanism which they felt 
helped them to take medicines (Quote 27). 
[Quote 26]“I feel there is no life without wife. After a certain age there is a desperate need 
for a partner … they will remind you and say, ‘have you taken your insulin?’ or ‘take your 
insulin and in the mean time I will prepare food for you and lay it on the table’ … this way, 
together you can look after diabetes better.” (gender not stated) Patient of Pakistani origin 
diagnosed with diabetes: UK study.233 
 
[Quote 27]"My daughter is a nurse. I learned a lot from my daughter. At first, she used to do 
all the monitoring and injecting and things, but now I can do them myself". Male of Pakistani 




2.4.4.4 The necessity of traditional remedies versus western medicines 
This theme covers a different concept of medicine taking to the theme “beliefs about the need 
for and efficacy of medicines” in that patients experimented with traditional remedies in 
parallel with western medicines. Many patients made use of traditional remedies alongside 
their western medicines and did not associate herbal medicine with the perceived toxicity 
associated with medicines prescribed by the doctor (Quotes 28-32). Not only were traditional 
remedies viewed as necessary, they were also viewed as effective, with one patient describing 
how traditional remedies were efficacious in controlling cholesterol levels (Quote 28). 
Patients also described a number of positive attributes of traditional remedies, including the 
fact that these remedies “make quite a difference” (Quote 29), have no side effects (Quote 30), 
provide balance (Quote 30) and are natural (Quote 31). In some cases patients described 
traditional remedies as being better at tackling illnesses (Quote 31) and able to control the 
adverse consequences of illness (Quote 32).  
[Quote 28]“There are some things like ginger and garlic that we use. These two things are 
good for a man’s health. The more you use it the better it is. They reduce cholesterol, it 
makes a difference to heart attack too”. Male Immigrant of Indian origin diagnosed with 
diabetes: Canada study.239 
 
[Quote 29]“I always check my levels, and then take my tablets, and if I need to I’ll have 
some chocolate or something. I’ll also take some ‘kurvat ni phaki’ [bitter powder] ... this 
makes quite a difference to me. This is from Dubai ... whatever happens I always take my 
medication ... I use karela as well”. Female of Indian origin diagnosed with diabetes: UK 
Study.227 
 
[Quote 30]“It’s fine, there’s no side-effects, it’s all herbal ... there should be more 
information about these things. We also use Neem [Azadirachta Indica] powder, which we 
used to use for malaria in India, we got this from here. We alternate these remedies, to 
balance the different things”. Male of Indian origin diagnosed with diabetes: UK Study.227 
 
[Quote 31]“Its green medicine. Its natural medicines and it has a reputation for maybe 
tackling conditions that western medicines are not so used to”. (gender not stated) Patient of 
Indian origin diagnosed with diabetes: UK Study.228 
 
 
[Quote 32]“First I take a quarter spoon of turmeric in warm water, then I use Meth 
[fenugreek], and then I take ammo [again], which reduces the amount of gas we get ... 
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turmeric is an antibiotic, oftentimes diabetics get this and that, and I still don’t have any 




South Asian patients were open about the fact that traditional and herbal remedies were 
widely available. Media within the South Asian community often portrayed these remedies in 
a positive light (Quote 33). Family and friends were important in decisions to use alternative 
medicines, and in some cases would supply these medicines (Quote 34).  
[Quote 33]“There was an article ... in a newspaper which we get from India, and my niece 
sent the Jambu (rose apple) powder from India ... but you can get this information from 
Gujarati newspapers here as well. Karela we also use, both as a curry and tablets”. Male of 
Indian origin diagnosed with diabetes: UK study.227 
 
[Quote 34]“Well, we’re from India, so my mother and others used them. My brother was 
always using these medicines ... he used to write to me with advice and send them to me”. 
Female of Indian origin diagnosed with diabetes: UK study.227 
 
 
Some patients placed more faith in western medicines than traditional remedies (Quotes 35 
and 36). One patient spoke of how they had moved away from traditional remedies to accept 
medicines prescribed by the doctor (Quote 35), while others spoke of how traditional 
remedies played a large role in the management of diabetes in South Asian countries (Quote 
36).  
[Quote 35]“I used to take juice of bitter gourd for sugar [diabetes] problems….Now I have 
stopped that. I have been given a tablet by the doctor and eat that once a day”. Male Immigrant 
of Indian origin diagnosed with diabetes: Canada study.227 
  
[Quote 36]“Homeopathy in India is very big and homeopaths are everywhere. A lot of people 
go to them and don’t go to a doctor. My wife said to me you should go to a homeopath but 
actually I don’t believe in that,. I believe in medicines”. (gender not stated) South Asian of 





2.4.4.5 Communication  
Health professionals’ communication styles influenced the way patients viewed the disease 
process and medicines (Quotes 37 and 45). Some patients felt that they were not always fully 
informed about disease management and how the medicines would help to control their 
symptoms (Quote 39). Some expressed a lack of engagement with the decisions that many 
GPs made and did not understand the treatment plan (Quotes 39-42).  
[Quote 37] Daughter: They have done it only recently. My mother had an appointment in 
September, but I could not go with her because I had personal problems from the surgery, they 
never bothered to chase that appointment from September to January. I myself took my mother 
to the surgery, that when they found my mother HbA1c reading was 12.9. The tablets my mother 
was taking, she was supposed to take one tablet daily, but she was taking the same tablet twice, 
which she should not have done. South Asian of Indian origin diagnosed with diabetes: UK 
study.231 
  
[Quote 38]“One thing is, if you were having a side effect from your medicine, you could discuss 
it with your doctor, or the nurse. Yes, yes, I see. But this has happened and I talk with doctor 
about it. And he tell me it will pass and it did. PB. So you can already do that? Oh yes, if want 
to ask questions, then I do already. I can do that with doctor. He say we can do that.” (gender 
not stated) South Asian of Indian origin diagnosed with diabetes: UK study.112 
 
[Quote 39]“I’ve seen it happen. They’ll be waiting to ask questions about their medicines or 
what have you and then not feel like they can when they get in there. I’ve felt like that myself, 
haven’t you? It’s like you don’t think you can ask any questions when you get in the room with 
the doctor”.(gender not stated) South Asian of Indian origin diagnosed with diabetes: UK 
study.112 
[Quote 40]“ The doctor had then taken lots of tests and he gave the medicines. He didn’t say 
anything in particular about how to take care of my heart he just gave the medicines”. (gender 
not stated) Sikh Immigrant of Indian origin diagnosed with CVD: Canada study.238 
 
[Quote 41]“We take tablets, but how are we supposed to know if it’s in control or not? I’ve got 
this stick thing to measure it with and I have also got this machine and with that you know what 
it is, whether it is 7.5 or 8.5 or whatever”. Male of Pakistani origin diagnosed with diabetes: 
UK Study.235 
 
[Quote 42]“He was giving me medication but wasn’t asking me for any urine sample or 






Some patients drew a comparison between receiving diabetic care in countries such as the 
UK and South Asian countries (Pakistan and India) and where paying for medicines was 
suggested as a barrier to adherence to the medication regimen (Quote 43). It was suggested 
that patients with better financial resources were able to receive better treatment in Pakistan 
(Quote 44). Patients often compared and contrasted different health systems: for example, 
patients felt that the healthcare system in the UK was trustworthy than countries such as India 
and Pakistan. This view had an impact on the way patients communicated with UK doctors 
about their medicines, and followed advice (Quote 45). 
[Quote 43]“It depends how rich you are, how much money you’ve got for the 
medication......they would go to the doctor but paying for the medication or being told you will 
have this and you’ve got to pay this much every month for a tablet, it’s highly unlikely that 
they’re going to stick to that regimen”. Male of Pakistani origin diagnosed with diabetes: UK 
study.242 
 
[Quote 44]“The poor over there (Pakistan) die, because they can get no treatment. Doctors’ 
pockets over there are so big, they’re full of notes”. Female of Pakistani origin diagnosed with 
diabetes: UK study.220 
 
[Quote 45]“You know how it is there, our doctors don't really pay attention. They are more 
concerned with the amount of money they are making. First they will give you a lighter 
medication, which will make you go back to them again and again until they give you something 
else. And by that time, you will be feeling better anyway.” Male of Pakistani origin diagnosed 






2.5 Discussion of the systematic meta-synthesis  
This systematic meta-synthesis was conducted to help inform the subsequent work in this 
thesis in relation to RA. Here, the researcher presents a discussion of the findings of this 
review; however, and linking of this review to the findings of this thesis, will be provided in 
Chapter 6. The benefits of adherence to medicines in CVD were presented in section 1.4 
though that section represented a global view and was not specific to South Asian patients. 
This section will focus on South Asian non-adherence issues.  
This systematic meta-synthesis review has identified five interacting themes related to 
adherence to medicines for diabetes and CVD described by people of South Asian origin. 
Concerns about medication toxicity were described as a reason for not taking medicines as 
prescribed, though beliefs about the need for and efficacy of medicines were identified as 
important. Beliefs in traditional remedies and patient-health professional interaction appeared 
to play an important role. Patients’ beliefs about traditional remedies caused some to doubt 
the efficacy and necessity of prescribed medicines.  
The beliefs about medicines of diabetic and CVD patients identified in this systematic meta-
synthesis review were similar to those identified in other disease areas such as cancer,243-
245asthma,246 renal failure,247;248 and RA.249 Furthermore, beliefs about medicines and the use 
of traditional remedies play an important role in medication adherence. This has been noted 
more amongst female than male South Asian patients.250 The use of traditional remedies 
influences patients’ decisions to take western medicines. Furthermore, patients have been 
shown to delay in seeking medical treatments even after noticing symptoms hoping that 
traditional remedies will alleviate their symptoms.243 It has been suggested that the views of 
practitioners who may promote traditional/alternative therapies should also be addressed.251 
These practitioners have been shown to hold different views about illness and disease 
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compared with orthodox practitioners.252 Moreover, South Asian patients have been shown to 
feel more satisfied with traditional remedies than with western medicines.253 
The review also identified that patients were less concerned about the long-term management 
of their underlying illness. This may be associated with the cultural stigma attached to illness, 
particularly diabetes. Evidence in other disease areas such as cancer has shown that in South 
Asian patients, coping with chronic illnesses is more centred on family support and spiritual 
beliefs,254 compared with patients from other ethnic groups [24 African American, 34 Asians, 
26 Latinas and 18 “Caucasian”] which could have potential impact on treatment choices. For 
example, emerging research shows that women whose views are centred on spiritual beliefs 
tend to cope less well with chronic diseases compared to those whose views are based on 
understanding the chronic disease.244;245 South Asian women’s challenges in coping with 
chronic illness may differ from the general population and in addition language barriers and 
societal stigmas may also influence treatment decisions.244 
From the review presented in this chapter, it appeared that diabetic patients were often 
unaware of the impact of fluctuating poor adherence on the long term consequences of 
uncontrolled diabetes. Similar findings have been documented in a study looking at asthma 
control in South Asian patients which found that patients who were less aware of the benefits 
of using systemic corticosteroids and preventive treatment had poor asthma control.246 
Furthermore, that study found that the provision of education on asthma and how to control 
symptoms reduced the admission rates for White but not for South Asian patients, suggesting 
that different patients process the same information in different ways. In the diabetic and 
CVD review, patients were hiding medicine taking from members of the community; in some 
cases this led to non-adherent behaviour. Again these concepts are linked with the perceived 
efficacy of and concerns about medicines. Similar themes have been reported by another 
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review with patients from other countries such as the US, UK, Brazil, Sweden, Canada, 
Finland, Netherlands, South Korea and Spain255 who had also expressed views about the need 
for and efficacy of medicines, intentional non-adherence to medicines, toxicity of medicines 
and polypharmacy and the necessity of traditional remedies.255 The authors also noted that 
side effects were the main reason for patients self-adjusting or stopping medicines for 
hypertension and the researcher has also found this to be similar in her review. In another two 
separate studies beliefs about medicines were reported to be different amongst South Asian 
patients compared with non-South Asian patients.8;91 Furthermore the review which focussed 
on patients of European background,255 found that hypertensive patients with high adherence 
had an understanding of hypertension which mapped onto the biomedical model. However, 
this concept was not found in the researcher’s review. One of the explanations for this could 
be that many South Asian patients did not understand the disease process and were unclear 
about the reasons for taking their medicines. Patients’ understanding and acceptance of the 
diagnosis is an important component of medicine taking and disease self-management. 
Cultural influences and social misconceptions of diseases have been reported to hinder 
patients’ understanding of disease in South Asian patients.256 
The researcher’s review identified a number of beliefs which appeared to be culturally 
specific to patients of South Asian origin. Social stigma may hinder patients’ full 
participation in disease management.257 Understanding the cultural links258 and illness 
perceptions may help HCP in planning interventions to enhance patients’ involvement in 
disease management.170 The researcher’s findings highlight the need to develop a theoretical 
framework that will enable health professionals to fully understand the factors influencing 




2.6 Strengths and weakness  
This review synthesised a range of international qualitative studies exploring beliefs about 
medicine taking among people of South Asian origin with diabetes/CVD. However, the 
researcher identified only one study conducted in South Asia. Therefore, the findings of this 
review have been strongly influenced by the perceptions of people who have migrated to 
western countries. A limitation of this review was that some South Asian journals were not 
indexed in Medline, Embase or CINAHL. For example, “Cardiology and angiology: an  
International Journal” was included in Index Medicus but was not indexed by Medline, 
Embase or CINAHL: therefore, the researcher was not able to identify all potentially relevant 
research studies published in the South Asian region.  
2.7 Summary of the systematic meta-synthesis  
This review has identified a range of beliefs which play key roles in influencing adherence to 
medicines. Further research is required to assess the impact of these specific beliefs on the 
management of diabetes and CVD in South Asian patients, and to assess ways of addressing 
these potential barriers to medicine taking. These findings may help to inform the work on 




CHAPTER 3: Research Design 
The literature in the field of rheumatology patients’ care has used a range of quantitative and 
qualitative approaches to investigate the experience of medicine-taking. This thesis utilised a 
mixed-methods approach. Before this explaining this, the relevance of theoretical use within 
the research design will be higlighted.  
As discussed in section 1.6 there are theoretical models that provide an understanding behind 
an individual’s non-adherent behaviour. The quantitative survey was driven by the SRM-
CSM164 and NCF125 models. The validated questionnaires (Chapter 4) provided an 
understanding into patients’ beliefs about DMARDs, their association with perceptions about 
RA and  adherence to DMARDs. The qualitative interviews further explored illness 
perceptions and beliefs about medicines and how patients used these beliefs to make 
decisions about taking their DMARDs (diagram 3).  





Does the problem 
fit solution?   
Interpretation of illness 
Information sought 
through symptoms or 
social messages   
Necessity beliefs and 
concerns about medicines  
 
Developmental of cognitive 
representation of illness 
and “THEN” decision to 
take treatment or not 
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3.1 Methodological approach mixed-methods 
This section will describe the choice of methodological approach selected to conduct this 
study, and will expand on the reasoning behind these choices. 
Mixed methods are a procdure for collecting, analysing and mixing or integrating both 
quantitative and qualitative data259. The purpose is to gain better understanding of the results. 
One of the designs of mixed methods is sequential explanatory design260. This involves 
collection of quantitative data and then qualitative data in two consective phases within one 
study and this approach was used for the thesis.261 Diagram 4 illustrates the use of sequential 
explanatory design and its use within the research design. The diagram also higlights the link 




Diagram 4: Showing the sequential explanatory design procedures and application of 
theoretical framework within the research design 
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The sequential explanatory design (as described above) included [1] employing 
questionnaires that were only selected to determine the significant factors that impacted on 
high and low adherence in the two ethnic groups but was also to understand theory of 
medication adherence (section 1.6) and [2] undertaking qualitative interviews to identify 
reasons for high and low adherence in both ethnic groups. By testing the extent to which 
variables had an impact on patients’ medication adherence, it helped informed questions that 
were required during an in-depth investigation. Interviews provided a detailed understanding 
of patients’ decisions surrounding whether to or not to take their medicines. The qualitative 
method is further described in Chapter 5.    
3.2 Reflection on cross-cultural qualitative research  
Before moving forward, the researcher will reflect on involving South Asian patients in her 
study. Since this section is describing her own reflection of interviewing South Asian patients, 
she will discuss her relevant personal characteristics and refer to herself in the first person.  
I specialised in rheumatology as a nurse specialist in 2001. In 2003, I took up a post as a 
nurse researcher and developed a profile of research around issues related to ethnicity in 
musculoskeletal practice. I am of British Indian ethnicity and speak a number of languages, 
including English, Hindi, Punjabi, and Urdu. 
People from minority ethnic populations are known to be under-represented in research262 
and this is a problem in RA studies as well.85 As disease outcomes are influenced by  
ethnicity (as described in section 1.8), the need for a deeper understanding of ethnic 
influences on health behaviour becomes paramount.187 Existing research has highlighted that 
people from different ethnic groups hold different beliefs about health and illness.4;148;220 
Many patients of White European and North American origin embrace the biomedical model 
of disease and illness, while patients from some ethnic groups. For example African 
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American, African-Caribbean, Latino and Asian embrace religious, spiritual, emotional and 
social processes.89 The concepts mentioned above are continued to be reported as influencing 
factors on disease perception.263 Moreover, patients from different ethnic backgrounds share 
a view that illness does not only manifest itself at the physical level, but that the above 
mentioned factors play a role.148 The fundamentally different illness beliefs held by people 
from these ethnic groups give rise to the need to understand these views and how they may 
impact upon poor disease outcomes.  
I have been involved in previous RA research projects that included patients from a South 
Asian background.8;65;91 Of course, working with this population brings challenges for 
example recruitment into research as well as advantages in the context of being a researcher 
from the same ethnic background as the patients for example, being able to speak the same 
language and sharing many cultural values.264 Patients’ representations of illnesses and the 
role of ethnicity within diseases are very well illustrated by extensive work done in diabetes 
amongst the South Asian population.4;148;220;226 The logistical challenges of including ethnic 
minority populations identified by many researchers include language and cultural 
differences and  South Asian patients have been shown to have a poor understanding of what 
research entails and how new knowledge may help future developments.265 In areas where 
there has been an opportunity to include South Asian patients with a researcher being from 
the same ethnic background, this has been viewed to potentially introduce bias.266 For 
example, if patients know that the researcher is a health professional they may feel obliged to 
give politically correct answers or the gender of the researcher may lead to challenges in 
recruitment. If the researcher is female, some male patients might not be willing to take part 
in the research.264 Equally, not including South Asian patients in research is also viewed as an 
important ethical and political concern within the health system and potentially has greater 
consequences for health inequalities which have been widely reported.201 Many studies have 
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made use of interpreters and these show how rich data can be obtained to help understand the 
dynamics of patients’ health beliefs and illnesses.267 
My first and biggest challenge was to minimise the health professional distance and instigate 
a friendly relationship in order to detach from my professional role as a nurse specialist for 
both ethnic groups. This was particularly important during the qualitative phase of the project. 
I attempted to establish a disconnection between my primary professional role and that of a 
researcher. For the South Asian patients I began this by using cultural markers of respect such 
as “Auntie”268 (with patients who were older than myself) proposing that such an approach 
created a friendly environment. In contrast, addressing patients as “Auntie” was not required 
for the White British patients. Once this was established and the interview was underway, a 
switch was made to a more formal tone. It was a huge advantage for me that none of the 
patients interviewed were under my clinical care: therefore, patients were more at ease to talk 
openly about their views about medicines and their condition. The quote below illustrates one 
patient’s anxiety about taking part in the study and the way that knowing that she would be 
able to communicate in her own language reassured her. These anxieties were not noted in 
the White British patients who appeared more relaxed during the interviews. [Quotes 
illustrated below were taken from the interviews conducted].  
“K first of all you know I was very nervous about coming today. I didn’t know what you were 
going to be like: I thought Gosh will she be able to talk to me in Punjabi? But after talking to 
you just now I am err… I feel better”. [43, homemaker, Punjabi speaking Female Asian 
patient].  
 
My second challenge was to obtain consent from the patients. I observed that fear about 
taking part in research was particularly evident in the South Asian patients. Signing an 
official document raised many questions due to lack of awareness of the research procedure. 
These patients needed to be given more assurance about the research procedure than did the 
White British patients. The issue of data confidentiality had to be made very explicit for 
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South Asian patients. In contrast White British patients were familiar with these procedures 
and therefore understood issues relating to data confidentiality. Numerous reminders were 
given at the initial stage of each interview emphasising that patients were able to terminate 
the interview at any point and that this would have no consequence for them or their care.  
Throughout the interviews permission to ask questions was sought from both ethnic groups. 
By doing this, I was signalling that patients remained in control of the situation. My 
positioning in terms of ethnic background allowed a sense of security and a shared 
understanding of ethnic influences in the context of the South Asian patients. The ethnic 
connection between the researcher and patients is illustrated in the following quotes.     
“You see, you are an Indian, so you know that our people start just massages for swelling but 
I think that this swelling isn’t the same”.[ 69, Retired, Punjabi speaking, Female Asian 
patient] 
 “People just say but you’re young how come you have arthritis? My mum thinks all 
psychological she says that I am being silly. You know how it is in our people, people at work 
think that what she on about... she only in her 20s. What the hell is she on about. Seriously no 
one will believe a word that I say. Even my husband to this day will not believe me. No one 
take me seriously I am in so much pain. No one talks about it there isn’t enough awareness 
about the disease. So I am just left...(patient gets very tearful)”. [33, self-employed, English 
speaking, Female Asian patient] 
“well you know that about 60% of our people have diabetes like now that’s how it’s become 
hmmm like a necessity to have diabetes in Indian families...[laughing] like you have 
Mercedes...” [Retired, Punjabi speaking, Male Asian patient] 
“You know when I was a bit younger I use to go to the temple do you go?...[KK answers] 
and I used to look at these people with joint problems. They would walk very slowly and they 
would say that oh my joints are swollen they are very painful. I always used to think how bad 
can this be?.....[pause] how can you have so much pain in your joints and why is this. At that 
point I never actually understood them I used to think its old age. Now that I have the 
condition I know what they were saying”. [This patient talked about the place from where his 
disease perception originated]. [Retired, Punjabi speaking, Male Asian patient] 
In summary, in the interview interactions between myself and patients my being from the 
same ethnic background as the South Asian patients enabled rapport to be sustained. I did not 
explore whether White British patients would have preferred to talk to a health professional 
from their ethnic background. I found that the White British patients displayed a more natural 
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approach to the research process than did the South Asian patients. For the South Asian 
patients, the process changed their attitudes towards the research procedure. My involvement 
may have bridged any distances that might have been constructed if a non-South Asian 
researcher were to interview them. My experience was that for both ethnic groups, listening 
closely and genuinely valuing patients’ opinions enhanced data collection and did not 
obstruct the interview interaction. It has to be recognised that had I been a RA sufferer, this 
might have led to different responses from both ethnic groups.  
3.3 Patient Engagement 
This section describes the involvement of patient research partners in this project via the 
Steering Group. Patients who took part in the Steering Group were RA sufferers and had 
previous experience of informing research projects.  
Involving patients as research partners is a crucial part of the research process.269  
Recommendations from the European League Against Rheumatism endorse patients’ 
representation.269 Generally in research, patients’ representation and involvement  has been 
given high regard in all phases of the research journey but obtaining patients’ views at the 
early stages of designing a research protocol has been shown to be particularly important.269 
With this in mind, an invitation to join the project Steering Group was offered to members of 
the well-established patient user group with the rheumatology department of Sandwell and 
west Birmingham hospitals NHS Trust. The user group has a regular meetings programme in 
the rheumatology department. A presentation outlining the research proposal was presented 
to the patient user group at one of their monthly meetings and a request was made for a few 
patients to join the project Steering Group. Four patients with RA (two White British and two 
South Asian patients) joined this group. None of these patients were being treated by the 
researcher from a clinical perspective. The group met on a six-monthly basis for discussions 
87 
 
on various issues and updates on the project. All variables and tools such as the Quantitative 
survey were discussed with this Steering Group.261 The most common methods for measuring 
adherence were discussed including questioning patients, patients’ logs, pill counts and the 
widely used medication electronic monitoring system (MEMS).128 This system involves a cap 
that measures opening and closing as dosages are taken, and is able to report on the times and 
dates at which the bottle is opened.  
The Steering Group strongly felt that the MEMS approach had the potential to change the 
patients’ behaviour and was therefore not appropriate.261 Patients preferred a self-reported 
tool, such as MARS,119 which is phrased in a way that sanctions non-adherence. However, 
patients did acknowledge that by using this approach adherence might be over-reported by 
some patients. On commencing qualitative work a meeting was held with the Steering 
Committee members, who were asked to comment on the items/concepts/perceptions to be 
explored. Here, patients recommended that themes that drive patients to adhere well to 
medication be explored in the group of poor adherers. It was further suggested by the 
Steering Group that recommendations made by the high and poor adhering patients should 




CHAPTER 4: QUANTITATIVE SURVEY  
4.1 Introduction to Chapter 
This chapter begins by describing the process of data collection, translation and piloting of 
questionnaires, patient recruitment, sample size, and methods of data analysis. A brief 
synopsis of each questionnaire will also be given. This then leads to the presentation of the 
results in the following sequence: [1] an overview of the demographics profile of the study 
population; [2] the differences between variables in the two ethnic groups; [3] the univariable 
analysis of all patients showing which variables were found to significantly influence 
medication adherence; [4] data on the multivariable analysis showing the conclusion.   
4.1.1 Ethics and Research Governance approval for quantitative survey   
The study was approved by the South Birmingham Research Ethics Committee (Appendix 1).  
All patients gave written informed consent to take part in the study. Patients also gave 
consent if they were willing to be contacted for a follow-up study (Chapter 5, qualitative 
phase). Patients’ data were recorded as stated by the research ethics guidelines and patient 
confidentiality was maintained throughout the study.   
4.1.2 Data collection 
This section describes the content and scoring of the five questionnaires used for data 
collection.  
4.1.1.1 The Beliefs about Medicines Questionnaire 
1. The Beliefs about Medicines Questionnaire (BMQ) is a validated tool139 has Specific and 
General versions (Appendix 5). The BMQ-Specific assesses people’s beliefs about 
specific medicines and comprises two scales (as discussed in section 1.6). The five-item 
Specific Necessity scale assesses beliefs about personal need for medicines: in this case, 
views about DMARDs used in treating RA. A higher score indicates a stronger belief in 
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personal need for the medicines. The Specific Concerns scale comprises six items 
assessing concerns about the potential adverse consequences of taking medicines: a 
higher score indicates stronger concerns about the potential adverse consequences of 
medicines. Using the standard method of scoring,  adjusted Specific Necessity and 
Concerns scale scores were calculated by dividing total scores by the number of items in 
the scale (possible range 1-5).119 A Necessity-Concerns Differential score (NCD; possible 
range -4 to -+4) specific for DMARDs was calculated by subtracting the adjusted Specific 
Concerns score from the adjusted Specific Necessity score. Patients’ NCD scores are 
positive if the necessity beliefs are rated more highly than concerns and negative if 
concerns are rated more highly than necessity beliefs. The BMQ-General comprises two 
scales that deal with more general views about medicines as a whole. The three-item 
General Overuse scale assesses beliefs about the way in which medicines are used by 
doctors and the extent to which doctors place too much emphasis and trust in medicines 
(higher scores indicate higher agreement with the premise that medicines are overused by 
doctors). A five-item General Harm scale assesses beliefs about the intrinsic properties of 
medicines and the degree to which they are perceived as essentially harmful (with a 
higher score indicating stronger views about medicines being harmful). Again, adjusted 
scale scores were calculated by dividing total scores by the number of items in the scale 
(possible range 1 to 5).119   
4.1.1.2 The Medication Adherence Report Scale 
2. The Medication Adherence Report Scale (MARS-6) is a validated tool138 was used to 
assess self-reported adherence to DMARDs (Appendix 6) (in this case, adherence to 
DMARDs in RA). Responses to six items assessing the frequency of both 
unintentional (e.g. ‘I forgot’) and intentional (e.g. ‘I decided to miss a dose’) non - 
adherent behaviours were recorded using a 5-point scale where 1= very often, 2= 
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often, 3=sometimes; 4= rarely; 5 = never. The score range for the scale is 6 to 30, 
with higher scores indicating higher reported adherence. As mentioned earlier, 
previous studies have dichotomised the MARS scores.138 The overall MARS scores 
were used in the majority of the analyses but patients were also categorized into high 
or low adherers (MARS ≥ 26 or <=25), as stated in the published protocol.261 
4.1.1.3 The Illness Perception Questionnaire 
3. The Illness Perception Questionnaire (IPQ) is a validated tool163 it measures people’s 
perceptions about illness representation (as discussed in section 1.6) (Appendix 7) in 
this case, perceptions of RA. Responses are recorded on a five–point scale with the 
following dimensions: the chronicity of disease, a cyclical timeline (five items about 
the nature of RA), the consequences of RA (six items about the impact of RA), 
personal control (six items representing positive beliefs about one’s own ability to 
control RA), treatment control (five items representing positive beliefs about the 
treatment), illness coherence (five items about the patient’s personal understanding of 
RA), and emotional representation (six items about emotions caused by RA).  
4.1.1.4 The Health Assessment Questionnaire 
4. The Health Assessment Questionnaire (HAQ) is a validated tool270 measures people’s 
functional status and includes questions related to activities that involve both upper 
and lower extremities (Appendix 8). The HAQ measures the ability to perform twenty 
activities of daily living with four response categories (without any difficulty (score 0), 
with some difficulty (score 1), with much difficulty (score 2), unable to do (score 3). 
A higher score indicates a higher level of disability.  
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4.1.1.5 The Satisfaction with Information about Medications scale 
5. The Satisfaction with Information about Medications scale (SIMS) is a validated 
tool110 comprises seventeen items to assess the type of information that people require 
in order to facilitate the safe self-management of medication  (Appendix 9); in this 
case, RA patients’ satisfaction with information about DMARDs. Each item refers to 
a particular aspect of their medicines.  Examples include “How to use your medicine” 
and “What you should do if you experience unwanted side effects”. Patients rated their 
perception of the quality of information they had received about aspects of their 
medicine as ‘too much’, ‘none’, ‘too little’ (all scored as 0) or ‘none needed’ or ‘about 
right’ (scored as 1). The SIMS has two components: [1] ‘Action and usage of 
medicines’ refers to information received about, for example, how medicines work to 
control the condition and how to use medicines (nine items; scores range from 0 to 9 
with a higher score indicating higher satisfaction) and [2] ‘Potential problems’ refers 
to information received about, for example, what participants should do if 
experiencing side effects of the medicine (eight items; scores range from 0 to 8 with a 
higher score indicating higher satisfaction).  
4.2 Translation of questionnaires  
Although many of the questionnaires mentioned above have been used extensively170;179;271, 
there is little evidence of their cross-cultural validity in RA. Generally, health related quality 
of life measures have been translated but not validated in certain ethnic groups. This has led 
to the translation of many of the questionnaires and their subsequent use in the relevant 
population.272;273 With this acknowledgment, this study has used IPQ, MARS and SIMS 
questionnaires for the first time in South Asian patients with RA.274 The HAQ and the BMQ 
have been used in the researcher’s previous work but were not translated.8 For the purposes 
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of this study, the HAQ, IPQ, BMQ, SIMS and MARS were for the first time independently 
audio translated into Hindi, Punjabi and Urdu by health professionals (two doctors and the 
researcher), followed by back-translation to ensure linguistic validity.274 This was because the 
study took place in a largely multicultural city in which 18.5% of the population is of South 
Asian origin.9 Furthermore, previous work has reported that about a third of the South Asian 
population attending Rheumatology clinics within the department required interpreters and 
about 33% of that population were not able to read the script of their preferred language.219 
Consequently, written translation of the questionnaires would exclude a sizable proportion of 
potentially eligible subjects. To test the logistics of filling in the questionnaire, the translated 
audiotapes were piloted amongst a group of patients from Sandwell and West Birmingham 
Hospitals NHS Trust. The following section describes the work undertaken to translate the 
questionnaires.  
In adapting questionnaires from one language to another, standardized methodology is used 
to ensure that the instrument does not lose its psychometric properties274. The validity and 
reliability of an instrument can vary as a result of translation not only because of the 
linguistics but also because of the specific social and cultural features of the country. 
Therefore, an assessment of the Punjabi, Urdu and Hindi translations was necessary, as a 
percentage of the South Asian patients were not able to read written English material.274 The 
objective of this was to demonstrate the translation and validation process of the Punjabi, 
Urdu and Hindi version of the MARS, BMQ, the SIMS, and the IPQ. However, the 
researcher did not validate the use of these questionnaires in South Asian populations. In 
accordance with standards established by the International Quality of Life Assessment 
Project Group,274 the questionnaires were translated from the original language (English) into 
Punjabi, Urdu and Hindi independently by two native speakers of Punjabi, Urdu and Hindi 
who possessed a proficient level of English.  
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The preparatory work for this exercise comprised several meetings with two doctors. 
Consultations were organised by the researcher and the two doctors to discuss the feasibility 
of utilising translated questionnaires.274 Meetings were held at the University of Birmingham 
and several telephone conversations also took place. Once a plan of translation had been 
established it was agreed that translations would be done independently by the two health 
professionals and the researcher. Any differences were then discussed and resolved by a 
consensus between the three translators, and a provisional forward translation was generated. 
These versions were the basis for the reverse translation process conducted by two native 
English speakers who were highly fluent in Punjabi, Urdu and Hindi. Each person 
independently conducted a back-translation. These versions were evaluated by the researcher 
and the two translators. It was then decided that a pilot study would take place to test the 
feasibility of these translated questionnaires. The pilot study took into account the patients’ 
perspective in terms of understanding the translated language and dialects. In addition the 
practicalities of using the questionnaires were also taken into account.  These are discussed 
below.  
4.3 Piloting questionnaires  
The Punjabi, Urdu, Hindi and English versions of the questionnaires were tested on a small 
sample of twenty patients with RA. These were selected from the rheumatology department 
at Sandwell Hospital, Birmingham and were taking DMARDs. Patients from White and 
South Asian backgrounds were approached while they waited to see a rheumatologist or 
specialist nurse. A clinic room was made available for patients to fill in questionnaires. This 
pilot study demonstrated the feasibility of administering and completing the translated and 
English version questionnaire. This will now be discussed.  
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The translations were recorded on tape particularly for those patients for whom English was 
not their first language and for those who preferred to listen to the audio tape. Having 
established the translated questionnaires and those who used English version, the next stage 
in the development was to explore the practicalities of administering these questionnaires and 
the patients completing them. Therefore, a short interview took place with each patient in 
which patients individually provided feedback on the questionnaires. During these interviews 
notes were made on the patient feedback. The following recommendation was made by many 
of the patients: it was suggested that the researcher should offer the option of the audio 
recording and allow patient to choose whether they preferred an audio tape or were willing to 
fill in the questionnaires without the audio recording. Patients felt that questionnaires were 
easy to follow, particularly those who were able to speak and read English. A few patients 
highlighted that some might find it difficult to fill in the questionnaires given their hand 
disability and therefore suggested that assistance in using the pen should be offered. The 
South Asian non-English speaking patients favoured the audio tapes. They found the 
questions on the tape to be clear. However, it was mentioned that the process was a long one 
with limited time to answer questions. The following quotes illustrate patients’ feedback.  
“I think that you need to be careful because there are a lot of questions here and someone 
who can’t hold a pen for too long cos of their joints being painful might just find it difficult. 
Like mine … but I found your assistance very useful”. [White,  45 year, female].  
“Yeh, I think this is really good way of engaging patients who can’t read English. I mean 
having read the questions myself and listening to the tapes I think like my mum would take 
part in this” [South Asian 34 year, male].  
“I think that your way of using the tapes is good method. Not many patients from our 
background would stop to fill these in if the tapes weren’t there” [South Asian, 50 year, 
female].   
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4.4 Recruitment  
The study was conducted in the outpatient rheumatology departments of Sandwell and West 
Birmingham Hospitals NHS Trust and the University Hospitals Birmingham NHS 
Foundation Trust. The rheumatology departments’ core aim is to provide care for patients 
with different rheumatological problems. The team has links with physiotherapy and orthotics 
services. Patients were identified via follow-up rheumatology clinic lists. Hospital clinical 
letters were screened by the researcher to identify patients who fulfilled the inclusion criteria 
as follows;  
• All patients must fulfil the 1987 American College of Rheumatology (ACR) 
classification criteria for RA.217 
• Patients must have been diagnosed with RA for more than three months.  
• Patients to be over 18 years.  
• Patients must have been taking at least one DMARD / have been on DMARDs in the 
past have been offered a DMARD in the past.  
• Patients must be of White British or South Asian background (this information was 
obtained from hospital records and from patients).  
• Patients must be able to speak English, Punjabi, Urdu or Hindi (this information was 
obtained from patients).  
Patients were classified as being of South Asian origin if they had three or more grandparents 
who had been born in India or Pakistan and also regarded themselves as being of South Asian 
origin following the approach in a previous study8. Patients were classified as being of White 
British origin if they had three or more grandparents who had been born in the UK or Ireland 
and also regarded themselves as being of White British origin.  
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Consecutive patients with RA were approached during their normal routine rheumatology 
appointment over seven month recruitment period. To reduce selection bias, the researcher 
did not approach any patients who were under her care. The researcher approached the 
identified patients while they were waiting to see their consultant or nurse specialist. Details 
of the study were discussed with the patients. If patients expressed an interest in taking part in 
the study, a Patient Information sheet outlining the study was given and they were given time 
to ask questions before being asked for their consent (Appendices 2, 3 and 4). Those patients 
who required more time to decide were given the researcher's phone number and asked to 
contact her if/when they decided to participate. In this situation, an additional visit was 
required on the part of the patients to complete the study forms. Patients who agreed to take 
part in the study were asked if they could be contacted for the follow-up study.  
4.5 Sample size 
In total, 310 patients were identified through routine rheumatology follow-up clinic lists, and 
of those, ninety two were excluded due to either cancellation of appointments or the patients 
not attending their appointment (Figure 3). A total of 218 patients were approached, of whom 
thirty eight declined to participate. The White British group (ninety one patients) were 
recruited before the South Asian group (eighty nine patients). Patients who helped with pilot 
































Eligible patients (n=310) 
Approached (n=218)  
Excluded:  
Cancelled appointment (n=15) 
Did not attend appointment (n=77)   
Participants (n= 180)  
Declined to participate (n=38) 
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4.6  Method of data analysis   
Quantitative survey data were analysed using PASW Statistics software version 18 (SPSS, 
Chicago, Illinois).275 Categorical data are summarised as counts and percentages, while other 
data are presented as means and standard deviation if normally distributed or as median and 
interquartile ranges. Fisher’s exact test was used for the comparison of nominal variables.276 
T-tests were used for those variables that were normally distributed.276 Nonparametric Mann-
Whitney tests were used for those variables that were not normally distributed.276 To examine 
the relationship of SIMS, BMQ and IPQ within each ethnic group Nonparametric Spearman 
correlation was used.276 Nonparametric Mann-Whitney and Kruskal-Wallis tests were used to 
compare the MARS scores for categorised variables as the MARS scores were not normally 
distributed. 276 The sample size of 176 (88 patients from each ethnic group) had been 
identified as being able to detect with at least 80% power a significant Pearson correlation 
coefficient at the 5% level if the true significant correlation of adherence and beliefs about 
medicines was less than or equal to -0.21 or greater than or equal to +0.21. This correlation 
was based on a previous study that investigated the relationship between beliefs about 
medicine and adherence.138 In that paper the researchers found a Pearson correlation 
coefficient of 0.21 between necessity score and adherence and a Pearson correlation 
coefficient of -0.33 between concern score and adherence. Thus, the sample size  would 
enable the current study to detect correlations of these magnitudes with at least 80% power. 
However, having obtained the data, it was discovered that data was not normally distributed. 
Therefore, the Spearman correlation was used. This had little effect on the power of the study.  
The overall MARS scores were used in the majority of the analyses (as planned in the study 
protocol design259 and suggested by previous study138;170;261) though the referenced 
study138;170;261 suggest dichotomizing MARS scores at the scale midpoint. The referenced 
studies138;170;261 recommend using overall MARS scores, as this provides richer information 
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and which is lost when the scale is dichotomized.138 Spearman correlation was used to assess 
the association between continuous variables and MARS scores. A multivariable general 
linear model was used to predict overall MARS. The variables that were adjusted for in this 
model were pre-specified in the study protocol.261 The model with adherence to DMARDs as 
the dependent variable was fitted, adjusting for age, sex, number of years of education, 
significant predictors on univariate analysis, and clinically relevant factors such as disease 
duration, DAS28, HAQ scores and DMARDs that are commonly used to treat RA (any 
additional variable that was noted to be significant in the univariate analysis was also 
adjusted for). An interaction with ethnicity was examined, and if this was identified, all 
subsequent analysis was stratified by ethnicity (South Asian vs. White British). Binary 
logistic regression was used to carry out analyses of variables with dichotomous MARS 
















Table 5: Summary of demographic and clinical data collected and questionnaires used 
in the quantitative survey  
Demographic Clinical Questionnaires  
Age CRP Medication Adherence Report Scale  
Gender  ESR Beliefs about Medicine 
Level of education  Disease duration  Illness Perception Questionnaire  
Employment  Functional 
disability  
Satisfaction with Information about Medicines  
Language spoken by 
patients 
DMARDs and 
anti-TNF use  
Health Assessment Questionnaire  
Language spoken by GP    
Patient’s Literacy    








In the following, the term “adherence” refers to patient self-report of medication adherence.  
This section will present the results of the quantitative phase.  
4.7.1 Demographic data (showing comparison between the two ethnic groups) 
The demographic details of patients are shown in Table 6. South Asian patients were younger 
(p=0.006, t-test) and included a significantly greater proportion of women compared to the 
White British group (p=0.024, t-test). There were no significant differences between the two 
groups in the number who had received formal education at a university level (p=0.538, 
Mann-Whitney). There were differences in employment status between the two ethnic groups 
(p=0.001, Fisher’s exact test), such that a higher proportion of the South Asian population 
were housewives. There were significant differences in patients’ languages and patients’ self-
reported literacy level between the ethnic groups. There were more English speaking patients 
in the White British group (p<0.001, Fisher’s exact test) and a greater proportion of patients 
in the White British group were literate. There were also significant differences between 





Table 6: Demographic data for all patients split by ethnic groups  
 
White  South Asian P value 
   (n= 91) (n=89)    
Age; years, mean (SD) 57.74 (12.74) 52.46(12.94) 0.006a 
Female (%) 56 (61) 69 (77)  0.024 a 
Level of education n (%)                                                                                             0.538c 
Primary 0 (0) 11 (12)   
Secondary  49 (54) 33 (38)   
College  21 (23) 26 (30)   
University  21 (23) 18 (20)    
Employment n (%)                                                                                                     0. 001b                
Full time  33 (36) 31 (35)   
Part time  3 (3) 8 (9)   
Unemployment  3 (3) 1 (1)   
Never employed  0 (0) 1 (1)   
Off work due to RA 12 (13) 15 (17)   
Off work for other reason  19 (21) 7 (8)   
Home - maker  4 (4) 18 (20)   
Retired 17 (19) 8 (9)   
Preferred language spoken by patients  (%)                                                         <0. 001b                                                             
English  91 (100) 51 (57)   
Punjabi  0  (0) 29 (33)   
Urdu  0  (0) 6 (7)   
Hindi  0  (0) 3 (3)   
Language spoken with GP                                                                                        <0.001b 
English  91 (100) 68 (76)   
Punjabi  0   (0) 16 (18)   
Urdu  0   (0) 3 (3)   
Hindi  0  (0) 2 (2)   
Patient Literacy                                                                                                         <0.001b                                                                          
Yes  90 (99) 71 (80)   
No 1 (1) 18 (20)   
Number of years in UK, mean (SD) NA 31.76 (11.6)   
DAS CRP , mean (SD) 4.02 (0.83)* 3.76 (0.81)* 0.034 a 
DAS ESR , mean (SD) 3.93 (0.94)* 4.34 (1.3) * 0.394 a 
Number of years of education  
median (interquartile range) 14 (11-16) 15 (11-17) 0.439 c 
Disease duration (years) 
median (interquartile range) 5 (2-11) 7 (3-13) 0.173 c 
Health assessment questionnaire score 
median (interquartile range) 1.25 (1-1.38) 1.25 (1-3) 0.927 c 
Oral / biologic DMARDs n (%) 
Methotrexate 77 (84.6) 81 (91.0) 0.256 b 
Sulphasalazine 38 (41.8) 42 (47.2) 0.549 b 
Hydroxychloroquine 10 (11.0) 11 (12.4) 0.820 b 
Anti-TNF 45 (49.5) 35 (39.3) 0.181 b 
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Other  8 (8.8)  7   (7.9)  1.000 b 
Questionnaires  
BMQ   median (interquartile) 
Specific Necessity 4.00 (3.80-4.20) 4.00 (4.00-4.00) 0.833 c 
Specific Concern  3.50 (2.83-4.00) 4.00 (3.83-4.00) <0.001 c 
NCD  0.33 (0.00-1.10) 0.00 (0.00–0.17) <0.001 c 
General Overuse 2.67 (2.00-3.33) 3.33 (3.00-4.00) <0.001 c 
General Harm  2.40 (2.00-3.00) 3.60 (3.00-4.00)  <0.001 c 
SIMS   median (interquartile) 
SIMS action and usage  9 (7 - 9)  8 (6 - 9) 0.006 c 
SIMS potential problems  6 (5 - 8) 6 (4 - 8) 0.060 c 
IPQ      median (interquartile) 
Identity  6 (5 - 8) 6 (5 - 7) 0.851 c 
Timeline  24 (23 - 27) 24 (22 - 25) 0.001 c 
Consequences  22 (18 - 24) 22 (19 - 24) 0.794 c 
Personal control  20 (17 - 23) 19 (17 - 23) 0.626 c 
Treatment control  16 (14 - 18) 16 (15 - 18) 0.914 c 
Illness coherence  18 (14 - 20) 15 (11 - 20) 0.041 c 
Timeline cyclical   15 (14 - 16) 16 (14 - 16) 0.017 c 
Emotional representation   22 (18 - 24) 24 (22 - 24) 0.004 c 
a t-test, b Fisher’s exact test, cMann-Whitney, * (CRP was available on ninety one 
 White British and eighty six South Asian participants, ESR was available on ten  
White British and eighteen South Asian patients at the time of recruitment).  
BMQ = Beliefs about Medicines, NCD = Necessity Concern Differential, SIMS = Satisfaction  
with Information about Medications Scale and IPQ = Illness Perception Questionnaire.   















4.7.2 Disease related variables  
The Disease Activity Score 28 calculated261 using the CRP (DAS28-CRP) was higher (active 
disease) in the White British patients than in the South Asian patients (p=0.034, t-test). The 
disease duration and HAQ did not differ between the two ethnic groups. Furthermore, there 
were no significant differences between patients in the two groups in terms of the DMARDs 
that they were on.  
4.7.3 Beliefs about medicines and ethnicity 
The Specific Concern (p<0.001, Mann-Whitney), General Overuse (p<0.001, Mann-Whitney) 
and General Harm (p<0.001, Mann-Whitney) scores were significantly higher in the South 
Asian patients, indicating more negative views of medicines in general and with regard to 
their DMARDs in particular. There was no significant difference between groups in the 
Specific Necessity scores for DMARDs. The NCD score was significantly higher in the 
White British patients (p<0.001, Mann-Whitney), indicating that their beliefs that DMARDs 
were necessary outweighed their concerns about DMARDs to a greater extent than was seen 
for the South Asian patients.  
4.7.4 Illness Perception and ethnicity 
There were significant differences in the IPQ domains. Illness coherence (patients’ 
understanding of RA) (p=0.041, Mann-Whitney) was lower in the South Asians, indicating 
that South Asians were more likely to have a poor understanding of RA. The timeline 
(patients’ view of disease as acute/chronic; p<0.001, Mann-Whitney) timeline cyclical 
(fluctuant disease; p=0.017, Mann-Whitney) and emotional representation (emotions 
generated by patients; p=0.004, Mann-Whitney) were significantly different between the two 
groups, indicating that South Asians were more likely to view RA as a short-lived as opposed 
to a chronic disease, to experience RA symptoms to be more fluctuating and to feel more 
negative emotion related to RA.  
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4.7.5 Satisfaction with information and ethnicity  
The SIMS action and usage scores were higher in the White British group (p=0.006) 
indicating that White British patients were more satisfied with information received about 
DMARDs  compared to South Asian patients.  
4.7.6 Correlation between SIMS, BMQ and IPQ within each ethnic group 
South Asian patients’ negative views about medicines being harmful and overused were 
found to correlate with lower levels of satisfaction with information about how medicines 
work to control RA symptoms (Action and usage and potential problems) (p=<0.001) (Table 
7). However, the overuse scores for action and usage and potential problems of the White 
British patients were correlated with level of satisfaction (p=0.027; p=0.028), but harm scores 
were not.  The correlation between patients’ perception of the adequacy of information about 
their prescribed DMARD and their beliefs about medicines in general were stronger in the 
South Asian patients. White British patients with higher concern had lower SIMS potential 
problems scores (p=0.031), as did those in the White British group with lower necessity-
concern differential (p=<0.001). 
South Asian patients had higher levels of satisfaction with information about DMARDs if 
they had a higher degree of personal control over symptoms (p=<0.001), had positive views 
of treatment (p=0.014), viewed these to be effective in controlling symptoms and had a 
greater understanding of RA (p=<0.001). The White British patients who viewed their RA 
symptoms to be less fluctuant were satisfied with the information received on potential 





Table 7 Correlation between SIMS and BMQ within each ethnic group 
 White British  P value  South Asian  P value  
Action and usage    
Overuse   -0.232 0.027 -0.389 <0.001 
Harm 0.154 0.146 -0.427 <0.001 
Potential Problems   
Concern  -0.226 0.031 0.061 0.567 
Overuse  -0.230 0.028 -0.269 0.011 
Harm  -0.185 0.078 -0.305 0.004 
NCD  0.333 <0.001 0.072 0.500 
 
Table 8 Correlation between SIMS and IPQ within each ethnic group 
 White British  P value  South Asian  P value  
Action and usage    
Personal control  -0.015 0.887 0.540 <0.001 
Treatment control  0.005 0.966 0.259 0.014 
Illness coherence  0.091 0.389 0.469 <0.001 
Potential Problems   
Personal control  0.083 0.431 0.446 <0.001 
Treatment control  0.136 0.197 0.270 <0.001 
Illness coherence  0.201 0.056 0.413 <0.001 
Identity  -0.210 0.046 -0.074 0.493 




4.8 Medication adherence measured by MARS overall scores  
4.8.1 Medication adherence and ethnicity: univariable analysis  
The distribution of the MARS scores by ethnicity is shown in Figure 4.  Both when using the 
overall MARS score (p=0.013, Mann-Whitney) and when treating it as a dichotomous 
variable (p=0.011, Fisher’s exact test), there was a significant difference between the two 
ethnic groups. A greater proportion of the White British group had higher adherence scores 
than the South Asian group.  
 
Figure 4: Showing vertical line of dichotomous MARS. (Filled square = South Asian 
patients, open circles = White British) 
For example the graph shows that 42% of South Asians had MARS scores of 25 or less 



























High adherence Low adherence 
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4.8.2 Medication adherence and other variables: univariable analysis 
There were significantly greater adherence scores in the English - speaking patients (both 
ethnic groups) (p<0.001, Mann-Whitney) (Table 9). Patients who said they spoke with their 
GP in their preferred language had higher adherence scores compared to those who did not 
(p=0.002, Mann-Whitney). Patients who were born in the UK had higher adherence scores 
than did those born in India (p=0.015, Dunn’s test). Patients who were more educated had 
higher adherence scores (p=0.014, Spearman correlation). Patients who had higher General 
Overuse (p<0.001, Spearman correlation) and General Harm scores (p<0.001, Spearman 
correlation) had significantly lower adherence scores. The NCD scores were correlated with 
MARS scores; patients whose perceived need for treatment outweighed their concerns about 
it had higher self - reported adherence scores (p=0.005, Spearman correlation). Both SIMS 
components, action and usage (p<0.001, Spearman correlation) and potential problems 
(p<0.001, Spearman correlation), were correlated with MARS, with patients who were more 
satisfied with information on DMARDs having higher adherence scores. The two IPQ 
domains - personal control (p=0.012, Spearman correlation) and illness coherence (p<0.001, 
Spearman correlation) - were correlated with MARS, with patients who had better personal 
control and understanding of the disease having higher adherence scores. The IMD score was 
not associated with adherence scores for either group (White British, p=0.320; South Asian, 




Table 9: Univariable analysis of medication adherence as measured by overall MARS 
scores (Data for 180 patients) 
Categorical variables  
MARS Scores 
Median (interquartile)  (p value) 
Gender                                                                                                                               0.982a 
M 28 (25-30)   
F 28 (24-30)   
Level of education                                                                                                            0.083b 
Primary  26 (24-27)   
Secondary  27 (24-30)   
College  28 (25-30)   
University  28 (26-30)   
Employment                                                                                                                      0.219b 
Full time  28 (25-30)   
Part time  28 (22-30)   
Unemployment  30 (28-30)   
Never employed  23 (NA)   
Off work due to RA 26 (23-30)   
Off work for other reason  26 (22-30)   
Home maker  26 (24-29)   
Retired 29 (26-30)   
English spoken by patients                                                                                            <0.001a                        
Yes  28 (26-30)   
No  24 (22-28)   
Same language spoken by patients and GP                                                                   0.002a                                     
Yes 28 (25-30)   
No 24 (22-27)   
Literacy level                                                                                                                     0.053a 
Yes 28 (24-30)   
No 24 (24-28)   
Ethnicity                                                                                                                            0.013a 
White British  28 (26-30)   
South Asian  26 (23-30)   
Oral /Biologic DMARDs                                                                                                   
Methotrexate    0.202a 
Currently on  28 (24-30)   
Not on  26 (25-28)   
Sulphasalazine                                                                                                                  0.058a 
Currently on  26 (23-30)   
Not on  28 (25-30)   
Hydroxychloroquine                                                                                                        0.621a 
Currently on  28 (22-30)   
Not on  28 (24-30)   
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Categorical variables  
MARS Scores 
Median (interquartile)  (p value) 
Anti-TNF                                                                                                                           0.199a 
Currently on  28 (24-30)   
Not on  27 (24-30)   
Patients’ country of birth                                                                                                0.014b 
UK 28*(25-30)   
India  26*(22-29)   
Pakistan  28 (27-30)   
Continuous variables (Spearman correlation)         
Age  0.093 0.212 
Number of years of education   0.183* 0.014 
Number of years in UK -0.177 0.165 
Disease duration  0.058 0.438 
DAS CRP 0.032 0.674 
DAS ESR  -0.252 0.196 
HAQ -0.055 0.465 
IMD  -0.075 0.315 
Questionnaires   
BMQ      
Specific Necessity  0.052 0.489 
Specific Concern -0.114 0.127 
NCD   0.209** 0.005 
General Overuse -0.309** <0.001 
General Harm -0.300** <0.001 
SIMS   
SIMS action and usage  0.386** <0.001 
SIMS potential problems  0.469** <0.001 
IPQ   
IPQ Identity  -0.126 0.092 
IPQ Timeline  0.071 0.343 
IPQ Consequences  -0.052 0.492 
IPQ Personal control  0.187* 0.012 
IPQ Treatment control  0.085 0.258 
IPQ Illness coherence   0.294** <0.001 
IPQ Timeline cyclical   -0.138 0.065 
IPQ Emotional representation  -0.097 0.197 
aMann Whitney,  b Kruskal Wallis  * India vs UK P=0.0154 (Dunn’s Test) * = significant at 
<0.05, ** = significant at <0.01. BMQ = Beliefs about Medicines, NCD = Necessity Concern 
Differential, SIMS = Satisfaction with Information about Medications Scale and IPQ = 





4.8.3 Multivariable analysis of medication adherence measured by overall MARS scores  
Multivariable analysis included age, sex and all variables that were significant in the 
univariable analysis (Table 10). There were significant effects of ethnicity and both SIMS 
components on adherence scores and there was also a significant interaction between 
ethnicity and the SIMS action and usage component. The effects were similar to those 
observed in the univariable analysis. South Asians had lower adherence scores compared to 
White British patients. Patients with higher SIMS scores had higher adherence scores. The 
interaction between SIMS action and usage and ethnicity was significant (p=0.005, F test) 
with SIMS action and usage having a greater influence on adherence in South Asian than in 
White British patients. The multivariable analysis was repeated using dichotomous MARS 
scores. The same variables were significant in both multivariable analyses with the exception 
that age was only significant when the MARS was treated as a binary variable. This 




Table 10: Multivariable analysis of medication adherence as measured by overall 
MARS scores (Data for 180 patients) 
 B Confidence interval  P value  R2         
for model  
    0.328 
Age (years) -0.012 -0.049 - (0.025) 0.523  
Sex  (male)  -0.754 -1.754- (0.245) 0.138  
Number of years in education -0.022 -0.095 - (0.050) 0.540  
English spoken by patient  -0.492 -2.384 - (1.399) 0.608  
Same language spoken by 
patient and GP 
1.447 -0.466 - (3.360) 0.137  
Born in Pakistan a 2.071 -0.023 - (4.165) 0.053  
Born in India a 1.575 -0.158 - (3.307) 0.075  
Ethnicity (White British)  7.333 2.924 - (11.743)    0.001**  
BMQ 
NCD 0.079 -0.590 - (0.749) 0.815  
General Overuse  -0.193 -0.478 - (0.092) 0.183  
General Harm -0.049 -0.250 - (0.153) 0.635  
SIMS  
SIMS action and usage (South 
Asian patients) 
0.560 0.163 – (0.958)    0.006**  
SIMS action and usage (White 
British patients)  
-0.202 -0.595 – (0.191) 0.311  
SIMS potential problems  0.428 0.217 - (0.639)     <0.001***  
IPQ  
IPQ Personal control  -0.070 -0.205 - (0.066) 0.310  
IPQ Illness coherence  0.086 -0.038 - (0.211) 0.174  
     
Interaction      
SIMS action and usage x 
ethnicity b 
  0.005**  
a = reference category born in UK. b The significant interaction indicates that the effect of 
SIMS action and usage varies with ethnic group: hence there are two separate sets of values 
for South Asian and White British patients.  ** = significant at <0.01 *** = significant at 
<0.001.  
BMQ = Beliefs about Medicines Questionnaire, NCD = Necessity Concern Differential, 





4.8.4 Comparison between hospital sites and adherence: univariable analysis  
Both when using the overall MARS score (Kruskal Wallis p=0.249) and when treating it as a 
dichotomous variable (Fisher’s Exact test p=0.453) there was no significant difference in 
MARS scores between the hospital sites.  
4.9 Medication adherence measured by MARS as a dichotomous variable    
 
4.9.1 Medication adherence and variables: univariable analysis 
Patients who were more educated had higher adherence scores (Kendall’s tau-b, p=0.011) 
(Table 11).There were significantly higher scores in the English speaking patients (Fisher’s 
Exact p=<0.000). Patients who spoke the same language as their GP were also shown to have 
higher adherence scores (Fisher’s Exact p=0.005). Patients of White British origin had higher 
adherence scores compared to South Asians (Fisher’s Exact, p=0.011). Patients who were 
born in the UK were found to have higher adherence scores than were those born in India 
(Fisher’s Exact, p=0.005). Patients for whom concerns outweighed the benefits of DMARDs 
had lower NCD scores and thus had lower adherence scores (Mann Whitney, p=<0.001). 
Patients who had lower adherence scores had higher concern (Mann Whitney, p=0.006), 
overuse (p=<0.000) and harm scores (p=<0.000). Patients who were satisfied with 
information on DMARDs had a higher level of adherence scores (Mann Whitney p=<0.000). 
Patients who had better control (Mann Whitney, p=0.025) and understanding of the disease 
(Mann Whitney, p=<0.000) had higher adherence scores. Patients who viewed their disease 




Table 11: Univariable analysis of medication adherence measured by MARS as 
dichotomous (Data for 180 patients shown in number and %) 
Categorical Variables  Higher Adherers  (p value) 
 MARS scores of 26 ≥ 
n (%)  
Showing Comparison 
of categorical variables  
Gender                                                                                                                                           0.390a 
M 40 (73)  
F 82 (66)  
Level of education                                                                                                                         0.011b 
Primary  6 (55)  
Secondary  49 (60)  
College  35 (75)  
University  31 (80)  
Employment                                                                                                                                  0.139a 
Full time  46 (72)  
Part time  7 (63)  
Unemployment  4 (100)  
Never employed  0 (0)  
Off work due to RA 17 (63)  
Off work for other reason  15 (56)  
Home maker  12 (55)  
Retired 21 (84)  
English spoken by patients                                                                                                        <0.000a 
Yes  107 (75)  
No  15 (40)  
Same language spoken by patients and GP                                                                               0.005a                                                     
Yes 116 (71)  
No 6 (35)  
Patients’ Literacy                                                                                                                         0.004a                                                                                 
Yes 115 (71)  
No 7 (37)  
Ethnicity                                                                                                                                         0.011a 
White British  70 (77)  
South Asian  52 (58)  
Oral biologic DMARDs    
Methotrexate                                                                                                                                  0.808a 
Currently on  106 (67)  
Not on 16 (73)  
Sulphasalazine                                                                                                                               0.109a 
Currently on  49 (61)  
Not on  73 (73)  
Hydroxychloroquine                                                                                                                     0.621a 
Currently on  13 (70)  
Not on  109 (69)  
Anti-TNF                                                                                                                                        0.263a 
Currently on  58 (73)  
Not on  64 (64)  
Patients’ country of birth                                                                                                             0.005a 
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Categorical Variables  Higher Adherers  (p value) 
UK 86 (74)  
India  25 (50)  
Pakistan  11 (85)  
 
 








of high and 
low 
adherers  
Continuos variables  
median (interquartile) 
 
Age  58 (52-61.5) 55 (49-62) 0.926c 
Number of years of education  12 (9-15)  15 (11-17) 0.015c 
Number of years in UK 34 (30-43)  30 (19-40) 0.313c 
Disease duration  7 (3-14.5) 8 (4-13) 0.615c 
DAS CRP 3 (3.4-4.4) 3 (3-4) 0.991c 
DAS ESR  4.1 (3.8-5.2) 4.3 (3.2-4.9) 0.365c 
HAQ 1 (1-1.4) 1 (1.1-1.2) 0.378c 
IMD 32 (19-48) 37 (16-48) 0.302c 
Questionnaires median (interquartile)    
BMQ     
Necessity  20 (20-20) 20 (20-20) 0.780c 
NCD -4 (-4 - -4) -4 (-4 - -2) <0.001c 
Concern 24 (24-24) 24 (22-24) 0.006c 
Overuse 12 (10-12) 9 (8-12) <0.000c 
Harm 20 (18-20) 15 (13 -20) <0.000c 
SIMS    median (interquartile)    
SIMS action and usage  6 (4-7) 9 (7-9) <0.000c 
SIMS potential problems  3 (.50-5.0) 6 (5.0-8.0) <0.000c 
IPQ       median (interquartile)    
IPQ Identity  6 (5.0-7.0) 6 (5.0-8.0) 0.788c 
IPQ Timeline  23 (22-24) 23 (22-25) 0.056c 
IPQ Consequences  22 (20-24) 20 (18-24) 0.338c 
IPQ Personal control  18 (16-19) 20 (18-23) 0.025c 
IPQ Treatment control  16 (14-16) 17 (15-20) 0.342c 
IPQ Illness coherence  11 (10-12) 18 (12-20) <0.000c 
IPQ Timeline cyclical   16 (16-16) 15 (12-16) 0.100c 
IPQ Emotional representation  24 (22-24) 24 (18-24) 0.024c 
aFisher’s Exact Test,  bKendall’s tau-b Test, c Mann Whitney Test * India vs UK P=0.014 
BMQ = Beliefs about Medicines, NCD = Necessity Concern Differential, SIMS = 




4.9.2 Multivariable analysis of medication adherence measured by dichotomous MARS scores  
All the variables that were significant in the univariable analysis as well as age and sex 
(Table 12) were included in a multivariable analysis. There was a significant effect of 
ethnicity on both SIMS components with a significant interaction between SIMS action and 
usage. South Asians were more dissatisfied with information received about DMARDs and 
were more likely to be lower adherers compared to White British patients. SIMS action and 




Table 12: Multivariable analysis of medication adherence measured by MARS as 
dichotomous variable 
     
 Odds ratio Confidence interval  P value  
    
Age  0.978 0.944 - (1.013) 0.220 
Sex  0.731 0.294 - (1.815) 0.499 
Number of years of education 0.936 0.877 - (1.000) 0.050 
English spoken by patients 0.553 0.090 - (3.396) 0.522 
Same language spoken by patients 
and GP 
0.536 0.093 - (3.080) 0.484 
Patients’ literacy level  1.788 0.326 - (9.805) 0.503 
Born in India  6.324 1.190 - (33.604) 0.030 
Born in Pakistan  14.260 1.592 - (127.698) 0.018 
Ethnicity (White British)  255.372 4.231 - (15413.621) 0.008 
BMQ    
Concern  1.073 0.905 - (1.272) 0.419 
NCD 1.064 0.899 - (1.260) 0.472 
Overuse  0.865 0.675 - (1.108) 0.250 
Harm 0.915 0.767 - (1.092) 0.324 
SIMS    
SIMS action and usage  1.730 1.167 - (2.566) 0.006 
SIMS potential problems  1.267 1.054 - (1.523) 0.012 
IPQ     
IPQ Personal control  0.967 0.853 - (1.096) 0.599 
IPQ Illness coherence  1.021 0.917 - (1.138) 0.702 
IPQ Emotional representation  0.965 0.867 - (1.075) 0.519 
Interaction     
SIMS action and usage (White) a 0.547 0.333 - (0.899) 0.017 
a = SIMS action and usage (South Asian): the significant interaction indicates that the effect 
of SIMS action and usage varies with ethnic groups.   
BMQ = Beliefs about Medicines, NCD = Necessity Concern Differential, SIMS = 





4.10 Discussion  
The findings presented in the results section were similar in both sets of analysis (MARS 
overall and dichotomous). Both analyses showed lower self-reported adherence amongst 
South Asians compared with White British RA patients. Poor self-reported adherence to 
DMARDs was associated with dissatisfaction with information about side effects (SIMS 
potential problems) in all patients. There was an interaction between ethnicity and 
dissatisfaction with information about how DMARDs work to control the condition and how 
to use DMARDs (SIMS action and usage), such that dissatisfaction with information about 
the action and usage of DMARDs was a greater predictor of adherence scores in South Asian 
patients than in White British patients. Non adherence scores were also associated with both 
specific and general beliefs about medicines. Patients who rated their concerns about 
DMARDS as high relative to their ratings of their personal need for DMARDs to control RA 
and maintain present and future health, reported lower adherence. DMARD adherence scores 
were also correlated to more negative social representations of medicines as a whole with low 
adherence scores associated with a perception that medicines are fundamentally harmful and 
are overused by doctors.  
The only existing work carried out in the area of beliefs about medicines amongst South 
Asian patients with RA is by the researcher.8;91 Other work, however, has shown beliefs 
about medicines to correlate with medication adherence, although South Asian patients were 
not represented in these studies.34 The study findings will now be compared to existing 
literature.  
Firstly, previous studies investigating beliefs about medicines among RA patients found as 
did this thesis that patients had strong concerns about potential side effects of 
DMARDs.33;34;44 For example, Neame and Hammond34 reported concern scores to be 
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associated with non-adherence and the thesis findings suggest that concerns about potential 
adverse consequences of DMARDs may be particularly prevalent in South Asian patients. In 
a Danish study among RA patients, it was found that, during the first year of taking 
DMARDs, adherence to methotrexate among patients with RA was explained by strong 
views of a personal need for DMARDs.277 Furthermore, this thesis found that South Asian 
patients tended to have more negative views about medicines as a whole. In common with a 
previous study of medication beliefs and adherence in RA,34 the researcher found no 
association between sociodemographic factors  (age, gender, level of education) and non-
adherence score.  
This thesis found that patients’ dissatisfaction with information about the action and usage of 
DMARDs and potential problems related to taking DMARDs was also associated with non-
adherence scores, and that these effects were strongest in the South Asian patients. The 
multivariable analysis suggests that these results cannot be attributed simply to barriers to 
accessing information due to age or educational level, as the effect remained when 
controlling for these factors. Dissatisfaction with information may occur because of a lack of 
fit between the information provided to patients and their existing beliefs and also more 
importantly, patient dissatisfaction with information about medicines is often correlated with 
specific concerns.278 Those with higher concerns are more likely to seek explanations for the 
need for medication.109 For example, patients who view RA to be an acute condition might 
need to be provided with a more convincing rationale for taking long term treatment in 
periods of low disease activity. The correlation of SIMS and IPQ show that those patients in 
whom there was a better understanding of RA had higher SIMS scores. This means that better 
understanding of RA was associated with higher satisfaction with information. The desire to 
receive a range of information that helped them to weigh up the benefits and risks of taking 
DMARDs has also been expressed by patients in other RA studies.33;279 However, these 
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studies did not report data on ethnicity. An ethnic difference in adherence levels has been 
reported in some other chronic diseases. For example, lower treatment adherence has been 
reported in blacks and Asians with hypertension,280 heart failure103 and diabetes281 compared 
to Whites. Studies in systemic erythematosus (SLE) (another disease associated with arthritis 
though also with a wide range of extra-articular features), report ethnic differences in cultural 
beliefs and practices,4;281 concerns about long term harmful effects of drugs, poor 
communication with physicians,282 and the use of complementary medicines and prayer as 
alternatives to western medicines,283;284 Other factors, such as concerns about long term 
effects of medicines are unlikely to be unique to a particular ethnic group, but are more likely 
to be related to the individual’s experience with medication.285 Similarly, a study conducted 
in the US found that Hispanic RA patients were more likely to stop DMARDs therapy if their 
experience with glucocorticoids was more positive in controlling RA symptoms.286 A study 
comparing sixty eight African American and fifty four White women with SLE identified 
barriers to adherence which appeared to be ethnicity-specific, in that depression and poor 
memory predicted low adherence, while non-adherence in Whites was related to lack of trust 
in physicians and perceived treatment inefficacy.287 The thesis has also found low perceptions 
of treatment efficacy in the South Asian patients. In a separate study based in the UK, Pyne 
and colleagues288 presented results on medication adherence amongst ethnic minority groups 
from the Indian subcontinent. Ninety patients who had various autoimmune rheumatic 
diseases were included in that study, which found that non-adherence was more common 
among non-English speaking Asian patients. This pattern was also noted in the present thesis. 
Immigrants generally retain their traditional cultural beliefs and practices including ideas 
related to diseases and their treatments, and these might have an impact on adherence to 
medication.216 In the current study it was discovered that South Asian patients born abroad 
were lower adherers. This has also been demonstrated by another study that assessed 
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medication adherence in SLE patients from Jamaica: the country of origin of most of the 
black patients in the UK cohort.289 This study showed differences in practices of taking 
medication such as fear or experience of side effects and the use of herbal remedies. The 
current study did not record patients’ use of herbal remedies. The association between beliefs 
and adherence seen within the current sample is consistent with theoretical predictions 
regarding the importance of beliefs about medicines in patients with RA.261 These findings 
provide further support for the Necessity-Concerns Framework in non-adherence, which 
suggests that these “common-sense appraisals” of treatment can impact on adherence.114 
Within this framework, the beliefs held by patients about treatment arise from a range of 
factors, including personal experience and culture, as well as from information provided by 




4.11  Strengths and weaknesses  
This study was the first to look at medication adherence amongst South Asians in RA. The 
quantitative approach allowed identification of the factors affecting medication adherence. 
The study had a number of limitations including the fact that adherence was self-reported. It 
is widely recognised that all approaches to measuring adherence have their limitations.98 The 
methodology to be used to measure adherence in the present study was discussed with the 
patient Steering Group for the study, who recommended a self - report strategy.261 Further 
studies may need to combine a self-report measure with other techniques in this population.98 
Further, this is the first study in RA to have used a number of questionnaires (SIMS, IPQ and 
MARS) that were independently translated into three languages for the South Asian 
population. It is possible that some views specific to this population are not captured via these 
questionnaires. For example, in the researcher’s previous qualitative work, patients’ views 
about disease and medicines were influenced by their beliefs about fate and culture.91 Also 
when providing a response to some of the domains within the IPQ (‘This RA will pass 
quickly’, ‘I expect to have this RA for the rest of my life’, I have the power to influence my 
RA’) patients gave additional explanations during conversation to those present in the 
questionnaire. For example, for nearly all these statements, there were ten patients who talked 
about the course of their illness being up to God, but this option was not available in the 
questionnaire. For this reason, caution is recommended in the use of the IPQ in South Asian 
patients. Finally, this study was cross-sectional, preventing the researcher from drawing 
conclusions regarding which factors were causally related to non-adherence. Despite the 
limitations mentioned above, this study provides novel insight into RA patients’ poor 
adherence within these two ethnic groups in that it looked at a cohort of patients with higher 
and lower adherence to DMARDs.  
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4.12 Summary   
In summary, non-adherence to DMARDs between the ethnic groups was associated with 
patients’ beliefs about DMARDs and their views about medicines in general, together with 
their satisfaction with the type and amount of medicines information they had received. 
Future interventions promoting adherence should take these factors into account and tailor 




CHAPTER 5: QUALITATIVE PHASE 
5.1 Introduction to chapter 
This chapter begins with ethical approval and then with a description of patient recruitment, 
and sample size. This then leads to the development of the interview schedule, data collection 
and the method of data analysis. Themes arising from the data are presented in the following 
sequence: [1] symptom severity; [2] illness perception; [3] perceived benefits and risks of 
DMARDs; [4] the quality and quantity of information. During the interviews, patients’ 
experiences of taking DMARDs and their perceptions of the challenges they face in adhering 
to their medicines were explored.  Patients’ recommendations to improve adherence to 
medicines are presented, along with a discussion of the findings and conclusion.  
5.1.1 Ethics and Research Governance approval for the Qualitative Phase  
The study was approved by the South Birmingham Research Ethics Committee (Appendix 
10). All patients gave written informed consent to take part in the study. These patients had 
participated in the quantitative survey (Chapter 4) of the study and had given consent to be 
contacted for a follow – up study (Appendices 11 and 12).  
5.1.2 Recruitment  
Of the 180 patients, who had taken part in the quantitative survey (Chapter 4) 178 had given 
permission to be contacted. Patients were stratified into high and low MARS tertiles for the 
selection of interviews.261 In addition, patients’ ethnicity and gender were also included in 
this stratification. Invitation letters together with Patient Information sheets were sent to those 
patients who had agreed to be contacted  during the quantitative survey.  Patients were invited 
for a one - to - one, one hour interview to discuss issues surrounding medication adherence 
(Appendices 13 and 14). The interviews were conducted at the patients’ convenience at one 
of the hospitals that patients attended for their rheumatology appointments. Although the 
interviews took place in a hospital setting, they were conducted away from the clinical 
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environment at the hospital (for example, not in the environment where patients would 
normally be assessed for their disease activity). The interviews were conducted on the 
hospital sites in a designated area (for example, hospital postgraduate centre).      
5.1.3 Sample size 
Out of the 178 patients who gave permission to be contacted for interviews, a list was created 
that stratified a total of 112 patients into high (White British 33, South Asian 17) and low 
MARS scores (White British 23, South Asian 39). The remaining 66 patients were in the 
middle tertile. The stratification also included gender and ethnicity. From the stratification list 
36 patients were approached (high adherers ten White British, eight South Asians: low 
adherers six White British; 12 South Asians) of whom 16 declined to take part. Patients were 
selected purposively to ensure a mixture of age, gender and ethnicity, language spoken, 
employment status were included. Each patient was contacted for interview, and if the patient 
agreed then arrangements for interview were made. However, if the patient declined to take 
part the next patient on the list was contacted. This sequence of recruitment was performed 
until data saturation had been reached.290A total of 20 patients agreed to participate (ten high 
adherers: six White British, four South Asians; ten low adherers: three White British, seven 
South Asians). It has been suggested that the number of patients used in qualitative research 
is a matter of judgment in the data emerging. A large sample may dilute the in-depth meaning 
of the data, equally, a small sample may not capture the full meaning of the data.291. Patient 




5.1.4 Development of interview schedule (piloting)   
A proposed topic guide was developed after the results of the quantitative survey. The topic 
guide used questions broadly based on the Necessity Concerns Framework and SRM170 
(Appendix 15). The topic guide was discussed with the patient Steering Group.  The topic 
guide included initial questions that were general (e.g. “What do you think about your 
DMARDs?”), and were followed with prompts based on the Necessity Concern framework 
(e.g. “How necessary do you feel the medication is for you?” and “Do you have any concerns 
about DMARDs?”).  
Furthermore, questions were asked about patients’ adherence and non-adherence to 
DMARDs, including stopping and changing the doses of DMARDs and reasons for doing so. 
In addition, the patient Steering Group felt it was necessary to obtain patients’ 
suggestions/recommendations on improving medication adherence. The resulting interview 
schedule was designed to enable the researcher to explore adherence issues, illness and 
treatment perceptions, and beliefs about medicines.  
5.1.5 Data collection 
Each interview was digitally recorded and later downloaded to a university computer where 
the interview was transcribed verbatim and analysed as described in more detail in the next 
section. 
5.1.6 Methods of data analysis for Qualitative Phase 
In each group (patients with high and low adherence) there was a mixture of White British 
and South Asian patients. A maximum variety approach was used to capture a broad  





Table 13: Demographic characteristics of interview and patients who declined 
Ethnic group High adherers Low adherers 
 N=10 N=10 
South Asian: Gender 
    Male  1 2 
    Female  3 5 
   Age (years) 41 (mean) 47 (mean)  
Language spoken: 
    English  3 3 
    Punjabi  1 4 
Employment:  
   Employed  2 3 
   Unemployed - - 
   Homemaker 1 1 
   Retired  - 2 
   Off work due to RA 1 1 
 
White British: Gender  
   Male  2 1 
   Female  4 2 
  Age (years)  49.5(mean) 43 (mean) 
 Language spoken: 
   English only  6 3 
Employment:  
  Employed  2 1 
  Unemployed 1 - 
  Homemaker 1 - 
  Retired  1 2 
  Off work due to RA 1  
 
Decliners                                       N=3                                                    N=5                                                 
South Asian: Gender   
  Male 2 1 
  Female  1 4 
  Age (years) 51 (mean) 53.5 (mean) 
Language spoken:  
  English 2 3 
  Punjabi 1 2 
Employment:  
  Employed 3 3 
  Unemployed - - 
  Homemaker - 2 
  Retired - - 
  Off work due to RA - - 
 





White British: Gender                   
  Male 1 2 
 Female 3 1 
 Age (years) 56.5 (mean) 58 (mean) 
Language spoken:  
 English 4 3 
Employment:  
 Employed 3 2 
 Unemployed - - 
 Homemaker - - 
 Retired - 1 
 Off work due to RA 1 - 
 
An inductive approach was used to explore the motivations and barriers to medication 
adherence.292 Organisation and coding of the data were carried out. Initial coding consisted of 
analytical summaries of patients’ accounts, which were then categorised and labelled with an 
overarching description of the data.293 Later in the analysis procedure, the initial coding was 
revisited and the more recent codes were tested against earlier categories. Charmaz293 
suggested six questions to ask of data during the initial coding process:  
1) What process(s) is at issue here? How can it be defined? 293 
2) How does this process develop? 293 
3) How does the research patient (s) act while involved in this process? 293 
4) What does the research patient (s) profess to think and feel while involved in this 
process? What might his or her observed behaviour indicate? 293 
5) When, why and how does the process change? 
6) What are the consequences of the process?  
Validation of initial coding was undertaken by the researcher. Blind coding of selected 
interviews with two clinicians (PG and AJ) and a medical sociologist (SG) was undertaken.293  
A summary of each interview was sent to patients for validation. Patients were in agreement 
with the summary of their interview. Coding categories that lacked concordance were 
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discussed within the team (PG, AJ and SG) and absorbed into the coding framework. The 
initial codes were then grouped together into the most frequently occurring categories. 
Related categories were then linked together.294 This involved the researcher taking the 
developed categories and coded data and linking them between the two ethnic groups. This 
sequence of constant comparison was carried out until no new codes were found to 
connect.292 During the coding, the researcher looked for demographic, factual (e.g. disease 
symptoms) and/or conceptual meaning, such as whether there were any issues about 
medication adherence related to gender or what aspects of the patient’s story helped to 
explain the meaning of medication adherence. The researcher focused on  themes that related 
to medicine adherence. In addition, attention was paid to more specific topics (beliefs about 
medcines, certain domains of IPQ). Results that were shown to be signficant from the 








5.2 RESULTS       
This section will present the results of the qualitative study. Each theme will be explained in 
detail.  
Four main themes related to adherence were identified in both high and low adherers: [i] 
Symptom severity. [ii] Illness Perception. [iii] Perceived benefits and risks of DMARDs. [iv] 
The quality and quantity of information (Table 14). The sub themes further helped the 
researcher to understand adherence to DMARDs. The sub themes underlying high adherence 
differed from those underlying low adherence. While the reasons for high adherence were 
similar in individuals from the two ethnic groups the reasons underlying low adherence 
differed. Each theme is illustrated with quotations extracted from the transcripts. The 
researcher also cites the numbers of patients who agreed with certain concepts of medication 












Table 14: Comparison of themes and sub-themes by adherence level and ethnic group 
Themes High adherers  Low adherers  South Asians  White British 
Symptom 
severity 
• Severe onset of 
symptoms  
• Family history  
• Mild symptoms 
(patient view) 
 
• Mild symptoms (low 
adhering patients’ view) 
 
 
• Severe symptoms (low 




perception    
• No cure for 
disease 
• Long term 
disease 
• *Seeking cure for 
disease 
• Acute disease   
 
• *Seeking cure for disease 
• *Acute disease   
• Disease not viewed as serious  
• RA viewed as a disease of the 
elderly  
• *No cure for disease 






• Benefits outweigh 
concerns  




• *More concerns 
about toxicity than 
benefits  
• *More concerns about 
toxicity than benefits  
• Natural remedies safer 
• *Efficacy of advanced 
therapy seen as more 





• More satisfied 














• *Poor relationship 
with health 
professionals 
• *Poor knowledge 
about disease 
parameters 
• Lack of information, no 
experience of visual aids 
• Poor relationship with health 
professionals 
• Poor knowledge about 
disease parameters 
 
• *General lack of awareness 
of RA amongst the 
community influenced long 
term use of DMARDS 
• Lack of information, no 
experience of visual aids 
• Poor relationship with 
health professionals 
• Poor knowledge about 
disease parameters 
*No ethnic differences in high adherers but ethnic differences noted in low adherers  
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 5.2.1 Symptom severity (high adherence)  
Seven patients perceived RA medication to be very important; this was related to patients’ 
current experience of symptoms and their recollection of severe symptoms at disease onset 
[Quote 1]. They were also aware that uncontrolled RA could lead to future health problems 
[Quote 2]. As a result of both symptom severity and awareness of future risks, the high 
adherers viewed RA medicines to be important. In four patients, family history of RA 
appeared to increase the level of importance that patients afforded to RA medicines [Quote 3]. 
No ethnic differences were noted in this theme.  
Quote 1 “I will take this medication for the rest of my life. I wouldn’t stop taking them 
just to test it out. I just don’t want to go where I was”. [59, retired, English 
speaking, White patient]  
Quote 2 “I have no doubt in my mind that if I stop taking these medications then I 
know that I would be in a wheelchair”. [34, Nurse, English speaking, Asian 
patient] 
Quote 3  “I have had experience of my mother. She had exactly the same problem as 
me. She really suffered. I saw her disease develop over time. That really put 
the fright in me”. [34, Nurse, English speaking, Asian patient]  
 
5.2.2 Illness perception (high adherence) 
Regarding patients’ views about their RA, all ten high adhering patients stated a range of 
different reasons for the occurrence of their RA. None believed that the disease was curable 
therefore, they accepted the need for long term therapy [Quote 4]. They held the belief that 
taking the medicines would help to control the disease and this influenced patients’ decisions 








“I doubt it very much that it can be cured yes it can be controlled”. [62, 
retired, English speaking, White patient]  
Quote 5 
 
“You see without them I will not have a better quality of life”. [62, retired, 
English speaking, White patient]  
Quote 6 
 
“To be pain free and controlled the disease...I would say that’s my 
motivation to take them”. [51, off work due to RA, English speaking, 
Asian patient]  
 
5.2.3 Perceived benefits and risks of DMARDs (high adherence) 
Nine patients described the medicines as working to control their RA. Patients made 
comparisons between their medications; for example, treatment concerns and/or perceptions 
about efficacy were used to make these comparisons. For example, those who were taking 
anti-TNF (six patients) believed that their lives had been transformed through taking this 
class of medication. This implied that patients viewed anti-TNF to be more effective in 
controlling their symptoms than DMARDs. This was a shared view across both White and 
South Asian patients [Quotes 7 and 8]. The patients who had felt medication was necessary 
(all ten patients) expressed fewer concerns about medicines and did not question the necessity 
of DMARDs [Quote 9]. This appraisal was based on the themes above (symptom severity, 
views on control rather than cure). Five participants gave examples of how their disease 
flared when they had taken the decision to discontinue DMARDs for a while [Quotes 10 and 
11]. The remaining five gave examples of persistent presence of RA symptoms. These 
evaluations informed their views about how necessary the DMARDs were and patients 




Quote 7  “Rituximab has transformed my life now. The rheumatoid arthritis has 
kept under control since I have started on that” [62, retired, White 
patient]  
Quote 8  “Initially I couldn’t even bend my knees I couldn’t do my house hold 
chores, since I have been on Methotrexate ....yes I can do these now. I am 
a paediatric nurse and I am on my feet all the time. So for me to take the 
medicines is very important”. [36, manager, English speaking, Asian 
patient]  
Quote 9 “I think that sometimes you think I am taking all these medicines ....like 
Methotrexate they could damage your kidneys your liver....but I would 
rather have that danger rather than how I was before. So the dangers of 
the drugs that I hear don’t mean nothing to me because I want to be how I 
am now”.  [52, house wife, English speaking, White patient]  
 
Quote 10  “I stopped it for a while (MTX) but my flare had come back so I knew I 
had to take it”. [36, manager, English speaking, Asian patient] 
 
Quote 11 “I know this would get worse you see. It’s there all the time and stopping 
the medication will make it worse”. [42, machine operator, English 
speaking, White patient]  
 
 
A range of concerns about DMARDs appeared to be related to the different types of 
DMARDs used. For example, concerns about the negative side effects of a particular 
DMARD, previous experiences of side effects or long term side effects were mentioned by 
all ten patients. Three patients expressed the view that taking DMARDs was like taking 
poison and did not view these drugs to be “natural”. One South Asian patient viewed methi 
(an Indian herb) and ginger to be more natural than DMARDs [Quote 12]. However, the 
necessity drivers led the patients to prioritise, with DMARDs being given higher status 
[Quote 13]. Three patients evaluated DMARDs as being “less risky” than chemotherapy for 
cancer with which hair loss was seen as a concern [Quotes 14, 15 and 16] and therefore were 
found to be adhering to DMARDs. This implied that patients evaluated their concerns about 




Quote 12 “I do try and take methi (Indian herb) and ginger. I have fresh ginger 
everyday to help get rid of the toxins (swelling in joints)”. [51, off work 
due to RA, Punjabi speaking, Asian patient]  
 
Quote 13 “I really hate this medication (MTX). But I appreciate that I need to take 
it I guess it’s a reasonable compromise”. [62, retired, English speaking, 
White patient] 
 
Quote 14 “I thought look....there are people on cancer medicine where their hair 
falls out and I am not that bad to take these”. [42, machine operator, 
English speaking, White patient]  
 
Quote 15 “You know, at least I haven’t got cancer its only arthritis”. [52, house 
wife, English speaking, White patient]  
Quote 16 “I mean at least it wasn’t leukaemia or something, you know. I mean 
touch wood I mean it’s not bad as that: I mean it is bad but you 
know....cancer is a bad thing to have”. [55, unemployed, English 
speaking, White patient]  
 
5.2.4 Quality and quantity of information (high adherence) 
When patients were asked about what information they found useful as a basis for their 
decisions to take DMARDs, they gave a range of explanations. Eight patients believed that 
having seen a joint scan had helped them to put the disease severity into context and stated 
that they were less likely to stop taking their DMARDs after having seen imaging evidence of 
synovitis [Quotes 17-20]. The images also helped patients to understand the seriousness of 
the condition [Quote 21]. Two patients made reference to ultrasound scans and X-rays that 
helped them not only to understand the nature of the disease but also to accept it and come to 




Quote 17  “Dr XX scanned my joints and he showed me my joints and that helped 
me understand what was going on in my joints. He explained what was 
happening...there were different lights flashing and red was showing 
swelling in the joints”. [42, machine operator, English speaking, White 
patient]  
 
Quote 18 “The scan pictures really helped me to understand the disease and to be 
honest this really motivates me to take the MTX. You see I know why I 
have got to do it”. [36, manager, English speaking, Asian patient]  
 
Quote 19 “The scan showed me the lights flashing on my joint swelling. It made me 
scared and helped me to know how serious the condition can be” [51, off 
work due to RA, Punjabi speaking, Asian patient]  
 
Quote 20 “...but when she showed me the x-rays I understood the reasons for my 
pain and also saw the damage that the disease had caused” [55, 
unemployed, White patient]  
 
Quote 21  “When I saw the x-rays and the damage I thought you know... I need to 
listen to what is being said and accept this is for life. So I am taking my 
medication and slowly here I am today not that bad” [34, Nurse, English 
speaking, Asian patient]  
 
Quote 22  “It really makes a difference when you can get on with your doctors” 
mine explained the disease really well” [42, machine operator, White 
patient] 
 
Quote 23  “Yeh I mean it makes it easier when the team support is there it makes 
you feel that you are not alone and there is support there you know” it 
does make the journey that much easier otherwise you get lost and we 
take so many medicines [36, manager, English speaking, Asian patient]  
 
 
For some (six patients), changes in the measured disease activity parameters (blood tests, 
disease activity score) produced a positive effect in terms of deciding on the need for 
continuous DMARDs. For others (four patients) a good relationship with health professionals 
and an in-depth explanation of the nature of the disease [Quote 22], severity and risk of the 
disease for their health, explanation about the treatment options available and reassurance and 
support from health professionals provided patients with a positive outlook on taking 
DMARDs [Quote 23]. Leaflets and use of the internet were also highlighted as useful sources 
of information (four patients) though others (six patients) stated that leaflets on RA that they 
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had been given did not communicate effectively the seriousness of the disease and were not 
helpful in visualising how untreated synovitis could damage joints. The initial symptom 
experience, worsening disease, high level of pain, seriousness of the disease, ultrasound scans 
of joints, support by health professionals, and a good explanation of the nature of the disease 
all acted as motivational factors to take DMARDs and continue taking them.  
5.2.5 Symptoms severity (low adherence)  
The low adherers (ten patients) had similar experiences to that of high adherers [Quote 24]: 
however, there were six patients in whom symptom experiences were viewed to be mild at 
the beginning and as the treatment gave them relief, their reaction was to stop the medication 
as they thought that the disease had been cured [Quote 25]. This was only reported by South 
Asian patients.  
Quote 24 “I was in so much pain and I thought gosh I would die rather than staying 
in bed like that. ...it was bad”.  [44, Microbiologist, English speaking, 
Asian patient]  
Quote 25 “When I started on Methotrexate I was well for about five years. Because 
I was well for so many years and I didn’t really have any pain I made 
myself believe that the disease has cured” [69, retired Punjabi speaking, 
Asian patient]  
 
5.2.6 Illness perception (low adherence) 
In contrast to high adherers, the low adherers held the view that the disease was curable and 
medication was seen as a short term therapy. This was particularly the case amongst the 
South Asian patients (five patients) [Quotes 26 and 27]. Furthermore, patients formed their 
decisions about medicines based on their disease perceptions [Quote 28 and 29]. One South 




Quote 26 “For a year I really battled with myself. Even to now this day I believe 
that the disease can be cured….it will get better”. [33, self-employed, 
English speaking, Asian  patient] 
 
Quote 27 “I have been taking them for a year and now you would think that this 
could be cured...but it hasn’t”. [69, Retired, Punjabi speaking, Asian 
patient]  
 
Quote 28 “To be honest I thought I am 33 so maybe I am getting old or something. I 
mean this is only old person disease right ...I mean, for arthritis, people 
live with it they don’t take long term medicines”. [33, self-employed, 
English speaking, Asian patient]  
 
Quote 29  “You see I never heard of arthritis well, I didn’t think it would be in a 
young person like me. So I thought at the time I would be on paracetamol 
and it would go away”. [61, House wife, Punjabi speaking, Asian patient]  
 
5.2.7 Perceived benefits and risks of DMARDs (low adherence) 
Although the low adherers viewed DMARDs as necessary and agreed that these medications 
were helpful in maintaining their function, they also had concerns. In South Asian patients, 
fears about dependency resulted in either missing doses or stopping treatment for a short 
while [Quotes 30 and 31]. The increased concern about side effects and dependency was 
partly linked to lack of disease knowledge: again, this was mainly noted in South Asians. 
Some South Asians (five patients) believed that the long term usage of DMARDs could lead 
to additional physiological abnormalities [Quote 32]. Some patients (three) viewed DMARDs 
as poisonous [Quote 33]. In contrast two White British low adherers viewed anti-TNF drugs 




Quote 30 “I don’t like taking them (MTX) like the biggest thing for me is the hair 
loss you know”. [44, Microbiologist, English speaking, Asian patient]   
Quote 31 “I know that if I take these everyday then I am dependant on them for the 
rest of my life”. [37, Legal secretary, English speaking, Asian patient]   
Quote 32  “I read that these tablets can give you gastric problems. Then you have to 
take more tablets it’s a never stopping process”. [41, off work due to RA, 
Punjabi speaking, Asian patient]  
Quote 33  “You see these are not natural. I know I have to take them [DMARDs] but 
they are poisons. When I don’t need them I stop them for a while”. [61, 
House wife, Punjabi speaking, Asian patient] 
Quote 34  “I am on Humira and this keeps my disease under control. I don’t think I 
should keep taking my methotrexate when I am controlled more on this 
drug (anti-TNF) [41, Social worker, White patient]  
Quote 35 “ I will be honest with you....since I have been on these injections (anti-
TNF) I really think back why was I even taking these other ones” 
(Sulphasalazine) [63, Retired, White patient]  
 
5.2.8 Quality and quantity of information (low adherence) 
The low adherers (ten participants) reported different reasons for not taking their DMARDs. 
The themes for low adherence to DMARDs were linked to lack of awareness about RA in 
(six patients), [Quotes 36 and 37] this was noted amongst the South Asian patients. The 
majority of South Asian patients did not adhere to DMARDs, as they expressed the view that 
RA was not generally well known about or taken seriously within the South Asian 
community [Quote 2]. Some patients (five) held the view that arthritis was a disease of the 
elderly and could not understand the need for long term therapy, again this view was 
expressed by South Asians [as reported in section 7.1.6]. Some patients (five) had very little 
understanding of the fluctuant pattern of the disease [Quote 38]. Patients expected more 
information from their health professionals and felt that they were not always as aware of 
disease parameters compared with the high adherers [Quote 39]. When asked about whether 
the low adherers had experienced having an ultrasound, it was noted that none of the patients 
140 
 
in the low adherers’ group had been exposed to this test [Quote 40]. This finding was 
applicable to both ethnic groups.  
Quote 36 “Who cares if I have rheumatoid arthritis? Everyone has joint pains and 
this what people generally think”. [69, Retired, Punjabi speaking, Asian 
patient]  
Quote 37  “I still believe that this disease is not holding the same awareness as the 
heart diseases...so people don’t take arthritis seriously.....err the 
medication is not taken seriously”. [37, Legal secretary, English speaking, 
Asian patient]  
Quote 38 “I didn’t know that this disease can come and go like this. If I had known 
I would not reduce my medications”. [33, self-employed, English 
speaking, Asian patient]   
Quote 39 “no I wasn’t aware of this my doctor didn’t tell me (referring to disease 
activity measure -DAS). So this works like a blood pressure when it high 
you know it’s serious ? [41, off work due to RA, Punjabi speaking, Asian 
patient] 
Quote 40  “no I didn’t ever have anything like this”(referring to ultrasound scan of 
joints).[37, Legal secretary, English speaking, Asian patient] 
 
5.3 Suggestion for improving medication adherence given by patients with low 
adherence 
Themes that were reported to act as drivers for high adherers (experience with symptoms, the 
quality and quantity of information) were presented to low adherers to ask them about their 
thoughts about strategies to improve adherence to DMARDs. All low adherers (ten patients) 
agreed on the drivers that were suggested by the high adherers. When patients with low 
adherence were asked about the type of visualization tool that could help improve adherence, 
they said they would prefer to experience live ultrasound rather than static images of joints 
that were not their own. However, a few (three patients) did agree that pictorial representation 
of joints would be better than leaflets alone. Seven low adhering patients believed that the 
visualization of swelling in joints would enhance patients’ understanding of the nature and 
severity of the disease and the need to take medicines long term [Quotes 41 and 42]. All ten 
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patients further added that other disease parameters such as a blood based inflammatory 
makers or disease activity scores would also encourage patients to engage in disease control 
[Quote 43]. All ten patients suggested that good communication with health professionals, 
health professional support, better explanation of the risks of RA to health and patient support 
groups would all promote better medication adherence [Quotes 44, 45 and 46]. Three patients 
felt that the level of involvement in disease information should be left to the individual 
[Quote 47]. 
Quote 41  “I think the scan would change your attitude to how you think about 
medicines”...[44, Microbiologist, English speaking, Asian patient]   
 
Quote 42 “You see I need something to validate to show me that I have a condition 
serious as this” (rheumatoid arthritis). I think a scan can do this...”. [37, 
Legal secretary, English speaking, Asian patient]  
 
Quote 43 “My friend has a sugar monitoring machine he knows what a good and 
high level is. So if you told patients about disease activity levels it would 
encourage knowing how the medicine are working”. [69, Retired, English 
speaking, White patient] 
Quote 44 “Knowing how this disease will affect us in the future needs to be 
explained...so the seriousness of the disease does need to be told...” [56, 
off work due to RA, Punjabi speaking, Asian patient]  
 
Quote 45 “You see the disease isn’t viewed seriously, so if the risks aren’t explained 
then people will not take the medication seriously” [63, Retired, Punjabi 
speaking, Asian patient]  
 
Quote 46 “Knowing the team is there to support you... the journey is shared and if 
the patients are made to feel like this then it’s easier, you know”. [69, 




“hmm I am not sure on what would help...I think it doesn’t matter what 
you use to explain the disease: it’s all up to the individual, isn’t it? I mean 
if I want to know more then I will, but it’s all on how I want to take 






5.4 Discussion  
The discussion will focus on the findings of the qualitative phase and compare them with 
other published literature. It will examine the strengths and weakness of the qualitative phase 
and provide a summary. The theoretical interpretation of the findings of this section will be 
discussed in Chapter 6. 
This thesis has examined determinants of both high and low adherence levels in patients with 
RA of South Asian and White British origin. It has demonstrated that symptom experience, 
illness perceptions (illness representation), perceived benefits and risks and quality and 
quantity of information influenced adherence levels. There were similarities in the high 
adherers between both ethnic groups. However, differences were reported in the low adherers 
between the White and South Asian patients. For example, the South Asian patients based 
their decision not to take DMARDs on [a] a perception that RA was not serious, [b] a belief 
that RA was short-term and [c] a lack of general awareness of RA. In contrast, the White 
British patients based their decision not to take medication (methotrexate) as they held the 
view that anti-TNF treatment was more sufficient at controlling their RA symptoms. 
Insufficient information regarding [a] understanding of the disease, [b] patients’ perception of 
disease being either acute or chronic and [c] lack of discussion around disease parameters, 
were barriers towards taking DMARDs.  
The topic areas based around the NCF114 and SRM170 (as mentioned in Section 1.6) were 
useful as a structure around which to discuss adherence in RA patients helping to explore 
data from the quantitative survey in depth. The high adherers’ beliefs about taking DMARDs 
were grounded in necessity and concerns; this has been reported previously in RA studies34. 
The notions of necessity in patients who were informed of the personal need for therapy, 
derived from patients’ perceptions of illness - for example severity of symptoms stimulated 
medication use. Furthermore, patients who were adherent to treatment (both ethnic groups) 
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were convinced that RA could not be cured. Thus, the consequences of the condition and its 
controllability matched their expectations so they understood the need for long term 
DMARDs, which outweighed their concerns. Similar concepts have been reported in other 
diseases,109;138;180. Low adherence was associated with doubts about personal need for 
treatments and concerns about potential side effects. The way in which individuals judged 
their treatment’s necessity was related to their concerns. Moreover, as predicted by Horne et 
al,109;138 the necessity beliefs were interlinked with perceptions of the illness representations. 
For some patients, their common sense model of RA differed from the medical understanding 
of the disease. Due to symptoms being episodic, the low adherers tended to view their RA to 
be short term and non-serious. This was evident in the South Asian patients. The Indian study 
mentioned in section 1.10 which examined the delay between symptom onset and seeking 
medical help, also found that South Asian patients did not view RA symptoms to be 
serious.216 The study reported that South Asians were more familiar with traditional remedies 
than with western medicines and were found to be using these alongside western medicines. 
Similarly, the current thesis has also found that a few patients had high regard for traditional 
remedies and felt that these could help to improve their RA symptoms.  
The results of this thesis showed that patients’ perception about the need for treatment and 
decisions to continue taking DMARDs were reinforced by receiving adequate or inadequate 
information and the utilisation of real visual aids (ultrasound scan). The utility of 
pictorial/visualisation aids has been reported by other studies: for example, in relation to 
ovarian cancer it has been shown that the use of ultrasound scanning of the ovaries reduced 
patients’ anxiety and  improved their confidence and well-being.295 Encouraging results from 
other studies,296;297 found that patients who smoked and who were given an ultrasound image 
of their carotid artery showing atherosclerotic plaque were more motivated to stop smoking 
and were found to engage in more cessation behaviours. This intervention to modify 
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behaviour was based around the topics of the CSM. Evidence on the use of ultrasound in RA 
and its impact on patients’ experiences or understanding of the disease are not well 
documented.298 To date, one pilot study of eighteen RA patients has shown that the use of 
ultrasound reduces patients’ concerns about treatment. Furthermore, it showed that using 
ultrasound as an educational tool helped to increase necessity belief of treatment.298 However, 
the authors did not find an increase in medication adherence. Interestingly, there were only 
nine patients who were taking DMARDs at the time of ultrasound. The study also had a short 
duration of follow up (ten days) and had recruited small numbers of patients. The authors 
suggest that larger studies are required to look at the role of ultrasound in improving 
medication adherence in RA. The findings of this thesis showed that as well as visualisation 
of joints, viewing clinical parameters such as disease activity score and level of inflammatory 
markers played a crucial role in patients’ understanding of the need for long term therapy. In 
the high adherers, trust in HCPs and effective communication were described as important. 
The authors of another RA study have suggested that patients’ satisfaction with medical 
consultations and increased knowledge about RA and RA treatments positively affect 
adherence.299 The low adherers (predominately the South Asian patients) in the study were 
not convinced about the long term need for therapy. Their beliefs about the use of DMARDs 
influenced adherence in different ways. For example, these patients reported milder 
symptoms at the start of therapy and had more concerns about the toxicity of DMARDs, 
which is consistent with the quantitative findings of this thesis. These views about concerns 
about DMARDs are also consistent with the researcher’s previous work.8;91 One of the 
explanations for increased concerns about DMARDs in South Asians may be that they arise 




Patients of South Asian origin may need to be educated more about the differences between 
curing and treating RA with medicines. South Asian patients’ general awareness about RA 
within their community and medication used for its management apparently had a greater 
impact on their adherence to DMARDs. Lack of general knowledge and delay in initiating 
treatment has been reported in the researcher’s previous work.65;100 The qualitative phase of 
this thesis suggests that patients’ pre-conceived views about RA and illness representations 
are linked to their decisions about taking DMARDs. Preconceived beliefs about medical 
conditions have been shown to lead to increased concerns and fear. However, women with 
cancer found that ultrasound scanning helped to relieve misunderstanding about the 
condition300.   
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5.5 Strengths and weaknesses  
The successful recruitment of both White British and South Asian patients was an important 
strength as this study explored the differences of medication adherence amongst RA patients 
from White British and South Asian origin. The findings generated here, were from the same 
cohort of patients as the quantitative survey. This allowed the researcher to explore the 
reasons underlying beliefs about medicines and illness representations reported in the 
quantitative work. Bearing in mind the strengths of this study, it is also important to note its 
limitations. The patients who took part in the interviews might not be a representation of a 
wider group. The involvement of a researcher from the same ethnic background in 
interviewing South Asian patients might have influenced the findings. This point has been 
discussed under section 3.2 “Reflection on cross-cultural qualitative research”. Equally, the 
responses given by the White British patients might have been different if the researcher was 
from a White background85;268.   
5.6 Summary  
In summary, the findings from this phase can be used in helping to plan future interventions 
that may stimulate understanding of RA and DMARD use. This is particularly important for 




CHAPTER 6: DISCUSSION 
This chapter provides a detailed discussion of the study results. The chapter concludes with 
limitations, implications for research and clinical practice, future recommendations and a 
final conclusion.   
The objectives of the thesis were:  
1) To synthesise qualitative data on adherence to medication in South Asian 
patients with cardiovascular disease and diabetes.  
2) To assess the relationship between adherence to medicines and a range of 
variables (e.g. age, gender, level of education, socioeconomic status, 
occupation, employment status and disease duration) in patients with RA of 
South Asian (defined as originating from India or Pakistan) and White British 
origin.  
3) To explore the reasons underlying high and low adherence amongst these two 
ethnic groups of patients. 
Overall findings of the thesis  
The results of the systematic meta-synthesis showed that beliefs about medicines play an 
important role in medication adherence in diabetes and CVD patients. Furthermore, the 
results of this thesis have demonstrated that beliefs about medicines and illness perceptions 
differed between the South Asian and White British patients; these beliefs and perceptions 
were important in understanding differences in adherence between these two groups.  
The quantitative findings reported in Chapter 4 are suggestive of a relationship between 
beliefs about medicines and adherence to DMARDs. Dissatisfaction with information was 
particularly associated with poor adherence amongst South Asian patients. The findings of 
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the quantitative survey were further explored in Chapter 5: these remained consistent with 
patients’ beliefs about medicines, illness perceptions and satisfaction with information about 
medicines in explaining adherence to DMARDs. Lack of RA awareness amongst South 
Asian patients also seemed to influence the way patients viewed their DMARDs. These 
findings are important as they show that illness perceptions and beliefs about medicines are 
central to all patients’ decisions regarding whether to take medicines, therefore supporting 
evidence for theoretical frameworks such as the “Common Sense Model” (CSM)170 and the 
“Necessity Concerns Framework”119. Before discussing the quantitative and qualitative 
results, this section discusses the findings of the systematic meta-synthesis in the context with 
qualitative RA findings of this thesis.  
Patients’ beliefs about medicines have been shown to influence decisions about whether to 
take medicines as examined in Chapter 2 which discussed issues related to medication 
adherence. In an attempt to bring out the similarities between the data from the systematic 
meta-synthesis of South Asians with diabetes and CVD and the qualitative findings of this 
thesis, the researcher will compare these findings to identify whether there might be concepts 
about medicine taking that appear across diabetes, CVD and RA.  
The results of the qualitative phase of this thesis uncovered some interesting themes that were 
important in explaining non-adherence in South Asian patients with RA. Some of these 
themes were found to be similar to those stated in Chapter 2 (diabetic and CVD patients -
systematic meta-synthesis). For example, concerns about medication toxicity were apparent 
in diabetic4 as well as in South Asian RA patients. Interestingly, the role of the necessity 
beliefs of medicine was consistent with the findings of the systematic meta-synthesis. Both 
RA and diabetic patients evaluated the need to take medicines to control symptoms. However, 
there were factors that influenced their views of long term therapy. For example, stigma of 
disease and social support were linked to cultural influences and consequently this impacted 
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on non-adherence in the diabetic patients.226;233 This non-adherence may be associated with 
the cultural stigma attached to illness. This notion about the role of cultural stigma was also 
found in the qualitative phase of this thesis which identified a link between low adherence 
behaviours and particular illness representations about RA: for example, a desire for a cure 
for the disease. The diabetic patients in the systematic meta-synthesis often hid their medicine 
taking from their community230 and found it difficult to follow lifestyle changes. The South 
Asian RA patients did not believe that they needed long-term therapy because they viewed 
RA as a less serious condition and regarded it as a disease of the elderly. Furthermore, South 
Asian patients expressed the view that there was less awareness about RA amongst the Asian 
community compared to diabetes and CVD. The patients’ awareness about diabetes and CVD 
suggests that a diagnosis of diabetes, or CVD might have a different influence on medicine 
taking compared to a diagnosis of RA. For example, patients with diabetes might base their 
judgement about taking medicines on their blood sugar level.  
The diabetic patients in the systematic meta-synthesis made extensive use of traditional 
remedies to control their condition.227;228;239 However, this was reported by only a few of the 
RA patients, they also preferred traditional remedies and regarded them as safer than 
DMARDs. Beliefs in traditional remedies and patient-health professional interaction 
appeared to play an important role in the way diabetic patients perceived medicines,227;228;239 
with patient orientations towards traditional remedies and poor communication with 
healthcare professionals making them cast doubt on the efficacy and necessity of prescribed 
medicines.112;231  
The poor relationship with health professionals was also noted in South Asian RA patients. 
Similarities could be found between RA and diabetic patients in terms of lack of information 
about the fluctuating course of a disease and lack of awareness of the impact of poor 
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adherence on their long-term consequences.4;234 The broad thrust of these two sets of findings 
highlights that culture and beliefs about medicines appear to influence medication adherence 
and disease perception in these patient groups. There is a need for interventions that can 
demonstrate the ability to change patients’ behaviour, cultural habits and views of RA and its 
treatments.   
In conclusion, the systematic meta-synthesis of the literature regarding medication adherence 
in South Asian patients with CVD and diabetes and qualitative data of this thesis provided a 
useful platform for future research into the design of interventions for improving medication 
adherence in particular in the context of patients of South Asian origin. A systematic 
review258 of interventions that focused on lifestyle modifications for South Asian 
communities in the context of diabetes, suggested that factors that should be considered in 
developing interventions need careful thought, as this is still a developing area.258 These 
include [1] the use of community resources to publicise the intervention and increase 
accessibility, [2] identifying and addressing barriers to access and participation, [3] the 
development of sensitive communication strategies to manage information requirements, [4] 
working with cultural or religious values that promote or hinder attitudinal and behavioural 
change, and [5] accommodating varying degrees of cultural identification. An interesting 
example of this is provided in a recent study by Bhopal et al,301 using a culturally adapted, 
family-based intervention. Patients at risk of developing diabetes were recruited and family 
members played a key role in the study. The authors suggest that integrating studies within a 
community and family setting may be one way to promote and achieve positive disease 
outcomes. Another example of predicting the influence of cultural beliefs on health involved 
the use of a theoretical model in South Asian people at risk of developing CVD.302 The study 
recruited seventy five South Asian patients who had migrated from India and Pakistan. The 
authors found that these immigrants had different views about the causes of CVD related 
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events. A proportion of people in that study had resigned themselves to the fact that CVD 
related events occurred due to God’s will or stress and were found to place less emphasis on 
cholesterol, blood pressure control, exercise and smoking as potential modifiable risk factors 
for CVD. Through using a theoretical model of illness perception, the authors were able to 
predict key factors that might be used in designing an intervention to change health behaviour. 
Social stigma related to disease, community pressure and patients’ own illness perception and 
willingness to accept diseases may play a role for South Asian diabetic, CVD and RA 
patients. Therefore, lessons learnt from the thesis’s systematic meta-synthesis review bring to 
light the similarities between diabetic CVD and RA South Asian patients’ health beliefs and 
beliefs about medicines. However, RA South Asian patients seem to highlight different 
concept to diabetic patients, wherein the public are still becoming aware of symptoms of 
RA,65 seeking medical help and accepting treatments.11 The qualitative phase of this thesis 
discovered that lack of awareness about RA seemed to be an important factor in encouraging 
South Asian patients to accept DMARDs. It is suggested that there are two potential 
directions in which this area of work could develop.  
Firstly, at a clinical level, information should target patients’ CSM by providing an 
explanation of the need for DMARDs. As suggested by RA patients, the use of visual and 
imaging strategies could have an important role in promoting medication adherence, 
understanding of the disease process and future risks. There are as yet, inadequate data to 
enable a decision as to which approaches are of importance in interventions in RA. In order 
to progress understanding in the field of adherence to medicines in RA, there is a need to 
promote greater inclusion of theoretical models in such interventions for the promotion of 
behavioural change in RA patients. For example, work done with RA patients testing their 
CVD knowledge demonstrated how theory based intervention could allow patients to focus 
on modifiable behaviour changes towards reducing their risk of CVD.303 Theory based 
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interventions focusing on adherence issues could offer an opportunity to predict whether 
changes in adherence are attributable to illness/ treatment beliefs304 at which point suitable 
education can be delivered to patients. Secondly, projects should be developed to explore the 
South Asian population’s knowledge of RA and the way that this population may respond to 
the initial symptoms of RA. Research in Birmingham has already shown that there are long 
delays in seeking medical help with RA symptoms.65;100 The potential problems with delay 




The next section presents the findings from the quantitative survey and from the qualitative 
phase of this thesis in the context of the SRM and NCF models. Figure 5 illustrates the 
contributing factors that were found in this thesis to influence medication adherence at 
different stages of patients’ journey. These will be discussed next.  
Figure 5: The influence of the patient journey in making decisions about taking 
DMARDs in the context of common sense appraisal 
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The appropriate use of medication is essentially dependent on ability and motivation109.  
Several theoretical models have been developed to explain how people initiate and maintain 
actions to improve health outcomes.98;177 Prior to the introduction of the CSM a theoretical 
application for changing health behaviour in RA was provided by the work of Lorig et 
al.305;306 Lorig’s primary work has illustrated how using the self-efficacy theory in RA can 
improve patients’ sense of self-control and ability to cope with symptoms. Earlier work in 
RA provided evidence to help inform self-management programmes for patients.307;308 
However this approach had its limitations in demonstrating behavioural change288. More 
recently, there has been recognition that using techniques such as cognitive behavioural 
therapy (CBT) could help to change behaviour in RA patients.309-312 CBT is built around 
components of self-efficacy and has been designed to focus on the way a person copes with 
his or her disability. In RA, CBT has primarily been used to improve outcomes of pain, 
physical function and fatigue. For example, in a randomised controlled trial of 127 RA 
patients with fatigue, it was found that addressing behaviour related to fatigue improved 
coping and well-being.310 Another study conducted amongst 418 patients with chronic knee 
pain found that addressing patients’ health beliefs improved physical function. That study 
further reported lower health-care costs313 in the intervention group. Sharpe et al,312 also 
found that goal setting, pacing, problem solving, communication and assertiveness, helped to 
reduce symptoms related to depression and that patients consequently made less use of the 
health care system. In a study looking at self-monitoring and goal setting through the use of 
the CBT technique, the authors found that the intervention had reduced pain and increased 
patients’ levels of self-efficacy.309 In the context of interventions to improve medication 
adherence in RA, very few studies have been conducted.3 Studies have been successful in 
predicting factors such as “health beliefs” that affect medication adherence however, 
interventions using theoretical frameworks to improve beliefs about medicines and 
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medication adherence are still rare in RA.155 More importantly, these studies have mainly 
been conducted amongst European patients. Hill et al35 reported an improved adherence to 
DMARDs through delivering an education programme, although the effect tailed off after 
three months. However, a study conducted by Brus et al,158 did not achieve an increase in 
adherence to medicines in new onset RA through an educational programme. Neither of these 
studies used theories of behaviour. However, one study which looked at CVD risk factors in 
RA patients did make use of the CSM.303 It used the CSM to underpin an educational 
programme to change behaviour, allowing patients to identify which CVD risk factor would 
be the most suitable to modify first. The authors concluded that the CSM provided them with 
a platform to make behavioural changes in RA patients with CVD risk factors. In the authors’ 
further work,314 they randomized RA patients with CVD to the intervention group (patients 
received cognitive behavioural education) or the control group (patients received an 
information leaflet) and found improved intentions to increase exercise, eat low fat diet, lose 
weight and reduce blood pressure in the intervention group. However, the measured 
behaviours did not change. The authors suggest that larger studies are required that would 
detect behavioural changes.  Horne and Weinman170 suggest that the beliefs that contribute to 
positive or negative evaluations of medicines play an important role in the decision to take 
medicines. These concepts are recognised within the CSM and the Necessity Concerns 
Framework .170  
The necessity, concerns beliefs and common-sense representations were illustrated in the 
quantitative survey of this thesis (Chapter 4), where patients who had higher scores for 
necessity (need for treatment) and had a better understanding of RA were high adherers to 
DMARDs. This concept was also noted in the qualitative phase of this thesis (Chapter 5), 
where patients demonstrated the need for therapy by weighing the advantages and 
disadvantages of DMARDs mainly on the basis of RA symptom appraisal and the common 
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sense fit of the problem (RA problem vs solution). Similar results were reported in earlier 
work by Horne and Weinman,138 who looked at a range of chronic diseases (such as asthma, 
kidney disease, coronary heart disease and cancer) in 324 patients. That cross sectional study 
demonstrated a positive correlation of adherence with necessity beliefs and a negative 
correlation of adherence with concerns, suggesting that those with more positive beliefs about 
medicines were better adherers. Chambers et al,315 and Horne et al,119 also showed that 
medication beliefs were stronger predictors of self-reported adherence than were clinical or 
demographic variables. As mentioned in section 1.4.5 a recent review also found positive 
association between adherence and beliefs about medicines in a number of studies.34;277;299;316 
The literature cited above demonstrates that when making decisions related to the advantages 
and disadvantages of medications, patients face a dilemma as to whether or not to adhere to 
treatment. This was shown in the quantitative phase of this thesis, where the researcher found 
that South Asian patients had higher concerns about DMARDs and more negative views 
about medicines in general and that these correlated with dissatisfaction with information 
about DMARDs. The pattern of perceived necessity and concerns in adherence was also 
noted by these patients who were offered highly active anti-retroviral treatment317. However, 
in the qualitative phase of this thesis, patients’ concerns about the use of DMARDs were not 
only noted to be related to toxicity but also to be linked with lack of information about the 
disease process and patients’ views about the seriousness of RA: patients could not 
comprehend the use of toxic medicines. Therefore, patients judged their personal need for 
DMARDs relative to their concerns, which influenced their adherence to DMARDs. 




Horne et al suggest that in order to reach an agreement about the need for treatment, patients 
must be informed that their condition warrants this treatment.170;318 In this stage of decision-
making, perceptions of treatment necessity are closely bound up with representation of the 
illness as patients attempt to achieve common sense coherence (understanding the disease).156 
This was illustrated by the findings of the qualitative phase of this thesis where patients had 
an opportunity to view inside their joint through ultrasound scan. This had provided them 
with a shaped illness representation and gave them a convincing rationale for the need for 
therapy. Patients’ beliefs about control, cure and illness coherence (understanding of RA) 
were found to be associated with adherence levels in Chapter 4 of this thesis. These factors 
were further discussed in Chapter 5 where the researcher found that patients’ initial 
perceptions of treatment necessity and subsequent appraisal were influenced by the severity 
of their symptoms. The influence of symptom experience has also been shown in other 
studies,319-321 suggesting that messages about treatment necessity are likely to be more 
convincing if they match the individual’s representation of their illness. A recent review on 
medication adherence in RA155 has demonstrated that theory based interventions can result in 
a change in behaviour and that greater use of such interventions is needed in rheumatology. 
So far, theoretical models such as the Health Belief Model87 and the Theory of Planned 
Behaviour167 have been used to look at the psychosocial determinants of adherence.155 A 
number of studies have shown an association between psychosocial determinants of 
adherence.320;322;323 A more recent review by Horne et al119 found that there was a significant 
relationship between necessity, concern beliefs and medication adherence. Again, Horne 
suggests that patients’ evaluation of treatments is heavily based on the common sense 
rationale.119 In both phases of this thesis, the South Asian patients were found to lack a clear 
understanding of RA and to view the disease to be short term in nature. This misconception 
created confusion about the long term use of DMARDs. Fundamentally, theories are only 
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known to suggest “what” needs to be changed in order to generate behavioural modification 
and lack focus on “how” this can be induced.324 Michie et al324-326 argue that this should be 
the next step in forthcoming studies which should explore in detail “how” to translate 
behaviour change predictors into successful behaviour change. For example, in order to 
increase the impact of intentions on behaviour change, interventions should aim to promote 
intentions and motivation and further measure their stability.327 
As highlighted above, the South Asian RA patients studied displayed more negative beliefs 
about medicines than did White British patients. The differences are embedded in the lack of 
awareness about RA and its perceived perception as relatively non-serious disease. There is 
an urgent need for future interventions to change the misconceptions about RA in this 
population. Due to the complexity of the disease process as well as differences in patient 
beliefs about medicines, responses to DMARDs and TNF inhibitors tend to vary across 
patients328. Some patients may completely fail to respond to therapy and some might show a 
partial response. These unfavourable outcomes may necessitate the need to discontinue one 
therapy and switch to another. However, a major challenge lies in the patients’ perseverance 
with their medications, and this might prove difficult particularly, in South Asian patients, as 
they seek a “cure” for RA and not “control”. The findings of this thesis also present clinicians 
with a problem for the “treat to target” approach.329 This approach certainly seems to result in 
better clinical outcomes but a question might arise for South Asian patients: how can 
clinicians meet this target if patients are less adherent to their DMARDs? Therefore, 
theoretical interventions that can provide a common sense rationale might be of particular 




In summary, medication beliefs are important determinants of adherence in chronic diseases. 
Beliefs about medicines and the necessity and concerns construct provide a framework for 
operationalising key beliefs relating to adherence within the context of theories of social 
cognition and self-regulation. Health professionals in rheumatology practice must recognise 
that many patients start with considerable doubt about medicines and that these beliefs may 
influence how information about disease and medicines is interpreted: more importantly the 
way in which that information is delivered is likely to have a considerable impact on the way 
patients engage with treatments in RA. Finally, the thesis has identified, for the first time that 
there is lower adherence amongst South Asians with RA than amongst White British patients, 
and has highlighted the potential importance of visual representation in promoting adherence 




6.1 Limitations  
Several limitations specific to each of the phases have already been noted in the discussion 
section of Chapters 4 and 5. The following section outlines some broader limitations of the 
study.  
In the quantitative survey, patients’ depression scores were not collected. As mentioned in 
section 1.2.7 higher levels of depression could have impacted on adherence. Moreover, 
although data on symptom duration were collected, the researcher did not collect data on the 
level of delay to symptom presentation to GP. This could have shown whether patients with a 
long delay to symptom presentation had different views about DMARDs and adherence 
levels as opposed to early presenters. The cost of medicines and patients’ experience of 
obtaining repeat prescriptions were not collected in the quantitative survey. This could have 
highlighted the practical barriers to non-adherence. 
In the qualitative phase, the researcher did not explore patients’ views about other medicines 
that they were taking. For example, patients’ preferences for certain medications such as anti-
hypertensive medication, or use of steroids could have given an indication of whether they 
prioritised different medicines over DMARDs. The qualitative data suggested that RA 
patients might have had different views about the use of DMARDs and anti-TNF based on 
efficacy. Therefore, these views could have had an effect on adherence levels. However, this 
was not fully explored between the two ethnic groups.  
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6.2 Implications for research 
Previous research has indicated that beliefs about medicines can predict levels of adherence 
in RA.34 It is noteworthy that beliefs about DMARDs might change with disease duration: 
therefore, there is a need for longitudinal observation studies to look at the patterns of 
adherence in ethnic groups. In the light of the findings of this thesis, it may be possible for 
interventions to target RA patients’ illness perceptions and health-related behaviour in order 
to improve their medication adherence. Furthermore, researchers need to explore ways in 
which complex beliefs can be easily and quickly assessed by clinicians.  
6.3 Implications for clinical practice 
Clinicians need to consider patients’ ethnicity and beliefs when providing information about 
the need for long-term therapy. This research indicates that patients’ RA perceptions consist 
of their individualised beliefs. Uncovering and addressing these beliefs during routine 
consultation may positively influence adherence, communication and patients’ satisfaction. 
Clinicians need to adopt new approaches that will enhance patients’ understanding of taking 
long-term therapy. It is important that future interventions detect the presence of non-
adherence at an early stage and attempt to modify behaviours for later years.     
The use of visual aids (ultrasound or pictorial diagrams) may be appropriate in addressing 
perceptions of RA and the need for DMARDs. Moreover, based on the current research 
findings: messages for RA patients should aim to:  
• Empower RA patients by educating them about the natural history of their disease 
using visual representations that can help to shape accurate illness representations.  
Particular emphasis should be placed on available treatments and the consequences of 
uncontrolled RA.    
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• Using visual representation as an educational tool, disclose the realities of current RA 
treatments: that there is “no cure” but that the disease can be “controlled”. This might 





6.4 Future recommendations  
In future, work should be conducted to measure newly diagnosed RA patients’ adherence and 
persistence with medicines. It would also be interesting to evaluate the differences in 
adherence to and persistence with DMARDs in newly diagnosed patients of South Asian and 
White British origin to see which group persists with DMARDs and aim to build an 
intervention that would be based around theoretical framework. If the intervention is 
successful, the intervention should eventually be rolled out into early arthritis clinics. 
Furthermore, satisfaction with information about DMARDs requires further investigation 
particularly, amongst the South Asian patients. A need for a questionnaire that screens 
patients’ adherence within clinical setting is also required. Such a questionnaire could be 
beneficial in identifying low adherence and used during patient consultation to address and 
reduce low adherence to DMARDs. Findings from this thesis will be important not only to 
the rheumatological community but also to the wider medical and nursing communities, 




6.5 Final conclusion  
The results described within this thesis have extended the evidence relating to predictors of 
adherence to DMARDs in White British and South Asian patients. Adherence to DMARDs 
was higher in the White British than in the South Asian patients. This may reflect 
dissatisfaction with information about DMARDs. The level of satisfaction with information 
about DMARDs was correlated with negative views about medicines and illness 
representations. Results from this thesis suggest that provision of adequate information such 
as disease parameters, blood tests and form of pictorial imaging may be ways to improve 
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